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Ágrip 
Megintilgangur þessarar rannsóknar var að kanna á heildrænan máta notkun 
ættfræði- og krabbameinsgrunna í erfðaráðgjöf og hvernig slíkir grunnar 
nýtast til að búa til rafræn ættartré fyrir áhættumat í krabbameinserfðaráðgjöf. 
Íslenska landnemabreytingin í BRCA2 geni var notuð sem dæmi. Einnig var 
reiknað hver væri besta stærð ættartrjáa í krabbameinserfðaráðgjöf fyrir 
nákvæmt áhættumat. Ritgerðin byggir á þremur birtum greinum. 
Við rannsóknina voru þrjár mismunandi aðferðir notaðar. Í rannsókn I var 
gerð kerfisbundin leit að greinum sem lýstu notkun rafrænna ættfræði- og 
krabbameinsgrunna í klínískri þjónustu. Meginniðurstöður: Notkun slíkra 
grunna reyndist lítil eins og búist hafði verið við og eingöngu fjórar greinar 
lýstu notkun eða mögulegri notkun. Tvær greinanna voru umræðugreinar og 
ein var greinin var íslensk þar sem lýst var notkun upplýsinga frá 
Erfðafræðinefnd Háskóla Íslands, ættfræðigrunninum sem notaður var í 
þessari rannsókn.  
Rannsókn II var eigindleg og könnuð var upplifun og reynsla ráðþega í 
krabbameinserfðaráðgjöf þar sem notuð eru rafræn ættartré. Gögnum var 
safnað gegnum vef-rýnihópa og öll umræða fór fram á netinu. Í erfðaráðgjöf 
þarf að safna upplýsingum fyrir ættartré. Þær upplýsingar eru notaðar til að 
skýra erfðir og erfðamáta sjúkdóma. Meginniðurstöður: Þeir sem voru í 
rýnihópunum sögðust flestir hafa haft upplýsingar um og þekkingu á 
erfðaráðgjöf áður en þeir komu í erfðaráðgjöf. Flestir höfðu komið í 
erfðaráðgjöf vegna sterkrar fjölskyldusögu um krabbamein. Þátttakendur voru 
jákvæðir gagnvart notkun rafrænna ættfræðigrunna og treystu bæði fagfólki 
og þeim upplýsingum sem notaðar voru í erfðaráðgjöfinni með aðstoð 
ættfræðigrunns og krabbameinsskrár. Sumir höfðu áhyggjur af því að 
tryggingafélög gætu nálgast upplýsingar um þá og það gæti orðið til þess 
iðgjöld hækkuðu eða að erfitt yrði að fá tryggingar. Lög og reglugerðir um 
mismunun vegna erfðaeiginleika eru til staðar, bæði hér á landi og erlendis. 
Fjölskyldusamskipti voru ýmist óbreytt eða höfðu batnað í kjölfar niðurstöðu 
erfðarannsóknar. Þar sem niðurstöður slíkra rannsókna hafa áhrif bæði á 
ráðþega og ættingja er mikilvægt að samskipti innan fjölskyldunnar séu góð. Í 
rannsókn III var reynsla af rafrænum ættartrjám í erfðaráðgjöf metin ásamt 
því að reikna út bestu mögulegu stærð fyrir áhættumat. Meginniðurstöður: 
Notkun rafrænna ættartrjáa í krabbameinserfðaráðgjöf gefur möguleika á 
nákvæmu og yfirgripsmiklu áhættumati og minnkar kostnað frá því að nota 
hefðbundin handtteiknuð ættartré. Við reiknuðum ROC línurit (Reciver 
Operation Curves) og C-gildi sem byggt var á samaburði paraðra gilda til að 
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meta áhrif stækkandi ættartrjáa varðandi líkur á því að bera íslenska 
landnemabreytingu í BRCA2 geni. Bestu niðurstöður fengust með 3° 
ættartrjám. Engu breytti að bæta 4° við. Engin vandamál urðu við að afla 
upplýst samþykkis og ekki voru nein vandamál við notkun ættartrjánna.  
Ritgerðin endurspeglar klíníska reynslu við notkun rafrænna ættartrjáa. 
Þessi aðferð er vel þróuð á Íslandi og hefur verið notuð í 13 ár í 
krabbameinserfðaráðgjöf. Mikilvæg niðurstaða rannsóknarinnar er að besta 
stærð ættartrjáa eru 3° ættartré en þau geta náð yfir fimm kynslóðir. Slík 
ættartré er erfitt að gera öðruvísi en með hjálp rafrænna gagnagrunna.  
Í heild benda niðurstöður til þess að rafræn ættartré sem sækja gögn í 
rafrænan ættfræðigrunn og krabbameinsskrá, spari vinnu og mannafla í 
erfðaheilbrigðisþjónustu. Víða um heim eru til viðamikil ættfræðigögn sem 
nota mætti til að gera slík ættartré og á Vesturlöndum a.m.k. eru víða 
nákvæmar krabbameinsskrár sem mögulegt væri að nota á sama hátt og gert 
er á Íslandi. Það gæti gert að verkum að bið eftir krabbameinserfðaráðgjöf 
yrði styttri, að áhættumat yrði nákvæmara og að hægt væri að bjóða fleirum 
ráðgjöf. 
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Abstract 
The overall aim of this PhD thesis was to cohesively assess the availability 
and use of electronic genealogy databases and information from cancer 
registries to construct electronically generated pedigrees for risk assessment 
in genetic counselling. The thesis is built upon three published papers. 
Hereditary breast and ovarian cancer (HBOC), due to the Icelandic founder 
BRCA2 PV was used as an example. A second objective was to determine 
the optimal size of pedigrees for risk assessment in cancer genetic 
counselling.  
Three different approaches were used. Study I was a systematic literature 
review for articles describing the use of electronic genealogy and cancer 
databases in clinical service. Key findings: Published data on the use of such 
databases was limited, and the search identified only four articles fitting the 
search terms. Two of the papers were discussion papers. One of the four 
articles described an Icelandic study which applied information from the 
Genetical Committee of the University of Iceland. Study II was qualitative, on 
the experience of counsellees where electronically generated pedigrees 
(EGPs) were used in hereditary breast and ovarian cancer (HBOC) genetic 
counselling. Data was collected via an online focus group using an online 
discussion board. In genetic counselling, family health and genealogical 
history are collected to assess risk and clarify the inheritance mode of a 
suspected or known disorder. Key findings: Prior to genetic counselling, the 
majority of participants said that they had known about genetic counselling, 
and the most common reason for GC was a strong family history of cancer. 
Most participants were positive towards the use of electronic pedigrees and 
had trust in both the professionals and the information from the databases 
used to generate the pedigrees. Some, however, worried that insurance 
companies would obtain the information from the databases and possibly 
raise premiums or even deny insurance outright based on the information. 
Laws against genetic discrimination and the protection of personal data exist, 
both in health insurance and employment. The majority of participants had 
either unchanged or better family communication following genetic 
counselling. As relatives may have a diverse reaction to the offer of genetic 
testing, good family communication is essential.  
In Study III, the clinical use of electronically generated pedigrees was 
assessed, and the optimal pedigree size was calculated. Key findings: Using 
EGPs for risk assessment in cancer genetic counselling enabled accurate 
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and comprehensive risk assessment in HBOC families. Further, such use is 
cost-effective and reduces work. We used Receiver Operation Curves (ROC) 
and C-statistics based on pair-wise comparison to evaluate the effect of 
pedigree size on the prediction of the presence of the Icelandic founder 
BRCA2 PV. Optimal results were attained using pedigrees with 3° relatives. 
Adding 4° relatives did not improve the outcome. Obtaining informed consent 
for the construction of pedigrees was straightforward, and no breaches of 
security (i.e. leakage of classified or restricted information) were observed. 
Conventional methods of collecting and constructing large enough pedigrees 
are time-consuming and difficult compared to our approach.  
This thesis reflects the experience of a clinical genetic service using 
electronically generated pedigrees in clinical practice. This approach is well 
established in Iceland and has been used for over 13 years in cancer genetic 
counselling. It is efficient and without complications such as breach of data 
and mistrust on behalf of the counsellees. A significant result from this work 
is that the optimal size of cancer pedigree, 3° pedigree which can take up to 
five generations. Such a pedigree is very difficult and impractical to generate 
using the conventional handmade technique. This should create a motive to 
use EGPs in other countries where some or all the resources are readily 
available. 
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1 Introduction 
I trace the interest in genealogy in Iceland to the lack of trees. 
Because of the sparsity of trees, people opt for family trees and 
find themselves forests among their forebears. 
Einar Már Guðmundsson, in Angels of the Universe.  
The theme of this thesis, which is based on three published studies, is family 
history based on information from electronic databases, in cancer genetic 
counselling. Different motives and views were used in each of the three 
studies. The first study was a systematic literature review on the use of family 
history based on electronic databases in clinical settings (Stefansdottir, V., 
Johannsson, et al., 2013). The second study using qualitative methods and 
online focus groups assessed the counsellees experience of using 
electronically generated pedigrees (EGPs) in cancer genetic counselling 
(GC) (Stefansdottir, V. et al., 2016). Lastly, we conducted a study on the 
clinical experience of using EGPs. The numerical EGP data was used to 
calculate the optimal size of pedigrees for risk assessment in hereditary 
breast and ovarian cancer (HBOC) genetic counselling (Stefansdottir, V. et 
al., 2018). 
In Iceland, a high-quality cancer registry and an extensive, comprehensive 
genealogy database exist. Within the clinical genetic service there is a 
permission to use both databases for the construction of pedigrees and risk 
assessment. Taking advantage of this, we choose to use EGPs in HBOC 
genetic counselling as a topic in this study due to the number of cases.  
1.1 The family history  
Among the many health conditions from which people suffer, various cancers 
are common (Bray, F. et al., 2018). Pathogenic inherited germline genetic 
variants are thought to be the cause of about 5-10% of all cancers (The 
National Cancer Institute 2017; Tomasetti et al., 2017).  
The family history once kept on scrolls, or perhaps the first page of the 
family Bible has gradually made its way into medicine. The journey from 
merely recording the growing number of kin as the family got more extensive, 
to using the pedigree to determine the risk of an inherited disorder is long and 
winding, yet illuminating. Several important stages in its evolution are:  
Vigdís Stefánsdóttir 
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• Recording the growing number of kin, either orally or written on skin 
or paper. As examples, the Maoris made an art-form of reciting their 
Whakapapa, the layered order of their genealogies (R.N., 2001), 
while Icelanders used the hide of animals to write on and record their 
information  
• Connecting families into pedigrees, containing more genealogy data 
and understanding that family history could indicate patterns of 
inheritance, was an important step (Eisinger et al., 1998) 
• Adding information to electronic databases, enabling easy access 
and using the data in various ways to interpret inheritance (Faria-
Campos et al., 2015; Roque et al., 2011).  
Familiarity with one’s family history holds value for both the identification 
of relatives and the possible inheritance patterns of familial disorders. Well 
documented family history, including medical information, can help identify 
those at risk of familial disorder (Brennett, 2010; Robson et al., 2015).  
The recognition of the inheritance of disorders through family history is an 
old story. In the old Babylonic Talmud, quoted in “Innocent Blood: A History 
of Hemorrhagic Disease of the Newborn” (United Nations - Economic and 
Social Council), a reference exists to what is believed to have been 
haemophilia. Presumably, the children in question are boys: 
 “If she circumcised her first child and he died, and a second one 
also died, she must not circumcise her third child” (Obladen, 
2015).  
Early in the 20th century, A.E. Garrod published a paper in The Lancet 
titled “The incidence of alkaptonuria: a study of chemical individuality” 
(Garrod, 1996) where he described several cases of alkaptonuria within the 
closely related kinship. In this paper, he acknowledged the interpretation of 
William Bateson that the mode of inheritance of the disease seemed to follow 
a recessive inheritance pattern. Bateson was a Mendel protagonist and had 
corresponded with Garrod a few times about his research (Garrod, 1996).  
One of the earliest known documentation of a family history of hereditary 
breast cancer was published in Mémoires de l’Académie Royale de Chirugie 
(1757) and referenced in The Lancet (Eisinger et al., 1998). The paper 
described how the surgeon, Le Dran, told a story from a colleague who had 
recently diagnosed one of his patients, a 19-year-old nun, with breast cancer. 
She had refused mastectomy as she believed that she would die from her 
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disease, just as other people in the family had. Her prediction turned out to 
be correct (Eisinger et al., 1998). Much later, the Breast Cancer Gene 1 
(BRCA1) was linked to early-onset breast cancer (Hall et al., 1990; Margaritte 
et al., 1992). 
Others shared similar stories. In 1895, Alfred Warthin, who was a medical 
doctor at the University of Michigan in 1892-1931 (Warthin, 1913), discovered 
that his seamstress was very depressed and asked her why. She believed 
that she would die of cancer either in the gastrointestinal tract or her female 
organs, as so many in her family had done before her. Warthin became 
interested in her story and compiled her pedigree with the aid of a tumour 
registry at the University. He confirmed the family history and that the 
cancers she had described had indeed been known in her family for at least 
four generations. The seamstress herself died of metastatic endometrial 
carcinoma at an early age. In an article published in 1913, Warthin described 
her family as “Family G”, underlining how cancer appeared to have a strong 
familial component (Warthin, 1913).  
Henry Lynch was a resident of Internal Medicine University of Nebraska 
College of Medicine, Omaha in 1962. He visited a patient who told Lynch that 
he would die from colorectal cancer as it was highly prevalent in his family. 
This belief later proved to be correct, and the patient died as he had 
predicted. When a pedigree was made for his family, it showed segregation 
not only of colorectal cancer but also ovarian and endometrial cancers. From 
this family, the cancer syndrome, which later became known as Lynch 
syndrome, was documented for the first time (Lynch et al., 1966).  
Nathan et al. (2016) concluded that family history is still important in order 
to assess the risk of a familial disorder (Nathan et al., 2016). Genetic and 
genomic technology has advanced to the point where the entire sequence of 
a person’s genome can be studied (Aworunse et al., 2018; Heather & Chain, 
2016). As the science of genomics advances, the question of whether family 
history has a role in genetics has risen. In this context, one might ask if it is 
enough to sequence the genome, without the family history. In 2012, Pyeritz 
concluded that family history was still relevant in the light of genomic 
medicine to bridge the knowledge gap between the outcome of genetic 
testing and phenotypes. The article states that the family history needs to be 
reviewed as a clinical tool, for its validity and utility (Pyeritz, 2012). 
Further, Reuter (2018) in concluded that family history continues to have 
an important role in predicting the risk associated with specific variations in 
the genome (Pyeritz, 2012; Reuter et al., 2018). The above examples show 
that the application of family history in genetics is far from being irrelevant 
and has evolved. 
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1.2 Guidelines for a clinical family history  
In genetic counselling, family history is usually presented as a pedigree with 
standard nomenclature and symbolism (Bennett, 2012). Women are 
demonstrated as circles and males as squares. Affected family individuals 
are indicated with either a pattern or colour within the symbol. Documentation 
of three generations of the family is in most cases essential to determine the 
inheritance pattern in the case of Mendelian disorders. In Figure 1, degrees 
of relatedness for 1-3°of relatedness are explained. In a genetic health 
service, the gold-standard pedigree includes at least three-generations or 3° 
of relatedness if possible (National Institute for Health and Clinical 
Excellence, 2013) (NCCN, 2016). The third-degree pedigree is notably more 
extensive than the three-generation pedigree. 
Several guidelines exist on the size and content of a pedigree for risk 
assessment in cancer genetic counselling. The two most commonly used are 
the guidelines of the National Health and Care Institute (NICE) in the UK and 
National Comprehensive Cancer Network in the US (NCCN) (National 
Comprehensive Cancer Network, 2018; National Institute for Health and 
Clinical Excellence, 2013). The NICE guidelines for HBOC assessment are 
slightly different for individuals depending on if they have a personal history 
of cancer or not and whether the family history is obtained in primary or 
secondary care. In primary care, the recommendation is that a first- and 
second-degree family history should be taken, while in secondary care, such 
as in genetic services, third-degree family history is recommended. The third-
degree family history on both paternal and maternal side should include the 
age of diagnosis, type and site of tumours, the age of death, the current age 
of unaffected relatives and if relevant, whether the counsellee belongs to a 
population with known founder pathogenic variants in cancer genes. The 
NCCN guidelines recommends taking a third-degree expanded family history, 
including medical history on both paternal and maternal side, with attention to 
close relatives who have cancer. The pedigree information should include 
First-degree relations are parents, children and full siblings. Second-
degree relations are comprised of grandparents, aunts/uncles, 
nieces/nephews, grandchildren, and half-siblings. Third-degree 
relations include great grandparents, great grandchildren and first 
cousins. 
Figure 1. Degrees of relatedness. 
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types and sites of cancer, primary cancers pathology reports and the age at 
diagnosis. These guidelines are similar, although the NCCN guidelines ask 
for more detailed medical history. For clinical practice, the collection of 
relevant documents can be time-consuming. However, it can be challenging 
to assess the risk appropriately in the absence of adequate family and 
medical history.  
1.2.1 Barriers in collecting family history  
Collecting family information from counsellees in order to make an extensive 
pedigree in a cancer clinic may not always be possible. This can be in part 
due to lack of staff, full schedule and the limited clinical time allowed for such 
work (Ozanne et al., 2013). To determine the completeness of family history 
in medical records, Wood (2014) reviewed records for over 10,000 patients 
from 212 practices in the United States of America (USA). They found that 
first-degree cancer family history had been recorded for nearly 80% of 
patients with breast or colorectal cancer, and almost 65% for second-degree 
family history. Only 32.9% of patients with breast cancer and 22% with 
colorectal cancer had a complete family history, comprised of the type of 
cancers, age at diagnosis, dates of birth and dates of death (Wood et al., 
2014). 
Other known barriers for obtaining a large enough family history are small 
family size, limited knowledge of family history, or a lack of communication 
within the family (K. et al., 2003). As families grow, it may be more difficult for 
family members to obtain information about each other. Therefore, people 
may have less information about more distant relatives than closer ones 
(Augustinsson et al., 2017; Chang et al., 2006).  
To be able to provide an appropriate family history in cancer genetic 
counselling, counsellees must understand what kind of information is 
required. Lim & Hewison (2014) found that little over half (54%) of 300 
participants, all members of the staff at the Faculty of Medicine and Health, 
University of Leeds, United Kingdom (UK), understood the meaning of clinical 
family history and the extent of information required. Some of the other 
participants in the study erroneously believed that step-parents and their 
siblings, in-laws, spouses and even friends and colleagues were relevant to 
the clinical family history (Lim & Hewison, 2014). Considering the 
participant´s workplace, it is interesting that nearly half did not understand the 
meaning of clinical history fully. No similar study with a different population 
was found for comparison, but it would be interesting to study.  
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1.2.2 The clinical family history 
Exome and whole-genome sequencing have become more common in 
genetic testing. Those methods can lead to the identification of pathogenic 
variants (Gong et al., 2018; Ku et al., 2016). In this context, the importance of 
family history in genetic counselling must be evaluated. Further, a reason for 
assessing family history in genetic counselling could be to ensure the efficient 
use of resources by, i.e. indicating if genetic testing is needed and who would 
be the best candidate for testing.  
In the case of familial cancer, family history can prove informative of likely 
future cancer types in family members. In such cases, the family history can 
assist in the design of appropriate clinical surveillance and risk reduction 
strategies (NCCN, 2016). Supporting this, Nathan (2016) states that high-
quality and comprehensive pedigrees remain relevant at this time (Nathan et 
al., 2016).  
Several methods are used to record family history in clinical settings. One 
common way is to send questionnaires to the person who is coming to the 
service (Armel et al., 2009). When finished, the counsellee returns the 
questionnaire which is then used to outline a pedigree, and document the 
family history before the counselling session. Issuing questionnaires to the 
counsellee for completion allows them to seek genealogy information from 
their relatives before their clinic appointment, which has proven to be an 
efficient way of obtaining data (Armel et al., 2009). Another method is 
interview via telephone, where a professional and a counsellee, discuss the 
family history prior to the counselling session. There are also numerous 
electronic tools available for family history collection. Welsch et al. (2018) 
compared and reviewed 17 available electronic family health history (FHx) 
tools. Some of them allow patients to collect and record their FHx, thus 
reducing the time and work of the professionals in question. The authors 
concluded that the various tools had different approaches for collecting the 
family history, adding familial connections and providing disease information. 
They underscored the need to standardise these tools, and to enable 
integration with electronic hospital records (EHR). As the study only used 
FHx tools available in mid-2017 and due to the constant change in the 
availability of tools, the authors planned to keep an active inventory of such 
tools on the Global Alliance for Genomics and Health website (Welch et al., 
2018). Using electronic databases enables for safe storage and electronic 
documentation of all changes (Mahon, 2016). However, the information 
collected into the FHx tools are usually provided by the counsellee or 
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counsellees, and medical history must be confirmed. The relevant healthcare 
services need to confirm the history following consent from the individual in 
question. 
During the counselling session, family history can be further explored. If 
none has been collected prior to the in-clinic appointment, the counsellor can 
draw a pedigree on a paper. In my experience, in the Icelandic settings, 
drawing a pedigree in the clinic is helpful as it offers the opportunity to 
connect with the counsellee or family, establishes a relationship and enables 
for a better understanding of the family dynamics.  
1.3 Electronically generated pedigrees (EGP´s) in Iceland 
In the genetic counselling service at Landspitali, accurate genealogy- and 
tumour information can be available in a ready-made EGP at the time of the 
clinical visit (Stefansdottir, V., Arngrimsson, et al., 2013). Since 2007, the 
genetic services at Landspitali have been  premitted to use genealogy 
information from The Genetical Committee of the University of Iceland 
(GCUI) and the Icelandic Cancer Registry (Sigurdardottir et al., 2012) to 
construct electronically generated pedigrees (EGPs) in order to establish a 
family history of cancer (Stefansdottir, V., Arngrimsson, et al., 2013). Initially, 
the pedigrees were small, with three generations and one pedigree for both 
sides of the family of the counselee. The first EGPs were similar to the hand-
made pedigrees but differed in the amount and source of information. The 
pedigree size and degree of relation varied according to the age of the 
counselee. Younger people usually had smaller pedigrees than older ones.  
The workflow constructing pedigrees in the Icelandic cancer genetic 
counselling service at Landspitali was and is as follows: The counsellee 
consents in writing to have a pedigree constructed. If another member of the 
family has already been to genetic counselling and given consen, some of 
the family information may already exist. Due to the size of the pedigrees, a 
relationship with a distant former counsellee with a known pathogenic variant 
can sometimes be observed. The consent form goes to the GCUI where the 
pedigree information is composed. Then the Icelandic Cancer Registry 
(Sigurdardottir et al., 2012) adds relevant tumour information. Pedigree 
information is never disclosed to counsellees during counselling 
(Stefansdottir, V., Arngrimsson, et al., 2013; Stefansdottir, V. et al., 2016; 
Stefansdottir, V., Johannsson, et al., 2013). The EGPs tend to be quite large, 
with the most common size between 3-500 individuals. Therefore, an overlap 
is considerable, and individuals can appear in many pedigrees.  
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During the initial clinical visit, a conventional pedigree is most often first 
made by hand to clarify the counsellee´s knowledge of the family history and 
to gain insight into new, unrecorded cancers in the family. A handmade, 
conventional pedigree can be seen in Figure 2. This is partly because the 
ICR has about 12 months lag in reporting of cases. It is also helpful for the 
counsellor to do a handmade pedigree to explore the counsellee´s 
expectations, prior experiences, and family dynamics. These pedigrees are 
usually not used for risk assessment, except in the rare cases when no 
electronic information is available for constructing an EGP. Should any 
additional cancer information be documented in the handmade pedigree, the 
counsellor tries to verify the information to be able to use it in the risk 
assessment. Such information could be a newly diagnosed relative or a 
relative diagnosed abroad and not included in the Icelandic cancer registry. 
However, this is unusual, and it may be difficult to verify diagnosis made in 
other countries. In those cases, the official information is used for the risk 
assessment, but the additional information kept in mind when risk and 
surveillance are discussed. 
1.4 Presumed consent 
In genetic counselling, the counsellee provides information about other family 
members, usually without explicit consent from most or all the relatives, i.e. 
the consent is presumed. The family history information is used for risk 
Figure 2. A fictional example of a handmade pedigree. 
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assessment on the assumption that the process could benefit the counsellee 
and possibly other family members. The information is kept secure (similarly 
as medical information within health care) to ensure minimum risk of harm.  
In medical genetics services, family history can be shared between 
professionals when needed, without consent from family members. This 
information may be used to assess risk for diagnosis or to help with 
surveillance or treatment (Lucassen & Hall, 2012). In the REFORM report in 
2018, data collaboration between practices was noted that:  
“... when GPs and hospitals share information, they can identify 
which patients are most at risk of unnecessary hospital 
admissions, reducing admission by up to 30 per cent. Better 
information sharing between mental health nurses and police 
has seen the number detained for mental health issues reduce 
by 80 per cent in some areas.” (Sarah Timmis S, 2018). 
Extensive research databases form the foundation of genetic population 
studies and bio-banks. In many scientific studies, the use of presumed 
consent for genealogy, genetic, and other medical information is considered 
acceptable and ethical. (Bauer, 2014; Brewster et al., 2004; Trivedi, 2008; 
Wylie & Mineau, 2003).  
1.5 Genealogy 
The personal wish to learn one´s origin is common. People have 
systematically recorded their family history, either orally or in writing, for 
thousands of years. The Book of Genesis provides a precedent in its record 
of one of the earliest recorded genealogical accounts: 
“Cain knew his wife, and she conceived and bore Enoch, and he 
built a city, and named it Enoch after his son Enoch. To Enoch 
was born Irad, and Irad was the father of Mehujael, and 
Mehujael, the father of Methushael, and Methushael the father 
of Lamech. Lamech took two wives; the name of the one was 
Adah, and the name of the other Zillah”, (Genesis 4:17). 
One very well-established and extensive family history is that of Confucius 
(551-470 BC). It is the most extensive known genealogical history in the 
world, according to the 2005 Guinness Book of World Records (Jim Patttison 
Group, 2005). Initially written by hand, the Confucius Genealogy was printed 
in 1080 AD and has been revised five times since, each time with an 
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accurate listing of all family members (China.org.cn, 2008). Korea has a very 
long history of keeping family records and many families trace their lineage 
back 700 years or more based upon the male family line, as described in the 
South Korea Genealogies website (Howard, 2012). The registries are named 
JokBo - in Korean , 족보. Many Korean families publish their personal 
records on the Internet. This is partly done to cherish the family history and 
also to acknowledge that these records are a national treasure (Howard, 
2012). Other interesting and long-term genealogy can be seen in the family 
history of the Royal Family of Japan, where one´s status has been 
determined according to place in the family tree (Agency, 2010) (Agency, 
2010).  
The Maoris have a strong sense of community, and in most families, 
someone is designated responsible for the collection and upkeep of the 
genealogy records. Initially recited orally, now many are kept on paper or 
electronically. Maoris can trace their ancestry back 30 generations or more in 
their ‘Whakapapa.’ The word whakapapa means to place something in 
layers, which is an appropriate description of genealogy (R.N., 2001).  
Figure 3. Landnámabók - Book of Settlement. Published by Helgafell 1948. Photo by 
author. 
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In Ireland, the old Leabhar na nGenealoch, or book of genealogies, 
contains an extensive collection of Irish genealogy data. It has notes on 
families from all parts of Ireland - of Viking, Gaelic and Old English origin 
(Firbishigh, 1649) - and gives a detailed description of the genealogy and 
names of settlers.  
Collection of family histories for personal or public use, has for a long time 
been a favourite interest in Iceland (Palomba et al., 2009; Palsson, 2002). In 
private and public libraries, a fair number of small and large genealogy books 
are available, allowing those interested in researching family histories. 
Initially, records of family history were kept for tracking assets and 
relationships. Examples can be seen in the Book of Settlement 
(Landnámabók Íslands), (Figure 3). The book includes a comprehensive 
overview of the settlement of Iceland in the 9th century and provides 
information regarding the distribution of land and assets. However, it is 
believed that much of what is described in the book, happened at least 200-
400 years before it was written (Jóhannesson, 1941; Tulinius, 2011). 
Icelanders began using paper in the 15th century. Until then, vellum, which 
is a prepared animal skin from sheep, goats or calves, was commonly used 
to write on (Gunnlaugsson, 2017). Many of the old scripts have been 
compiled and digitised and can be found at the website www.handrit.is and in 
museums such as the National Museum of Iceland. 
In 1746, priests were ordered to keep parish records, through which they 
kept track of marriages, deaths and births (Hallgrímsson, 1934). These 
preserved parish accounts have proven to be an invaluable resource for the 
development of genealogy records.  
1.5.1 Genealogy databases 
Although large electronic genealogy databases exist online, access to most 
of them requires at least some form of registration. Many require fees for 
access. (Ancestry, 1997; NextAdvisor, 2016). Some examples of large online 
genealogy databases are: 
• Scotland´s People database: an extensive genealogy database, 
holding much of Scotland´s birth, death, marriage, census and other 
information. Its statutory registers go back to 1855, the census back 
to 1841, and some of the church registers go back to 1560 (General 
Register Office for Scotland, 2007; Scotland, 2017).  
• Ancestry.com, a for-profit genealogy company which also offers 
direct-to-consumer genealogical DNA tests. It has over 11 billion 
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connections, 100 million family trees, and 20 billion records from at 
least 80 countries (http://www.ancestry.com, retrieved 16.08.16).  
• FamilySearch is an extensive public database, widely accessible and 
run by the Church of Jesus Christ of Latter-day Saints. The 
FamilySearch has gathered genealogical records worldwide for over 
100 years and at present, has over 4 billion names in its databases 
(The Church of Jesus Christ of Latter-day Saints, 2016).  
• The Verein für Computergenealogy, is not in itself a database but a 
significant genealogy portal for German genealogy databases. 
Retrieved from http://www.compgen.de, 2018.  
• Geneanet, launched in 1996, is a searchable database of genealogy 
records, genealogy societies and commercial genealogy companies. 
Most of the data is free to access, but some of the content is charged 
for, according to the decision of the submitter. Geneanet can be 
found at the website http://en.geneanet.org.  
• Cyndi´s list is a comprehensive genealogy research site with an 
index to online genealogical resources. (https://www.cyndislist.com, 
retrieved on 06.08.16).  
Databases holding medical and genealogy information are also available 
online. One example is the Utah Population Database (UPDB) with restricted 
access to scientists. It comprises genetic, demographics, medical and 
epidemiological information for over 9 million people (Huntsman Cancer 
Institute at the University of Utah, 2016; Niazi et al., 2010). Another extensive 
database is the Anabaptist Genealogy Database of Old Order Amish of 
Lancaster County. This database was formed to map pathogenic genetic 
variations within the Lancaster Amish (Agarwala et al., 2003b). A third 
example is the Icelandic deCODE genetics database, comprising extensive 
medical, genealogical and genetic information on Icelanders (Helgadottir et 
al., 2018).  
1.5.2 Icelandic genealogy databases  
Over time, some of the Icelandic genealogy records have been organised 
into electronic databases, both private and public. Some of the largest ones 
include The Icelandic Genealogy Society (The Icelandic Genealogy Society, 
2016), as a source of comprehensive data, and the IcelandicRoots database, 
which was initiated by Hálfdán Helgason, an Icelander with a keen interest in 
genealogy. The Icelandic Roots Heritage Organization in Fargo North 
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Dakota, USA now runs it. It is regularly updated and contains information on 
Icelanders living in Iceland and those who have emigrated, primarily to 
Canada and the USA (Icelandic Roots, 2016). Islendingabok (Book of 
Icelanders) at DeCODE Genetics, is particularly thorough. It is accessible, 
with restrictions, to anyone with an Icelandic ID number (Stefansson & 
Taylor, 2006). Unlike the databases mentioned above, the Genealogical 
Institute (ORG ættfræðiþjónusta) does not have a database accessible on the 
Internet, but, upon request, staff will help find genealogy information about 
Icelanders and those who have emigrated to Canada, USA and Brazil (Oddur 
Helgason, 1999). 
A large population-based genealogy database, (GCUI), in Iceland, has its 
origin in the great interest of genetics in the Western world following the 
Second World War. In the USA, specifically, one subject of interest was the 
relationship between the exposure of radiation and mutations during the 
height of the Cold War (Tulinius, 2011). Several population geneticists 
congregated to advise the United States Atomic Energy Commission (US 
AEC) on to the most efficacious means of performing research on the 
subject. At the time, some of these geneticists knew that Iceland had an 
isolated and concentrated population – an ideal environment for observation. 
One of the geneticists, Professor Luca Cavalli-Sforza, was also aware of the 
extensive genealogy information kept within the country, as well as the 
general interest in genealogy held by the nation (Olafsdottir, 2016). In 1965, 
the GCUI was formed with funds from the US AEC and has served since as a 
non-profit organisation (Olafsdottir, 2016; Tulinius, 2011). To ensure the 
exact relationship in families, a so-called, “mothers record,” was created for 
each mother, linking her to each of her children, as well as providing 
information on the father of the children (Tulinius, 2011). Initially, the 
database was generated from the information collected during the 1910 
national census; birth records, death certificates, as well as information from 
the censuses from 1703 onwards. It contains records of Icelanders that lived 
as far back as the 1800s. Additionally, information was obtained from parish 
records created between the years 1840-1910. The database was 
computerised and linked to the National Registry in 1953 (Tulinius, 2011). 
One of the primary objectives of the Genetical Committee has been to link 
the demographic data of Icelanders into pedigrees for genetic studies, both 
large and small, but it also aims to help those who have an interest in 
genealogy, or those with a need to access genealogy information, such as 
priests and lawyers (Olafsdottir, 2016; Tulinius, 2011). In 2007, the Data 
Protection Authority approved the use of the database in genetic health 
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services at Landspitali Hospital, as can been seen in more detail in the 
section on genetic counselling (Stefansdottir, V., 2016b).  
1.5.3 Collection of genealogy data from the Internet 
The Internet is a vast source of genealogical data as can be seen in Figure 4, 
where many of the sources are demonstrated. In addition to the information 
provided via the databases mentioned above, collection of genealogy data 
from the Internet has proven to be successful. Kaplanis et al. (2018), 
understanding the importance that family trees have in many fields, used 
publicly available online data to collect over 86 million individual profiles. Both 
demographic information and geographical locations were extracted from 
online sources. For further evaluation, data on ~80.000 individuals, from the 
Vermont Department of Health were collected and compared to the dataset. 
The result was a pedigree containing 13 million individuals (Kaplanis et al., 
2018).  
The ongoing Veterans Genealogy Project is an extensive collection of 
genealogical data with linkage to phenotypic data (Cannon-Albright et al., 
2013). The aim of the project is to create a genealogy/biomedical database of 
US citizens. In 2013, the database held genealogy data for over 22 million 
individuals in some areas of the US and was regarded to be the most 
extensive genealogy and medical data combination in the world. The Internet 
is the primary source of data for this project (Cannon-Albright et al., 2013).  
As commercial genealogy DNA databases grow, with the voluntary 
submission of DNA and family history, the likelihood of finding related 
individuals in one of them increases. Such data has already been used to 
solve crimes, and the associated ethical issues are being debated widely 
(Court, 2018). Users or consumers of direct-to-consumer sites may not 
realise that their data can be used for solving crimes (Forensic Genetics 
Policy Initiative, 2017; Samuel et al., 2018). 
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  Figure 4 Geneology data, collected from the Internet 
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1.6 Census 
The Statistical Division of the United Nations Economic Commission for 
Europe defines a population census as:  
“…the operation that produces at regular intervals the official 
counting (or benchmark) of the population in the territory of a 
country and its smallest geographical sub-territories together 
with information on a selected number of demographic and 
social characteristics of the total population (United Nations - 
Economic and Social Council), in 2015 conference of European 
Statisticians Recommendation, page 5).”  
Likely the most famous census mandate, at least in Western countries, 
was the one described in the Bible. This story, in the Christmas Gospel, has 
likely been the first introduction to a census to many - the registration of every 
human being in a predefined area.  
“In those days, a decree went out from Caesar Augustus that the 
whole world should be enrolled. This was the first enrolment 
when Quirinius was governor of Syria. So all went to be enrolled, 
each to his own town” (Luke 2:1-6, English Standard Version). 
Numerous large and small censuses have since been done for civilian, 
economic and military reasons. The first nationwide census of an entire 
country took place in 1703 in Iceland (Tulinius, 2011). The description of the 
motivation behind the census was:  
“to assemble a true accounting of all families in that country, 
from the best to the lowest person, in which shall be specified 
and explained the husband's and the wife's name, their children, 
and friends' names who at their home, also all servantmen, 
servant youths, servantwomen and girls, in summa no one 
omitted great and small, young and old, who are to be found in 
the whole country, wherewith the large number of poor at each 
location must be precisely observed and described.” 
(Gudmundsson, E. G., 2015). 
At the time, the entire population of Iceland numbered only about 50,000 
persons. All information from the census still exists, although some of the 
original documents have now been lost (Tulinius, 2011). In Hagskinna, The 
Icelandic Historical Statistics, the following information can be found 
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(translated by VS): In 1769 the next census was undertaken in the whole of 
Denmark. As Iceland was under the authority of Denmark at the time, the 
census was also applied to Iceland. After that, a census was undertaken in 
1801 and then every five years between 1835 -1860. After 1860, censuses 
were done in Denmark every ten years. Information from the Icelandic 
censuses was assessed in Iceland, instead of Denmark, from 1910. A 
nationwide census was performed regularly every ten years in Iceland until 
1960. The last conventional census was undertaken in 1981 (Guðmundur 
Jónsson, 1997). In 2011, a new type of census was completed using only 
electronic information available from the National Registry. The demographic 
information has been collected electronically since 2011 (Iceland, 2016b).  
1.7 National population registries 
Most Western countries have national registries containing similar 
demographic information. The information generally includes names, dates of 
birth, dates of death, unique identification numbers, addresses, relationship 
statuses and other relevant information. The Nordic countries all have 
National Population Registries with regular updates (CPR-kontoret; Ekbom, 
2011; Hagstofan, 2007; Population Register Centre, 2006; Registers Iceland, 
2018; Skattedirektoratet, 2007).  
The Icelandic National Registry (Þjóðskrá) was established in 1953 
(Tulinius, 2011). Everyone born in Iceland is registered at birth, and all who 
immigrate to the country are registered as well. Similar to other Nordic 
countries, Icelanders are identified in the registry by a national identification 
number (kennitala), a number composed of the date of birth in the format 
ddmmyy and four additional generated digits. The third digit is a control digit, 
and the last one indicates the century in which the person was born; 9 for the 
1900s and 0 for the 2000s (Iceland, 2016a). Companies and institutions are 
also provided identification numbers (The National Registry, 2016). Similarly, 
all bank accounts are inextricably linked to the national identification number 
of the owner. The National Registry is the basis for electoral registers 
(Ministry of Justice and Human Rights, 2016), such that the identification 
number is required in order to vote.  
1.8 Cancer registries 
Cancer registries can be hospital-based, pathology-based or population-
based as well as hereditary registries. Cancer registries register information 
about cancer and tumour diseases in a defined geographically population 
(Tyczynski, 2003). They are key data providers for monitoring cancer burden. 
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In order to establish a cancer registry, reliable sources of information and a 
system for collecting clinical and pathological data hast to be in place. The 
collected information includes demographic information, medical history, 
diagnosis, age of onset, pathology, haematology, cytology, and tumour site 
(Bray, et al. 2014). From the data, various statistics, such as incidence, 
survival and mortality rates, are published (Forsea, 2016). Population-based 
cancer registries (PBCR), are available in over 700 countries. Some 
countries have separate regional cancer registries, covering a specific area 
(Parkin, 2006). Germany was first to set up a population-based cancer 
registry in 1926 (Isabel dos Santos Silva, 1999). Since then, cancer registries 
(national or regional-based, population-based, hospital-based, or pathology-
based), have been established in many countries (Rodolfo Saracci and 
Christopher P. Wild, 2015). In most Western countries, registration into 
PBCRs is mandatory. 
Hospital-based cancer registries are generally used to keep and maintain 
diagnostic data on cancer patients in one or more hospitals. These registries 
differ in purpose and use from national or regional cancer registries as data is 
collected on patients only (Ringborg et al., 2008). Some of the first such 
registries were a bone-sarcoma registry which Dr Ernest Amory Goodman 
described in an article published in the American College of Surgeons 
Bulletin, in 1924, reprinted in 2009 (Codman, 2009). Another one was the 
hospital-based cancer registry at Yale-New Haven Hospital in 1936 (Missouri 
State Tumor Registrars Association, 2018). Further, in St. Marks Hospital in 
Middlesex UK, the Polyposis Registry initiated the collection of data on 
polyps in 1924. Numerous colorectal and polyposis hereditary cancer 
registries have since been created following this trend (Rothenmund et al., 
2013). Hereditary cancer registries help find individuals and families with 
specific hereditary cancers.  Examples of hereditary cancer registries are the 
Breast Cancer Family Registry in the USA, which as the name implies, 
focusses on breast cancer (Breast Cancer Family Registry, 2017). In the 
Netherlands, the Dutch Hereditary Cancer Registry was established in 1985 
with the aims of finding families with hereditary cancer, to encourage 
surveillance of high-risk individuals and promote research on improving 
surveillance protocols (Vasen et al., 2016). In general, hereditary cancer 
registries have diverse functions such as providing a basis for screening and 
surveillance recommendations, maintaining up-to-date information for 
families and health professionals, promote research, as well as to facilitate 
referral to genetic counsellors. The information is also used to assist with 
patient and family enrolment in research studies (Vasen et al., 2016).  
Introduction 
19 
1.8.1 The Icelandic Cancer Registry 
 “In order to succeed in this fierce battle, one must acquire 
knowledge about the enemy”. Professor Niels Dungal 1949.  
Professor Niels Dungal, in 1949, asked all Icelandic doctors for information 
and documentation concerning all their cancer patients (Jon Gunnlaugur 
Jonasson and Laufey Tryggvadottir, 2004). Dungal, who was a professor in 
pathology at the University of Iceland, became the first chairman of the 
Icelandic Cancer Society in 1951 (Tryggvadottir, 2014). The ICR 
has registered all instances of cancer in Iceland since May 10th 1954, and as 
a nationwide population registry, it contains comprehensive information. In 
2007, the ICR attained legal substantiation as one of the population-based 
health registries authorised by the Icelandic Directorate of Health and cancer 
registration was made mandatory (Sigurdardottir et al., 2012). The Icelandic 
Cancer Society continues to run the registry according to an agreement with 
the Directorate of Health, and electronic methods are used to collect and 
maintain most of the information. The completeness of the registry lies at 
around 99.15% (Sigurdardottir et al., 2012). 
The ICR collects tumour information from pathology and haematology 
laboratories, as well as from hospitals and other healthcare facilities. 
Information is also received and analysed regarding cancers notified on 
death certificates and in the population-based hospital discharge registry. 
This information relates mainly to clinically diagnosed cancer. In addition, 
cases of breast cancer have been registered since 1911 (Icelandic Cancer 
Society, 2016) as part of a broader study by G. Snaedal, who collected 
extensive information on breast cancer diagnosed between 1911-1965 
nationwide (Snaedal, 1965).  
The ICR and the clinical genetic services have developed a close, working 
relationship due to their collaboration (Stefansdottir, V., Arngrimsson, et al., 
2013).  
1.9 Risk assessment programs 
Several breast cancer risk assessment programs are available. The majority 
of them relate to the assessment of breast cancer risk in families with a 
history of breast and ovarian cancer, such as the Gail model or the Breast 
Cancer Risk Assessment Tool (National Cancer Institute, 2017). It is free to 
use and can be accessed on this website: https://www.cancer.gov/bcrisktool. 
In a recent article, the Gail model was shown to predict female breast cancer 
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better in American and European population than in the Asian population 
(Wang et al., 2018). Another risk assessment program is the Tyler-Cuzik or 
IBIS Breast Cancer Risk Evaluation Tool, which uses family and medical 
history to assess the likelihood of having a pathogenic mutation that can 
increase breast cancer risk. The program, which is only available for 
Windows™, can be downloaded from the website: http://www.ems-
trials.org/riskevaluator.  
BOADICEA, Breast and Ovarian Analysis of Disease Incidence and 
Carrier Estimation Algorithm, is a program developed in Cambridge UK. It is 
used to calculate the risk of the probability of having a pathogenic variant in 
several genes such as the BRCA1, BRCA2, PALB2, CHEK2 and ATM genes. 
It also calculates the risk of getting breast or ovarian cancer based on family 
history. However, at the time of the study, only the BRCA genes were 
included. BOADICEA is free to use and can be assessed online with a user 
account (Jervis et al., 2015). The BOADICEA program was chosen for the 
risk assessment in cancer genetic counselling in Iceland, mainly due to its 
performance in comparison with other similar programs (Terry et al., 2019). 
Other reasons included the possibility of a plug-in to the pedigree program 
PedigreeAssistant, used for the construction of pedigrees. Moreover, the 
authors were ready to help to adapt the program to the Icelandic situation.  
1.10 Breast cancer 
Cancer treats everyone the same – the rich and the poor, the slave and the 
queen. In Bathsheba´s Breast: Women, Cancer, and History, James Olson 
followed the history of breast cancer through the ages. The story began in 
490 BC when queen Atossa found a lump in her breast and ends in the 
modern era, where genetic tests determine the type of breast cancer and 
help with the treatment (Byler et al., 2014; Olson, 2002).  
The incidence of breast cancer in women in Western countries is high, 
with one in every eight women is diagnosed with the disease in their lifetime 
(World Health Organizaition, 2016). The National Comprehensive Cancer 
Network (NORDCAN) database (Engholm G, 2016) has information 
concerning cancer incidence and distribution in Nordic countries and shows a 
similar trend in these countries regarding breast cancer. Figure 5 shows the 
age-standardised rates over time for incidence and mortality cancer in 
Iceland from 1960-2016.  
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Breast cancer rarely occurs in males (Abdelwahab Yousef, 2017; 
Fentiman, 2009; Liu et al., 2018). However, those with the Icelandic founder 
BRCA2 PV, NM_000059.3: BRCA2:c.767_771delCAAAT  have a significantly 
increased risk, up to 69% at the age of 80 (Kuchenbaecker et al., 2017). 
According to information from Cancer Research UK, 250 males in the United 
Kingdom (UK) are diagnosed with breast cancer each year. In the USA, in 
2014, 2141 males were diagnosed with breast cancer (U.S. Cancer Statistics 
Working Group, 2017). According to NORDCAN statistics, 149 males were 
diagnosed with breast cancer in 2012-2016 in the Nordic countries. This 
number accounts for 0.6% of all new breast cancers. In 2013-2017, the age-
standardised rate per 100.000 (W) in Icelandic males was 1.1 as opposed to 
86.8 in women (Icelandic Cancer Society, 2016).  
On average, a little over 210 women were diagnosed in Iceland with 
breast cancer each year from 2013-2017 (Icelandic Cancer Society, 2018). 
Breast cancer accounts for about 27% of all cancers diagnosed in Icelandic 
women (Table 1). In contrast, three males were diagnosed with breast cancer 
on average per year in the same period (Icelandic Cancer Society, 2018). 
Approximately 40% of the males diagnosed with breast cancer in Iceland 
carry the Icelandic founder BRCA2 PV (Giordano, 2005; Thorlacius et al., 
1995), hereafter referred to as the Icelandic founder BRCA2 PV. 
 
Figure 5  NORDCAN: Breast cancer incidence and mortality in Iceland 1960-2015. 
Age-specific rates per 100.000 (4.11.2017).  
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Table 1. Breast cancer in Iceland 2013 - 2017 (Icelandic Cancer Society, 2018). 
To date, increased risk of breast cancer has not been observed in males 
who carry the Icelandic founder PV NM_007294.3: BRCA1:c.5074G>A 
(Thorlacius et al., 1995). However, this variant is very rare, making an 
accurate assessment difficult. In general, males with a PV in BRCA1 gene 
have a very slightly higher risk of breast cancer than the general population, 
although the risk is much less than for those with PV in the BRCA2 gene (Tai 
et al., 2007). The average age at breast cancer diagnosis in Iceland was 62 
years for women and 71 years for men (Table I). 
1.11 Hereditary breast and ovarian cancers  
In families with numerous cases of breast and ovarian cancers, there is an 
increased likelihood that it is caused by inherited genetic predisposition. A PV 
in either of the BRCA genes is then most probable (Petrucelli et al., 2010) 
although PV´s in other genes can increase the breast cancer risk as well. 
Among them, each with moderate breast cancer risk associated, are the 
ATM, CHEK2, PTEN, STK11, BRIP1, CDH1, PALB2, RAD51, TP53, BARD1, 
BLM, NBS1, RECQL and XRCC2 genes (Moran et al., 2017; Rousset-
Jablonski & Gompel, 2017); Kurian et al., 2017). Cancers other than breast or 
ovarian are seen in families with hereditary breast and ovarian cancer 
syndromes. Within families with a PV in either of the BRCA genes, cancer 
penetrance is highly variable, depending partly on the gene position of the 
variant and by the change of function caused by the variant (Lesueur et al., 
2018).  
1.11.1 BRCA1 and BRCA2 PVs in the Icelandic population  
In 1965, dr. Gunnlaugur Snaedal, a leading Icelandic obstetrician, published 
an article from his doctoral study. He had collected information on all breast 
cancer cases in Iceland from 1911-1955 (Snaedal, 1965). In 1982, Tulinus et 
al., drew attention to the increased risk of relatives of cancer patients, 
indicating a strong genetic component in some families (Tulinius et al., 1982). 
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In 1989, a study on the polymorphism of the HRAS proto-oncogene gene in 
breast cancer patients was published (Barkardottir et al., 1989). This was the 
first paper where many Icelandic researchers reported their joint efforts to 
identify genetic components that increased the risk of familial breast cancer. 
Results from linkage analysis on Icelandic hereditary breast cancer families 
played an important role in the cloning of the BRCA2 gene. Specifically, the 
Icelandic data contributed to the rapid narrowing of the linkage peak, 
containing BRCA2 gene on chromosome 13q (Arason et al., 1993; 
Gudmundsson, J. et al., 1996; Gudmundsson, J. et al., 1995; Tavtigian et al., 
1996; Thorlacius et al., 1995; Wooster et al., 1995).  
Shortly after the landmark paper by Mary-Claire King and her co-workers,  
in where the BRCA1 gene, located on chromosome 17 was shown to be 
associated with a high risk of breast cancer (Hall et al., 1990), a scientific 
group from Landspitali published a paper supporting this finding (Arason et 
al., 1993). The paper reported chromosome 17q linkage in two of seven 
analysed families. They also showed an original observation suggesting that 
a potential breast cancer gene might also increase the risk of prostate 
cancer. This effect did not appear to be confined to the 17q-linked families. 
This was an interesting observation, especially in connection with results 
from a previous epidemiological study, based on data from the ICR, 
suggesting a relationship between prostate, ovarian, endometrial and breast 
cancers (Tulinius et al., 1992). These Icelandic findings attracted attention, as 
reflected in an editorial in the March 1994 issue of Nature Genetics ("The 
prognosis for prostate cancer," 1994). Later, the high risk of breast and 
prostate cancer in most of the remaining families included in the study by 
Arason (1993) turned out to be due to a PV in the BRCA2 gene 
(Gudmundsson, J. et al., 1995).  
A study on breast and prostate tumours, as well as other tumour types 
from those with a pathogenic variant (van der Kolk et al.2010) in the BRCA2 
gene showed a very high incidence of loss of the wild-type copy of the 
BRCA2 gene in the tumour in all the cancer types studied (Gudmundsson, J. 
et al., 1995). The results, as well as results from other Icelandic studies, 
indicated a 2-3-fold increase of the occurrence of BRCA2 PV in cancer 
patients diagnosed with cancer in organs other than breast and ovary 
(Johannesdottir et al., 1996). These were among the very first results strongly 
suggesting that BRCA2 was a tumour suppressor gene and that it was not 
only involved in the development of breast- and ovarian cancer, but also of 
other cancers (Thorlacius et al., 1996; Tulinius et al., 1992).  
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For almost two decades, only two PVs in the BRCA genes were known in 
the Icelandic population; the BRCA1:5193G->A (Bergthorsson et al., 1998) 
and the Icelandic founder BRCA2 PV (Johannesdottir et al., 1996; Tavtigian 
et al., 1996; Thorlacius et al., 1996). The BRCA1:5193G->A PV is very rare, 
with a carrier frequency of <0.01%, (Rosa B. Barkardottir, personal 
communication) and had until recently only been found in three Icelandic 
breast cancer families (Arason et al., 1998; Bergthorsson et al., 1998). 
Recently, two new families with the BRCA1:5193G->A PV were identified, 
bringing the total number of families to five (Stefansdottir V., unpublished 
data). In contrast, the carrier frequency of the Icelandic founder BRCA2 PV is 
relatively high (0.6-0.8%) (Gudbjartsson et al., 2015; Thorlacius et al., 1997). 
Two studies found the frequency of the variant in Icelandic breast and 
ovarian cancer patients to be about 7%, highest (24-27%) in patients 
diagnosed with breast cancer younger than 40 years of age (Johannesdottir 
et al., 1996; Thorlacius et al., 1996). However, this may be an overestimation 
due to ascertainment bias and has not been established in newer studies. 
The frequency of the Icelandic founder BRCA2 PV is thought to be 
approximately 5% in Icelandic breast cancer patients (unpublished data) 
Recently, by sequencing the BRCA genes, using multiplex ligation-
dependent probe amplification (MPLA) and cancer panel testing, numerous 
additional pathogenic variants have been found in the BRCA genes in the 
Icelandic population. Among them are the pathogenic variants: BRCA1: 
c.386delG, c.981_982delAT, c.4096+3A>G, c.4041_4042del and BRCA2: 
c.8796del (Stefansdottir, unpublished data). However, the Icelandic founder 
BRCA2 PV (formally known as 999del5), remains by far the most common 
BRCA PV in Iceland (Janavicius, 2010). The BRCA1: c.386delG has been 
found in two large Icelandic families, connected by a common ancestor seven 
generations back (Stefansdottir, unpublished data). The BRCA1: 
c.981_982delAT has, to date, been found in only one family (Stefansdottir, 
unpublished data). The BRCA1: c.4096+3A>G has a carrier frequency of 
0.2%. Icelandic data show that this variant carries up to a 3.5-fold risk of 
breast cancer and more than a ten-fold risk of ovarian cancer (Th.R. personal 
communication). To date, through the cancer genetic counselling at 
Landspitali, this PV has been found in four families, all from the same 
geographical area in the country. Two are related by a common ancestor 
eight generations back. This PV has been reported several times in the 
Breast Cancer Information Core (MacInnis et al., 2013), with varied clinical 
significance. The BRCA1: c.4041_4042del and the BRCA2: c.8796del were 
each found in one family. The BRCA2 c.9234C>T has been found in one 
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family, where the Icelandic founder BRCA2 PV is segregating as well. It is a 
benign synonymous variant with the allelic frequency of 0.263% in Iceland 
(Th.R. personal communication). These findings indicate that the carrier 
frequency of all BRCA PV together in the Icelandic population is about 1%.  
1.11.2 Genetic counselling  
The term “genetic counselling” was first used in 1947 by Sheldon Reed while 
serving as a director of the Dight Institute for Human Genetics at the 
University of Minnesota (Reed, S. C., 1957; Reed, Sheldon C., 1974; Resta, 
2006). Reed understood that people had a great interest in how genetic 
diseases affected their family lives and found the need to devise a term to 
describe how individuals and families were helped to cope with effects of a 
genetic disease, without the eugenic overtones common at the time (Resta, 
1997). However, the idea of establishing a formal profession of genetic 
counselling has been credited to Melissa Richter, a professor in the 1960´s at 
Sarah Lawrence College in New York, where the first genetic counselling 
training program was established (Stern, 2009). Genetic counsellors, as 
genetic health professionals, are trained to help their counsellees understand 
genetics, assist in making risk assessments, and advise on testing and 
surveillance. The profession´s primary purpose is to assist those in need of 
genetic information (Paneque et al., 2001). They help facilitate accurate 
diagnoses, discuss the appropriate options for testing or reproduction, and 
offer psychosocial support to families using the service. Genetic counsellors 
have advanced training in counselling and genetics in order to interpret 
genetic test results and explain the results to the counsellee (Rantanen et al., 
2008). They ideally work within teams comprising medical geneticists, genetic 
nurses and clinical laboratory scientists working in molecular, biochemical 
and cytogenetics laboratories (Rantanen et al., 2008). A Master level degree 
in genetic counselling from an accredited program is the required training for 
new genetic counsellors in both Europe (Ingvoldstad et al., 2016) and the 
United States (National Society of Genetic Counselors' Definition Task et al., 
2006). The need for trained genetic counsellors increases as genetic services 
expand (Cordier et al., 2012). 
1.12 Genetic health services in Iceland  
The population of Iceland at the end of January 2019 was 356.991, with 
approximately 10% of the inhabitants of different origin than Icelandic 
(Iceland, 2016a). Most of the population (64%) lives in the Reykjavik capital 
area. Literacy is high, and over 97% of the population has access to the 
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Internet (Sigurdsson, 2015). The health care system is a mixture of 
government-funded and private practice (Sigurgeirsdottir et al., 2014). 
Landspitali – The National University Hospital of Iceland is in the capital and 
is the only hospital offering genetic health services. The Department of 
Genetics and Molecular Medicine (GMM) belongs to the Division of 
Diagnostic Medicine. The GMM comprises clinical genetics and genetic 
counselling as well as molecular, cytogenetic and biochemical laboratories 
with both prenatal and newborn screening. The department serves the whole 
country including limited GC services in the northern town, Akureyri. The 
genetic counselling unit was formally established in mid-2006 and organised 
cancer genetic counselling began within the GMM in December 2006.  
1.12.1  The team 
During the study, the clinical genetic health service team at Landspitali 
consisted of two part-time medical geneticists, a full-time genetic counsellor 
(GC), a part-time clinical cytogeneticist and a part-time oncologist trained in 
cancer genetics. (Stefansdottir, V., Arngrimsson, et al., 2013). The office 
manager performed clerical work and constructed the electronically 
generated pedigrees (EGP´s) while also managing most of the 
communication with the ICR. The clinical diagnostic work was undertaken by 
the medical doctors, while the task of providing information on genetic risk 
and potential options to patients was shared between the doctors and the 
GC. Cases were seen by either the counsellor exclusively or by a medical 
geneticist and a GC, depending on the issue. This practice is similar to the 
standard followed by many genetic services in other Western countries. 
Genetic nurses were not yet a part of the genetic healthcare service in 
Iceland, although this may be changing.  
1.12.2  Referral routes 
Self-referral to the genetic health services in Iceland is accepted, and is in 
fact, the most common form of referral. Health professionals can refer to the 
genetic services by email, phone and through the hospital electronic medical 
record. Self-referral is most common in genetic cancer services, followed by 
referrals from oncologists and oncology nurses and other healthcare 
professionals. The contact details for the genetic health services are 
published on the hospital website.  
1.12.3  Ethos of the clinical genetic service 
In genetic services, the importance of individual confidentiality is high, and 
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the counsellee often prefers to keep the appointment private (Stefansdottir, et 
al., 2013). To ensure equal access, self-referral is important. Most individuals 
receiving cancer genetic counselling in Iceland are self-referred, but in other 
cases, they have been advised by a professional to use the service, without a 
formal referral. Increasingly, as the genetic services are better known, 
professionals refer formally.  
Non-directiveness and freedom from coercion are one of the key features 
of genetic counselling. The following statement can be found on the website 
of the National Society of Genetic Counsellors, Code of Ethics in the USA, in 
Section II, Article 4:  
“Genetic Counsellors strive to enable their clients to make 
informed decisions, free of coercion, by providing or illuminating 
the necessary facts and clarifying the alternatives and 
anticipated consequences” (National Society of Genetic 
Counselors, 2017).  
On their website, the Association of Genetic Nurses and Counsellors in 
the UK have a similar text in their Code of Ethics: 
 “Enable clients to make informed and independent decisions, 
free from coercion, through the use of a range of counselling 
theories and styles. Respect the client's personal beliefs and 
their right to make their own decisions.” (Association of Genetic 
Nurses and Counsellors (AGNC), 2018).  
Counsellee´s decisions about issues such as surveillance and risk 
reducing surgeries, may not be the one most cost-effective, but one 
consistent with their values and place in life. This policy includes therapy 
decisions like, for example, a woman with a BRCA PV who may choose to 
have either a mastectomy or surveillance every six months, without regard to 
which option is more expensive for the society. The counsellors´ 
responsibility is to offer the counsellee the most accurate information, and 
support for any consequent decision making. 
1.13 A genetic “storm” 
In May 2013, the New York Times published a letter from the actress 
Angelina Jolie, revealing that she had a PV in the BRCA1 gene (Angelina 
Jolie, 2013). She explained her choice of double mastectomy as a preventive 
measure, knowing that she had a high risk of getting breast cancer in her 
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lifetime (Angelina Jolie, 2013). This event marked the beginning of an 
unprecedented increase in cancer genetic counselling, genetic testing for 
BRCA PVs and requests for risk-reducing mastectomy worldwide (Evans et 
al., 2015). In Iceland, the effect was noted immediately, as the media 
responded quickly to the news (Arnason V, 2014). In the first few days after 
the publication of Jolie´s article, several hundred people called the GMM, 
asking for cancer genetic counselling. This increase in service volume called 
for a change in the standard approach for the genetics clinic, as there was no 
increase in staff to cope with the increased demand for services. The first 
change regarded the genetic clinic appointments. Instead of allowing 60-90 
minutes for the first session, 30-40 minutes became the norm. Next were 
changes in the way of conveying the results of genetic testing. The number of 
telephone sessions increased, in place of many of the former standard in-
clinic/in-house appointments. Initially, only individuals who tested negative 
received results by telephone, but soon it became apparent that this was not 
optimal.  
Thus after 2014, the majority of counsellees received their results, 
whether positive or negative, by phone. However, initially during the pre-test 
counselling and then at the beginning of the telephone conversation when the 
results were communicated, all counsellees were asked in what way they 
wished to receive the results. Those who wanted more time or a session in 
the clinic could request this at any time. One of the benefits of using the 
telephone instead of in-clinic/in-house appointment was less waiting time for 
the return of results for the counsellee. All who received telephone genetic 
counselling were also offered a clinical appointment.  
For counsellees living at a considerable distance from the genetic clinics, 
using a telephone or other means of telemedicine is often less troublesome 
than travel. Many families where the Icelandic founder BRCA2 PV is 
segregating, live far from the cancer genetic counselling services in 
Reykjavik. Although this has not been formally assessed in Iceland, when 
asked, many counsellees found telephone sessions useful, and for some 
even better than an in-clinic session. Elsewhere, the use of 
telecommunication has increased as well (Hilgart et al., 2012). Studies 
comparing in-clinic and telephone genetic counselling for to HBOC have 
shown similar psychosocial and knowledge outcomes (Peshkin et al., 2016; 
Schwartz et al., 2014, Kinney et al., 2016). Of note, although the changes 
developed from pressure on the genetic services system, the change to 
giving test results by phone had at least the advantage of allowing the 
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counsellees time to adjust to the knowledge of their genetic status, before the 
clinical appointment.  
1.14 Facebook support group  
In 2013 a private Facebook support group for Icelandic women who tested 
positive for a BRCA PV was formed. The founders were two women with the 
Icelandic founder BRCA2 PV and the author of this thesis, as a genetic 
counsellor (Stefansdottir, V., 2016a). The group size increased quickly and 
soon became not only a support group for patients but also partly for the 
cancer genetic counselling service. Having a genetic counsellor on-board 
enables easy access for group members seeking advice or information. As 
well as being a group of peers, supporting and advising each other, the group 
also serves the purpose of providing information quickly when needed to a 
larger group - the families of members. The BRCA society in Iceland was formed 
subsequently and has been active and vocal on behalf of the BRCA community. 
The BRCA society Facebook page is open to everyone and can be accessed 
here: https://www.facebook.com/brakkasamtokin. Recently, (in August 2018) 
males with a BRCA PV in Iceland formed a similar private support group on 
Facebook.  
1.15 Summary 
Conventional collection of medical and family information is a lengthy 
process. The genetic assessment usually calls for a pedigree covering at 
least three generations or 3° relatedness with accurate medical information, 
which is difficult to collect and labour-intensive.  
Hereditary breast and ovarian cancer syndromes are identified and 
confirmed by genetic testing when possible. At the beginning of the study, 
only two BRCA pathogenic variants were tested for in HBOC cancer genetic 
counselling in Iceland. In many ways, circumstances in Iceland are unique, 
as interest in genealogy is extensive, and numerous databases exist 
alongside a comprehensive nationwide cancer registry. By using our 
databases, genetic services can generate electronic pedigrees with 
comprehensive data. This method leads to relatively large and more accurate 
pedigrees, which consequently improve risk assessment and surveillance 
plans. It also enhances the ability to identify those at risk in the family. While 
the use of electronic health records has increased over the years, utilising 
electronic genealogy databases in genetic health services is uncommon. 
Collection of family information through specific cancer registries and other 
disease registries is, however, well known, and family information does 
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accumulate over time in all genetic health care centres. Professionals 
exchange information as needed, with presumed consent from all included, to 
ensure excellent service to counsellees and their families.  
In this thesis, I cohesively assessed the use of electronic genealogy 
databases in genetic health services and evaluated how using electronically 
generated pedigrees was perceived. Additionally, I evaluated how using 
EGPs influenced the genetic health service, and finally, assessed the optimal 
size of pedigrees for HBOC genetic counselling.  
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2 Aims 
The overall aim of this PhD thesis was to cohesively assess the availability 
and use of electronic genealogy databases and information from cancer 
registries to construct electronically generated pedigrees for risk assessment 
in genetic counselling. Hereditary breast and ovarian cancer (HBOC), due to 
the Icelandic founder BRCA2 PV was used as an example.  
The thesis is built on three studies, published as three separate scientific 
papers. The specific aims of each study were as follows.  
The use of genealogy databases for risk assessment in genetic 
health service: a systematic review.	The aim of the literature review was to 
identify and analyse the existing work on the use of genealogical databases 
used to facilitate pedigree construction in genetic health care services. 
Counsellee’s experience of cancer genetic counselling 
with pedigrees that automatically incorporate genealogical and cancer 
database information. The aim of the qualitative study was to assess the 
counsellees´ experience where EGPs were used in HBOC genetic 
counselling. 
Electronically ascertained extended pedigrees in breast cancer 
genetic counseling. We aimed to determine the practicality of using large 
EGP ś in HBOC genetic counselling. An additional aim was to calculate the 
optimal size of a pedigree for risk evaluation in cancer genetic counselling.  
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3 Materials and methods 
The overall design of this thesis was based on exploratory sequential mixed 
methods (Ivankova et al., 2006). This approach can be used in studies 
focussing on an area of research, which is mainly exploratory and where the 
use of different research methods will enable diverse aspects of the topic to 
be dissected. I found it important to explore the use of EGPs from the 
perspectives of the key users – namely patients and professionals.  
The first part of the study was a systematic literature review to ascertain 
the previous use of EGPs in a range of settings. This was followed by a 
qualitative study to determine the impact on patients. The last study was 
done by quantitative methods to examine the use and impact of EGPs in 
clinical care. 
3.1 Study I design 
The litereature review question was: ‘What is known about the use of 
electronic genealogy databases, to generate electronic pedigrees in clinical 
genetics and genetic counselling? To answer the question, I did a systematic 
literature review using 12 combined search terms in five literature databases 
and the grey literature to find as many relevant papers as possible.  
The original search for the systematic review was performed in October 
2011 and is described in Study I (Stefansdottir, V., Johannsson, et al., 2013). 
As an update for this thesis, the search was repeated in December 2018. The 
updated review was done using a systematic rapid-review approach (Ganann 
et al., 2010). The databases, but not the grey literature, were searched using 
the same terms as in the first search to capture all papers with a title, 
abstract, or topic that included any of the phrases. The data limits were 2017 
and 2018. The searches were refined to exclude case reports and non-peer 
reviewed journal articles (newspaper and magazines), non-English papers, 
and animal studies. The original review was to provide a foundation for the 
subsequent study, and the update was used to determine changes to the 
peer-reviewed evidence base since the original study. Additionally, although 
not a part of a formal study, the author has been a subscriber of alerts from 
Google and Google Scholar, with the same search terms used in the study, 
since 2013 and has read the relevant daily alerts. The inclusion and 
exclusion criteria for the original systematic review can be seen in Table 2.  
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3.2 Study I, data sources 
The databases PubMed, Web of Science, EBSCOhost, OVID, and CINAHL 
were used to search for papers published in peer-reviewed journals, as well 
as the reference lists of relevant papers, theses, and articles in the grey 
literature. The Penn Libraries determined the grey literature as: 
“…created by researchers and practitioners in various fields,  
but is not controlled by commercial publishing.  
The groups that produce grey literature may be government, 
industry, advocacy or other organizations that disseminate 
information in the form of reports or working papers rather than by 
publishing scholarly articles in commercial journals” (University of 
Pennsylvania, 2017).  
3.3 Search terms 
The following 11 combined search terms were used for the review:  
• Genealogy database* AND genetic risk AND family history 
• Genealogy database* AND clinical genetics 
• Genealogy Database* AND medical AND family history 
• Cancer registry AND genetic service 
• Cancer registration AND clinical genetics AND genealogy 
• Database* AND family history AND genetic risk assessment 
• Genealogy database* AND cancer registry 
• Database* AND genealogy AND genetics 
• Genealogy AND database 
• Genetic counsel* AND clinical genetics AND genealogy 
• Cancer genetic counsel* AND genealogy. 
Collectively those search terms should identify articles in the literature that 
discuss the use of electronic databases in genetic counselling.  
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Table 2. Inclusion and exlusion criteria for the literature review 
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3.4 Study II, design 
In this study, a qualitative descriptive approach was used, with online focus 
groups, (Sandelowski, 2000) to experience, emotions, values and 
perceptions of participants who had undergone genetic counselling with 
EGP´s.  
Online focus groups (OFG) are commonly used in business for marketing 
research. Specific websites, such as iResearch allow researchers and 
interested participants to connect with a promise of anonymity in online focus 
group studies (iResearch, 2018). Those participating in focus groups for 
business, usually get paid or compensated for their time (Petrescu, 2018). 
This contrasts with academic studies where participants usually participate 
for free. Another platform, Facebook™, can be used for focus groups. The 
negative side of Facebook™ is that it is impossible to be anonymous and 
Facebook™ owns all the data added. However, using a secret Facebook™ 
group allows the participants at least some sort of privacy as the group is 
invisible to non-members (Lijadi & van Schalkwyk, 2015).  
In qualitative research, OFGs enable a different approach from face-to-
face groups (Hansen, 2006). The methods used can be either written (email, 
discussion boards) or audio/video meetings. Studies using OFGs can be 
performed either synchronously or asynchronously. The difference is the log-
on time; participants must all log on at the same time using the synchronous 
way (Fox et al., 2007) while they can log on when convenient in the 
asynchronous method (Zwaanswijk & van Dulmen, 2014). In both methods, 
facilitators moderate the group or groups to collect data through an 
exploration of topics (Kevern & Webb, 2001). The method chosen depends 
on the availability of participants and the topic.  
The asynchronous method was chosen mainly to enable participants to 
log on at their convenience and not to be bound to a specific timeframe or 
have to travel. These features would possibly encourage more active 
participation. In market research, online focus group studies are well known, 
but at the time of the study, less so in academia.  
The strength of using OFGs instead of a face-to-face focus group is 
mainly the anonymity among participants and easier recruitment (Newington 
& Metcalfe, 2014). Another benefit is that group members do not have to 
travel to a specific place for a meeting and therefore can participate when 
convenient, at home or elsewhere. (Zwaanswijk & van Dulmen, 2014). As for 
the information shared, some find it easier to share sensitive information 
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without personal identification (Tates et al., 2009). For the researcher, the 
data is accurate and already in a textual form which eliminates the need for 
transcribing and editing, saving workload and money (Kenny, 2005). 
Body language is an important factor in conversation. One of the main 
weakness of using an online focus group is the complete absence of body 
language and facial aspect, resulting in different group dynamics than in a 
conventional focus group. (Zwaanswijk & van Dulmen, 2014). Participants 
may also be multi-tasking and not with full attention on the task at hand when 
online. For some, not knowing who is corresponding, (anonymity) can be 
difficult. Lastly, not having access to a computer or not being comfortable 
with computer technology could be a barrier to participation.  
Weighting the pros and cons of OFGs, such as anonymity, the possibility 
to log on when convenient as described in the Introduction, overall, we felt 
that the advantages were greater than the disadvantages. Therefore, we 
decided to use this method.  
Figure 6 The registration page of the phpBB Forum. 
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Several online discussion/bulletin boards or forum are available. For this 
study, a phpBB forum which could be downloaded from the webpage 
https://www.phpbb.com was chosen. It is a free, open-source bulletin board 
accessible from anywhere, with an Internet connection. Figure 6 shows the 
registration page of the forum. The Icelandic Human Genetics Society hosted 
the forum for the study. The forum was kept secure and closed to the public 
to ensure the privacy and discussion of participants,. The host ensured that 
the IP numbers and email addresses of participants could not be accessible 
by anyone. Each participant chose a username and a password at 
registration. After each group had finished, the communication board was 
completely deleted. Figure 7 shows the outlook of the forum.  
3.5 Cohort. Study II 
Participants (n=19) were of Icelandic origin and had received cancer genetic 
counselling between 01.01.2007 and 31.12.2012 at Landspitali. Both males 
and females were invited to the study, in all 225 individuals - 158 females and 
67 males. All invited to the study had been tested for either one or both 
known Icelandic founder PV´s.  
Four online focus groups were selected (Stancanelli, 2010). From the 
original group of 225 individuals, 50 were selected randomly for each of 
Figure 7. The outlook of the forum. 
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group one to four, using the RAND function in the Microsoft program Excel™ 
(Microsoft). The number, average age and age range of participants is shown 
in Table 3. An invitation letter was sent by mail to each of the participants, 
first for group one. Their names were then removed from the original group 
(selection without replacement). The same method was used for groups two 
and three (50 each), but for group four only males who had not been in the 
selection of the first three groups were invited to the study.  
No males participated in the first three groups although some had shown 
interest. Males with a PV in the BRCA genes have a different experience and 
risk than females. We found it important to invite males only to the last group 
to obtain their views as well as learning more about their experiences 
Stefansdottir, V. et al., 2016) 
The average age of invited individuals (n=225) was 50.4 years (range 23-
86), but the participants´ average age was 52.2 years (Table 3). The 
youngest participant was 33 years and the oldest 69 years. Eleven were 
positive for either one of the Icelandic founder PV in BRCA genes, and eight 
were negative (Table 4). In the invitation letter, participants were informed 
that consent for participation was defined as either the return of signed form 
sent with the invitation letter or by email stating willingness to participate.  
  
Table 3 Number and age range of participants in the online focus groups. 
Vigdís Stefánsdóttir 
40 
Table 4. BRCA PV status and age of participants in the online focus groups. 
(Stefansdottir, V. et al., 2016) 
3.6 Instructions to participants 
Those who agreed to take part in the study received instructions about how 
to sign on to the forum and what to do to be a part of the group. Below 
information letter translated by the thesis author, can be seen. The original is 
in the supplemental files (Information letter):  
 
Dear participant 
Start by going to the Internet address: spjall.mannis.is. 
Before you start, you can make a new email address for yourself, for the 
purpose of this study, if you like. The IP numbers used when signing on to 
the website, cannot be observed and will not be collected.  
You need to click on „register“, in the right upper corner. There you can make 
your own username and password.  
When all have registered, I will get notified will add you to the board where 
we can discuss the question as you like before you reply to it. 
I would like everyone to reply to all questions if possible. It would be nice to 
have a chat as well, on the board. It is rewarding and can be great and 
informative for all, to have conversations on the board.  
All exchanges are done without personal identification, and it should be 
impossible to find out who you are, without your permission. However, any of 
you can send a private email to other participants at will.  
You can also exchange information or mail within the board, among 
yourselves by private messages.  
Thank you for participating. 
Vigdis Stefansdottir, genetic counsellor. 
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3.6.1 The questions  
At the time of the study the formal cancer genetic counselling service had 
only been available for a few years, or since the end of 2006. Early on, it was 
decided to seek permission to use the extensive genealogy database GCUI 
for the construction of EGPs in order to do better for risk assessment in 
cancer genetic counselling. Simultaneously, permission to add information 
from the Icelandic Cancer Registry was applied for. Both permissions were 
granted. This was a novel approach to cancer genetic counselling. Due to the 
novelty of the EGPs, it was of interest to survey the overall experience of the 
counsellees of the genetic counselling service as well as the EGPs. Thus, the 
questions were prepared not only to explore the experience of using the 
EGPs but also the genetic counselling service. We wanted to know if there 
was any change in the family dynamics following genetic testing (McInerney-
Leo et al., 2005), and how the family communication had changed 
(MacDonald et al., 2007). Lastly, we were interested in knowing how the 
overall experience of the genetic services had been (McAllister et al., 2011).  
The first two groups received identical questions posted sequentially to 
the forum. Each time a question had been posted, participants received 
notification by email. A week later, another reminder was sent if few or no 
replies had been posted on the board. Both on the discussion board and in 
the reminder email, the administrator encouraged participants to engage in 
communication and to post their own questions and comments.  
When the first two rounds had finished, the replies and communication 
were reviewed, and a decision was made to make small changes to the 
questions. The content of the questionnaire stayed the same, but the wording 
was changed in some of the questions. Therefore, instead of 10 questions, 
groups three and four received 15 questions, with some of the more complex 
questions made simpler and divided into two. The content of the questions 
remained the same for all groups. This is common in qualitative studies, 
where concurrent data analysis influences the data collection (Green et al., 
2007).  
Another change was made in the third and fourth group to prompt faster 
replies in the group and more engagement on behalf of the participants in the 
third and fourth group. This involved adding the questions to the board in two 
parts instead of one by one. The first seven questions were added together 
and the last eight shortly after.  
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3.6.2 Group 1 and 2, questions 
1. Why did you go for genetic counselling and what were your ideas 
about it beforehand? 
(An explanatory comment on the board, from the admin, for the 
questions below). “I would like you to ponder about the EGP´s we 
use for the risk assessment, made with the information from the 
genealogy database and Cancer Registry.  
2. Did you know anything about them beforehand – if it was possible 
to make them? What were your thoughts about the capability to 
make such extensive pedigrees? 
3. Did you have anything against using EGP´s in the genetic 
counselling and were you worried about other family member’s 
issues or attitude regarding the extensive information in the 
pedigree? 
4. Do you trust the information in the EGP? Any thoughts? 
5. What did you think about also having to give your information for 
a handmade pedigree? 
6. When you had to decide on genetic testing, how did you feel 
about your decision? Describe your feelings during the waiting 
period. 
7. Can you describe your emotions right after and for the first few 
days after you got the results? What about later? 
8. Has the family dynamics and communication changed after the 
genetic counselling? In what way? 
9. Do you think that anyone in your family is suffering from survival 
guilt? (Survival guilt can be described as when one feels “guilty” 
when not having a genetic mutation when others in the family 
have it). 
10. This question is a bit complicated and long: What do you think 
was well done during the genetic counselling? What do you think 
can be done better? 
a. Information before the testing,  
b. Information after the testing,  
c. Anything else?  
d. Lastly, is there anything else you want to share? 
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3.6.3 Group 3 and 4, questions 
1. Why did you come for genetic counselling? 
2. What ideas had you about the genetic counselling prior to your 
visit?  
3. Did you know anything about EGP´s prior to genetic counselling?  
4. Can you tell us about your thoughts when you knew that it was 
possible to get the extensive information from the electronic 
databases? 
5. Were you against using EGP´s in the genetic counselling?  
6. Did you worry about others in the family because of the use of the 
EGP and the information they contained? 
7. What did you think about also having to give your information for 
a handmade pedigree? (A comment from admin: This is only for 
those who had no relatives that have come before to genetic 
counselling).  
8. Did you trust the information in the EGPs? Any thoughts? 
9. When you had to decide on genetic testing, how did you feel 
about your decision?  
10. The waiting period for the results – can you say something about 
that? 
11. Can you describe your emotions right after and for the first few 
days after you got the results? What about later? 
12. Has the family dynamics and communication changed after the 
genetic counselling? In what way? 
13. Do you think that anyone in your family is suffering from survival 
guilt? (Survival guilt can be described as when one feels “guilty” 
when not having a genetic mutation, when others in the family 
have it). 
14. What do you think the genetic counselling has done well? 
15. What do you think we can do better?  
 a) Information before the genetic testing 
 b) Information after the genetic testing 
 c) Is there anything else you want to add? 
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3.7 Study III, design 
For this study, we used genealogical and PV data from those individuals who 
had received cancer genetic counselling due to HBOC at Landspitali between 
1.12.2006 - 31.12.2015. All were of Icelandic origin and had been tested for 
the Icelandic founder BRCA2 PV. Some had also been tested for the founder 
PV in the BRCA1:G5193A (n=1352). Families, with at least one family 
member positive for either of the founder BRCA PV, were defined as “families 
with BRCA PV.”  
After subtracting individuals with the BRCA1:G5193A (n=58) 1294 
remained and were divided into two sub-groups: a) those who belonged to a 
family with the Icelandic founder BRCA2 PV (sub-group I, n=523) and those 
without (sub-group II, n=771).  
In all, 104 women who had tested positive and 105 who had tested 
negative for the Icelandic founder BRCA2 PV were randomly selected from 
the groups by the Randbetween function in Excel (Microsoft). Each 
participant was given a unique number and was removed from the group 
after selection in order to not to choose the same number twice.  
For each proband, up to eight EGPs were made, with descendants from 
each of the eight great-grandparents. Some individuals appeared in multiple 
EGPs, either as a member of the family or married into the family.  
We estimated the average cost of generating ten EGPs within the genetic 
counselling service in Iceland. This was done by timing the consent process, 
the data transfer time, the upload of data, the time used for reviewing the 
data, and the final output with all relevant information for several pedigrees of 
different sizes to find the average workload. 
3.8 Data analysis 
3.8.1 Study I 
The papers were analysed for key codes, categories, and themes within and 
across papers. Meta-analysis was not possible, given the limited data found, 
and the findings were presented in textual form, under themes.  
The quality appraisal tool CASP checklist for cohort studies (Health) 
designed by the Critical Appraisal Skills Program (Critical Appraisal Skills 
Programme, 2010) was used to evaluate the research-based paper (Brewster 
et al., 2004) with the score set at 93%. It was not possible to formally 
appraise the quality of the discussion-based papers. 
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3.8.2 Study II 
A thematic analysis method was chosen for this study as it enables rich data 
to be collected and analysed without restrictive prior categories. Thematic 
analysis has minimal organisational effects. It allows for searching for 
patterns across the entire data set, rather than within each interview or data 
for each participant separately (Braun & Clarke, 2006).  
In thematic analysis, a theme or a pattern is found by looking at the 
frequency of the appearance in the text. Still, the researcher must make the 
judgement himself as a number alone cannot be a qualifier. This relates more 
to ascertain if the alleged theme captures essential issues related to the 
overall research question. We found it important not to try to fit the data into 
any pre-existing coding frame, rather to allow the pattern to emerge. The 
replies were coded into topics, categories and the following themes; 
motivation, information and trust, impact of testing, emotional response and 
electronic pedigrees. Two of the authors (VS and HS) independently coded 
the replies using descriptive coding by hand. Thematic analysis of data was 
made by the approach used by Braun and Clarke (Braun & Clarke, 2006), 
which includes identifying and analysing patterns or themes within the data, 
in a non-theoretical way. Examples of the analysis can be seen in Table 5. 
Categories were independently coded using descriptive coding.  
Codes, categories, and themes were discussed between two of the 
authors (VS and HS) until consensus was reached.  
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Table 5. Examples of the thematic data analysis in Study II. 
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3.9 Study III 
In study III, detailed one to six generation pedigrees were constructed within 
the pedigree software Clinical Pedigreeä (Cyril Chapman, 2016) using data 
from the GCUI (Tulinius, 2011) and the population-based Icelandic Cancer 
Registry (Sigurdardottir et al., 2012).  
The predictive model BOADICEA™ (Breast and Ovarian Analysis of 
Disease Incidence and Carrier Estimation Algorithm) (Lee et al., 2014; 
MacInnis et al., 2013) was used to calculate the likelihood of being a carrier 
for the Icelandic founder BRCA2 PV. The likelihood of having the BRCA1 
founder PV was not used in this study as the variant is very rare. The 
program used the Icelandic allele frequency 0.3 for the Icelandic founder 
BRCA2 PV and cancer incidence rates for Iceland (Gudbjartsson et al., 
2015). Search sensitivity was overall 0.8 (Lee et al., 2014; MacInnis et al., 
2013). Microsoft Excel was used as a datasheet for descriptive statistical 
analysis. The MedCalc™ Receiver Operating Characteristic (ROC) Curve 
Analysis (Hanley & Mcneil, 1982) was used to evaluate the effect of pedigree 
size on risk calculation for (MedCalc Software, 2016). The Area Under the 
Curve (AUC) - C-statistic for paired samples, based on exact binomial 
functions was used to assess how increasing the degree of relatives included 
in a pedigree would affect the classification of probands with regard to the 
Icelandic founder BRCA2 PV positive and the Icelandic founder BRCA2 PV 
negative.  
Statistical tests were two-sided. The difference, standard error, and 95% 
confidence interval (CI), and p-value of the differences between C-statistics 
were calculated with a significance level of 0.05 (95% CI did not include zero) 
(Delong et al., 1988).  
To further assess if the difference was because of an increased number of 
individuals or degree of relatedness, both the 3° and the 4° pedigrees were 
divided into two groups, according to size. The MedCalc program was used 
to calculate the statistical significance of the difference between the ROC 
curves for independent samples.  
We also converted the lower number group in the 3° pedigrees into 4° 
relative pedigrees to assess this further. This was done within the 
ClinicalPedigree program which allows for truncating and increasing the size 
of the pedigree according to the degree of relatedness. 
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4 Results 
4.1 Study I  
The systematic literature review was undertaken to assess the use of 
electronic genealogy databases in the context of genetic health service.  
The original search was performed in October 2011. As an update for this 
thesis, the search was repeated in December 2018 within the same 
parameters, excluding the grey literature. Apart from our own studies, no new 
paers fitting the inclusion criteria were identified in the repeated search.  
 
Figure 8 Selection of papers from the initial search in 2011. (Stefansdottir et.al., 2013) 
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The initial search retrieved 1035 titles. Of those, 260 were duplicates, and 
650 were excluded by title only, being non-human or not in English. The 
remaining 125 titles were analysed further, and 121 were excluded (Figure 
6). The four remaining papers were two original research papers, one 
Icelandic and one from Scotland. The two other papers were discussion 
papers (Cannon Albright, 2006; Tu & Mason, 2004). Table 6 shows the main 
outcome of the selected papers. The Icelandic paper described the use of the 
same genealogy database as was used in this study, but the paper from 
Scotland described cancer genetic risk assessment using database 
generated pedigrees in four major health care centres in Scotland.  
The first paper; “Organizing population data into complex family 
pedigrees: application of a second-order data linkage to State Birth Defects 
Registries” was a discussion paper with no original data (Tu & Mason, 2004). 
The authors discussed the possibility of linking individuals using previously 
collected data in various national and regional databases in clinical health 
care. They acknowledged that such linking for research was limited to a first-
order linkage, i.e., only linking the same individual to himself or herself in 
different databases. The authors suggested that being able to linking various 
data into pedigrees could significantly impact scientific genetic studies, and 
by additionally link environmental data as well, large-scale studies could be 
executed on gene-environment interactions.  
In the second paper; “Computerized genealogies linked to medical 
histories for research and clinical care – a national view”, (Cannon Albright, 
2006), the author discussed the possibilities of connecting genealogy data 
and medical records, and how it could increase the power of clinical and 
scientific research. This was a proceedings paper from the Australasian 
Integrative Medicine Association (AIMA) annual symposium. It describes the 
two geographical areas where ample resources existed for making accurate 
genealogical data linked to medical data, Iceland and Utah, and how the 
computerisation of their data began 30 years earlier (the paper is from 2006). 
The author also describes the collection of genealogy data for Utah and 
neighbouring states, going back to the founder population, including millions 
of individuals. In the concluding sentence, the author mentioned that linked 
genealogy and medical data were not used anywhere to access the familial 
risk of disease.  
In the third paper entitled “Impact of a cancer registry-based genealogy 
service to support clinical genetics services,” Brewster and colleagues 
described a survey looking at the effect of database-generated pedigrees on 
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cancer genetic risk assessment in four major centres in Scotland. The 
authors found that the pedigrees provided by the Scottish Cancer Registry 
were accurate and extensive and that using them changed the risk category 
in 41% of cases and the management in 23% of cases. They concluded that 
linking pedigrees to cancer registry could affect genetic counselling positively 
as the family history was more comprehensive (Brewster et al., 2004).  
The fourth paper “Systematic family screening for familial 
hypercholesterolemia in Iceland” (Thorsson et al., 2003) described the use of 
the Icelandic genealogy database in clinical service. The authors compared 
two methods of screening for familial hypercholesterolemia, a conventional 
screening method and a novel approach using the genealogy database to 
find relatives for systematic family screening. The latter method, systematic 
screening identified 19% more relatives than the conventional type. The 
results indicated that using genealogy databases to identify family members 
in a systematic way, could increase the number of those found to be at risk.   
In summary, there was very limited data in the literature describing the 
use of electronic genealogy and cancer registry data in generating pedigrees 
in genetic counselling. 
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Table 6 The four papers identified in the literature review, describing the use or potential 
use of genealogy databases in clinical genetic services, (Stefansdottir, 2013). 
Results 
53 
4.2 Study II  
This was a qualitative study with questions posted on a PHP Bulletin Board 
(phpBB) forum. The forum allowed the participants to discuss any of the 
topics among themselves as well as reply to the questions posted on the 
board. However, they did not use the opportunity to post comments despite 
encouragement from the board administrator. In general, participants were 
positive towards the use of EGP´s and did not oppose the use in genetic 
counselling. Participants had trust in both the service and the information. 
Obtaining consent for the EGP and explaining the reason for using it followed 
without complication. 
No security breach or misuse of information was noted during the 
collection and use of the data. Table 7 lists the emerging themes and their 
components arising from the replies. In the quotes, participants were 
identified by age genetic status (PV positive or PV negative). All replies are 
listed in supplementary files as Supp. replies.  
4.2.1 Reasons for attending GC 
The reason most participants had come for genetic counselling was a family 
history of either breast cancer or knowledge of the Icelandic founder BRCA2 
PV within the family. It could be very close relatives like mothers and sisters: 
“I decided to get genetic counselling because my mother died at 
49 after getting breast cancer and my sister’s mother also when 
she was 69. The oncologist advised it. I did not have any ideas 
about the genetic counselling beforehand, but of course, I had 
thoughts about what to expect, that is, if it turned out to be 
genetic and such” (PV negative, 45). 
The sense of duty to relatives diagnosed with breast cancer was present: 
“After my mother was diagnosed with BRCA2 gene, I felt I had to 
go when it was offered. I had no idea that this service was 
available, but then I had never given it any thought (PV negative, 
41). 
  
Vigdís Stefánsdóttir 
54 
Table 7. The main emerging categories, components and themes from the 
participants replies on the forum. 
Modified from Stefansdottir et al., 2015) 
Even though families were not large, the knowledge of cancers in relatives 
could encourage seeking genetic counselling:  
“After my breast cancer diagnosis, I talked to my doctor about 
how many in my family had had cancer. He felt that it was 
enough reason for me to go to GC. I had my sons, siblings and 
other relatives strongly in my mind, but my family which 
descends from my grandfather and grandmother is not large, 
and we are very close (carrier, 55).  
Some had relatives that had already been for genetic counselling:  
“As there is a lot of breast cancer in my family and many of my 
relatives had gone for GC and given me information, I decided 
that it was sensible to go, not in the least because of my 
descendants (PV negative, 67). 
Others had had the information letter forwarded from relatives:  
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 “I have an aunt who got breast cancer, and she had been asked 
to relay the information to us that we might carry the gene” (PV 
positive, 57).  
4.2.2 Trust 
Participants described their trust toward the genetic services, pedigree 
information, and cancer registry. Concern over family members’ attitudes 
regarding the use of information from databases was limited: 
 “I trust this information completely. I have no reason not to” (PV 
positive, 45). 
“I know professionals do this. Therefore, I trust the information 
100% (PV positive, 33). 
“Yes. I think this is all done very professionally (PV negative, 
36). 
 “I have no reason not to trust it, but I do not have enough 
knowledge about what the danger might be if the information is 
wrong. It is important that information like these to be accessible 
to the individual asking for them but not for others. No such 
information used in research should have personal identification. 
The individuals themselves should be able to get their own 
information” (PV positive, 56).  
4.2.3 Emotional response  
Some were stressed because of the testing and others found relief in 
knowing the outcome: 
“I was very stressed because it is a lot of hassle to test positive 
for the BRCA gene” (PV negative, 36). 
Others were happy to be able to have surveillance:  
“I did not find it terrible, but of course it was a shock but I 
somehow had expected this outcome. Maybe I am playing 
Pollyanna, but I think it is like this. My parents both died of 
cancer, and I have many siblings with a yes, others no just like 
expected. However, we can all expect to get cancers, but those 
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of us who had yes can have surveillance the others do not so I 
regard myself lucky” (PV positive, 44).  
Still, others had done a lot of thinking and decided to have the test: 
“When I finally decided to be tested I was very pleased about it. 
The waiting time was a bit difficult as I had imagined” (PV 
negative, 57). 
Some found family support valuable: 
 “I thought a lot about the results. I pondered about my children’s 
reaction. They would have to decide, I thought, what they 
wanted to do when I told them about the risk of having the 
mutation. I found it useful to talk to my relatives that are people 
my age who are in the same risk group. We met a lot during this 
period; three newly diagnosed with cancer were in the group and 
therefore easy to talk about the problem. I found it a lot of hassle 
to attend to the strict surveillance program. However, it turned 
out just to be anxiety. It is not a problem any longer.  
Participants had mixed emotions. 
So, the emotions were mixed, good/bad. Good to know, sad to 
have to think about it but then I got used to this, and I think it is 
good that my people know that I have this mutation” (PV 
positive, 55).  
There was some concern about insurance companies:  
“Yes, I trust the service as much as possible. Still, it is vital to 
ensure that insurance companies will not be able to access the 
information” (PV positive, 36). 
4.2.4 Impact of testing 
Having genetic testing had a great impact on most people however well they 
prepared for the results:  
“The results did not come as a surprise but are you ever ready 
for such knowledge? I do not think so. I got a bit scared as I had 
had breast cancer shortly before. I was worried about getting 
breast cancer again because now I knew for sure that the risk 
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was quite high. Nevertheless, I did not let the scare overtake 
me. I was just more convinced that I had done right and I just felt 
good about the decision” (PV positive, 55). 
Many felt it was preferable to know their genetic status, although the 
results were not optimal: 
When I had the results that I had the mutated gene, and on top 
of that I was a carrier, I was definitely taken back. On the other 
hand, I felt it useful to know my status and really nothing else to 
do but agree with the facts (PV positive, 45).  
The relief accompanying a negative result could also be difficult if others 
had a different outcome:  
“It was a relief, but at the same time, I felt bad because my sister 
had a positive result. I had bad conscious because I felt that I 
was the stronger one and should have been the one to have 
positive results instead of her (PV negative, 41). 
However, some did not think very much about the outcome until it was 
delivered:  
“Did not think about it much at the time” (PV positive, 57). 
4.2.5 Family communication 
Family communication remained unchanged or increased from before the 
genetic counselling. Some had worries about children and support from 
family members.  
“Family communication has not changed much, although we talk 
a lot about this (BRCA) as more and more have been tested 
positive. After I had breast surgery, cancer was found in the 
other breast, and I had to have another surgery. I found that 
difficult, and to know that two of my daughters had BRCA2 (PV 
positive, 54). 
“No communication within the family has not changed; people 
just talk about this on a positive note. Mostly we are aware of 
each other and who is positive (with mutation) and who is not 
and try to support each other. I asked everyone if they wanted to 
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get the letter… and all did… Most of those have been to GC and 
also their children who are old enough (PV positive, 54). 
4.2.6 Prior knowledge of EGP´s  
Some of the participants had prior knowledge of the possibility of generating 
electronic pedigrees. 
 “Yes, I knew about such electronic pedigrees, and I think it is for 
the good that it is possible to use it for such research” (PV 
negative, 67). 
“Yes, I did know that it was possible to make electronic 
pedigrees. I think it is self-evident to do so if data protection is in 
order” (PV negative, 64). 
Although some participants did not know about the EGP´s beforehand, 
they found them beneficial as in the following two accounts: 
 “No, I did not know about them (electronic pedigrees) before I 
came to you. It is great that it is possible to do this for those who 
want to know if they belong to a risk group or not” (PV positive, 
54). 
“I did not know about the electronic pedigrees before GC. I find it 
great that it is possible as it gives lots of information” (PV 
positive, 33). 
Others had realised that there had to be a way of accessing family 
information and had other questions as well:  
“No, I did not know about electronic pedigrees, but I realised that 
somehow it was possible to find out about the family connection 
regarding disorders. I find it great that it can be done as I think it 
can help with decisions if one is diagnosed with a serious 
disease. I would like to ask (probably obvious) are bio-samples 
available from everyone? (PV negative, 45). 
4.2.7 Attitude towards electronic pedigrees 
The overall attitude towards the EGP´s was positive: 
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“I am not at all against using electronic pedigrees in the GC and 
I am not worried about my relatives’ attitude as everyone is 
really positive towards it” (PV positive, 33).  
It was positive although they did not know beforehand:  
“I did not know until after the first visit to X (GC) and Y (Medic) 
that it was possible to make electronic pedigrees. I find this 
possibility to be a good thing. I find it very positive that people 
have access to such information if they want” (PV positive, 45).  
4.2.8 Overall experience 
Participants in the study had received genetic counselling at Landspitali and 
were approached to participate in the study as such. Explaining to the 
participants/counsellees during genetic counselling how the EGPs were used 
for risk assessment and obtaining consent to generate them was a straight-
forward process, with no complications. They generally assumed that 
genealogy information was already available, and that using such information 
was a regular part of the service.  
Occasionally during genetic counselling and in the qualitative study, the 
following questions were asked:  
a) if permission was needed from other relatives;  
b) if it would be possible for them to see or obtain a copy of their own 
pedigrees;  
c) if they would receive information about relatives unknown to them, and 
whether such details should be available in the pedigree information; and  
d) whether all disorders in the family would be seen in the finished 
pedigree.  
Replies to the participants regarding the above questions were as follows:  
a) No, permission is not needed from other relatives to generate a 
pedigree; 
 b) No, it is not permitted to share pedigrees with those in genetic 
counselling as they may include sensitive information about other people 
than themselves;  
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c) No, information about unknown family members is not shared even if it 
happens to be in the pedigree. It is not the role of the genetics services to 
disclose such information; 
 d) No. Iceland has only one public disease registry that can be used to 
add information to pedigrees, the cancer registry. Therefore, no other 
diseases or health problems would be included in the finished electronic 
pedigree.  
On the other hand, information disclosed by individuals themselves would 
be added as needed, to make the pedigree as comprehensive as possible.  
4.3 Study III 
The study was observational and descriptive. Results from testing one or 
both Icelandic founders BRCA PVs were available for 1352 individuals in 370 
EGPs at the end of 2015.  
The different pedigree sizes of the study families are shown in Table 8. 
Families with the Icelandic founder BRCA2 PV variation were 56. The 
average number of individuals in a family was 514 individuals (range 40-
2031). There were 314 families without a known BRCA PV, and the average 
number of individuals in those families was 497 (range 13-4197). Some 
overlap was found between the different categories of families. Where it was 
not possible to construct an EGP due to lack of knowledge of the biological 
family (in four cases), the proband was offered genetic testing for the founder 
BRCA PVs.  
4.3.1 Workload in constructing the EGPs 
Pedigrees were of different sizes and complexity. The estimated amount of 
work required for the construction of an average sized, a full set (eight) of 
EGPs for each proband was estimated to be up to three working hours, 
calculated by measuring all parts of the work needed for a medium sized 
pedigree. 
Information from the ICR included the type of cancers and age at 
diagnosis. The ICR has data on most breast cancers back to 1911 (Snaedal, 
1965) and other cancers back to 1954 when the ICR was established.  
  
Results 
61 
Table 8. Size of the EGPs for those attending the cancer genetic clinic, between 
1.12.2006 and 31.12.2015 at Landspitali. Data only includes those who were alive in 
1955 and those born before 1996. 
Modified from Stefansdottir et al., 2018). 
4.3.2 Types and numbers of cancers in the study families 
At the end of 2015, 755 of the tested individuals were members of one or 
more of the 56 families with the Icelandic founder BRCA2 PV. Of those, 340 
were positive (45%) comprising 233 females and 107 males. Table 9 shows 
the number of BRCA related cancers in participants alive in 1955, born 
before 1996 and tested positive for the Icelandic founder BRCA2 PV. Of the 
females, 86 (37%) had breast cancer (average age 49 years - range 21-82), 
three of them had in-situ breast cancers eight years earlier at average and 11 
(4.7%) two breast cancers. Ten (4.2%) of the females had ovarian cancer, 
earlier than average and nine (8.4%) males had prostate cancer. Seven 
males (6.5%) had breast cancer at the average age of 56 (range 46-70), and 
two of those had developed breast cancer twice. Two males with prostate 
cancers also had breast cancer.  
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Table 9. Number of subjects tested positive for the Icelandic founder BRCA2 PV from 
1.12.2006 and 31.12.2015 and their associated cancers diagnosed 1955-2015. 
 
 
 
Modified from Stefansdottir et al., 2018). 
4.3.3 ROC analysis of the optimal size of pedigrees for risk 
assessment  
The study group included 1352 individuals seeking HBOC genetic 
counselling at Landspitali, all having had genetic testing for the Icelandic 
founder BRCA2 PV. Some had also had testing for the BRCA1:G5193A PV. 
Those positive for the BRCA1 PV were subtracted (n=58), and from the 
remaining 1294, two sub-groups were formed by random selection (n=209). 
The first group included 104 women positive for the Icelandic founder BRCA2 
PV, and the second group had 105 negatives for the same PV. Related 
individuals to selected proband women were added incrementally to generate 
pedigrees with 1° to 6° relatedness. The average number of individuals in 
each degree of relatedness and the risk scores are shown in Table 10. The 
BOADICEA risk assessment program was unable to calculate risk for more 
than 275 individuals in one pedigree. This resulted in fewer families being 
included in the ROC analysis as the degree of relatedness got higher. 
However, this did not affect the calculation of 3 and 4° pedigrees as the 
highest number of individuals in 4° pedigrees was lower than 275. In 
contrast, some of the 5 and 6° pedigrees were not included due to their size. 
This may have affected the risk assessment for these categories of 
pedigrees. The lowest BOADICEA risk score for being a carrier for the 
Icelandic founder BRCA2 PV was 0.1% for all pedigrees. The highest risk 
score was relatively low for the 1° or 39%. In contrast, the highest risk score 
was similar for 2-6° relative, ranging between 86-93%. The complete risk 
score table is in the supplementary files (Suppl. risk score).  
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Table 10. The number and range of individuals in the different degree of relatedness 
and BOADICEA risk score for the ROC curve analysis 
Modified from Stefansdottir et al., 2018). 
Figure 9, A and B, shows the efficiency of predicting whether the individual 
had the Icelandic founder BRCA2 PV using pair wise comparison of ROC 
curves, adding increasing degrees of relatedness. C and D show the smaller 
and larger 3° and 4° pedigrees. 
The 1° to 3° sample size was 209 individuals, 104 positive (49,76%) and 105 
were negative (50,25%). Adding 2° relatives to the 1° relatives increased the C-
statistic from 0.62 to 0.70 (p <0.0023). The 95% CI was 0,291 to 0,134, the z 
statistics 3,046. The difference between areas was 0,815 and the Standard Error 
0,0268. Adding 3° relatives increased the C-statistic to 0.77 (p= <0.001). The 
95% CI was 0,0311 to 0,109, the z statistics 3,524. The difference between 
areas was 0,0701 and the Standard Error 0,0199.  
Inclusion of 4° relatives, group size 206, (103 positive and 103 negative) did not 
significantly affect the C-statistic which decreased to 0.76 (p=0.30). The 95% CI 
was -0,00988 to 0,0318, the z statistic was 1,029. The difference between areas 
was 0,0109 and the Standard Error 0,0106. The lower number group in 3° 
pedigrees was converted into 4° relative pedigrees for further evaluation but 
there was no improvement in the C-statistic (0.718).  
For further evaluation of the relationship between the pedigree size and 
efficiency of risk assessment, the 3° pedigrees were split into two groups, 
ranked based on number of individuals (Figure 9C). The lower number group (n 
=105, average no. of individuals 30, range = 9-46) had a C-statistic of 0.723 
(0,626 to 0,807, SE 0,0505) but the higher number group (n=104, average no. of 
individuals 133, range = 46-220) had a C-statistic of 0.823 (0,736 to 0,890, SE 
0,0419). The pair wise comparison of ROC curves showed that the 95% CI was 
Vigdís Stefánsdóttir 
64 
0,0294 to 0,228, the z statistics was 1,512. the difference between areas was 
0,0993, p=0,1304 and the Standard Error 0,0656.  
The 4° pedigrees group was also split in two groups, according to size. The 
lower number group (n =103, average no. of individuals 56, range = 15-87) had 
a C-statistic of 0.719 (0,622 to 0,804, SE 0,0509), but the higher number group 
(n=103, average no. of individuals 145, range 87-257) had a C-statistic of 0.815 
(0,727 to 0,885, SE 0,0423). The pairwise comparison of ROC curves showed 
that the 95% CI was -0,0338 to 0,226. The z statistic was 1,449. The difference 
between areas was 0,0959, p=0,1474 and the Standard Error 0,0662. 
A. Pedigrees including 1°, 2° and 3° relatives. B. Pedigrees including 3° and 4° relatives. 
Increasing the size of the pedigree from 3° to 4° did not improve prediction. C. The 
smaller and larger 3° pedigrees. D. The smaller and larger 4° pedigrees. Pedigrees with 
3° relatedness showed the best outcome. Comparison of pedigrees including 3°and 4° 
relatedness.  (Stefansdottir et al., 2019) 
Our conclusion, based on these results, was that the optimal size for risk 
assessment in HBOC genetic counselling, in this application was the 3° 
relatedness pedigree. There was no gain of efficiency by including the 4° 
relatives. In summary, the clinical experience of using EGPs was very 
favourable. They were convenient to use and gave better information than 
conventionally-made manual pedigrees. No adverse effects were noted.  
Figure 9. ROC curves demonstrating the effect of pedigree size on the efficiency of 
Boadicea risk calculations in predicting the presence of the Icelandic BRCA2 PV.  
 
65 
5 Discussion 
The main aim of this study was to evaluate the use of electronically 
generated pedigrees (EGPs) in HBOC genetic counselling risk assessment. 
The project was prepared and carried out in three different studies; as a 
systematic review, a qualitative study, and a quantitative study, to collectively 
gain knowledge and understanding of the various pertinent aspects. 
The systematic literature review had the primary goal of mapping the 
current use of electronic genealogy databases in the genetic health service  
(Stefansdottir, 2013). There was limited evidence of the use of such 
databases found in GC, for generating pedigrees, reflecting the little use of 
this method outside of Iceland.  
The qualitative study was done to illuminate the counsellees´ 
understanding and experience of having a genetic risk assessment for HBOC 
based on EGPs (Stefansdottir, V. et al., 2016). The results showed that 
participants agreed with the use of EGPs, and had trust both in the service 
providers and database information. There was some, albeit limited, concern 
regarding data security, especially about the potential for more restrictive 
insurance in the future. The concern was mainly that relatives, especially 
children or grandchildren of BRCA positive individuals would be denied 
health insurance if the information and genetic test results were accessible to 
third parties, such as insurance companies.  
The final study described the clinical genetics services experience of 
using EGPs, including the optimal size of the EGPs for HBOC risk 
assessment. The results showed a positive clinical experience of using a 
genealogy database and cancer registry as the source of data for 
constructing EGPs. Further, pedigrees including 3° relatedness, were 
determined to be the optimal pedigree size.  
5.1 Current use of electronic databases 
The terms used in the literature search were chosen carefully and included 
the words usually found in connection with the topic. Using both single words 
and combined search terms increased the chance of finding relevant papers 
compared to using only single words. 
The literature review did not show much evidence of the use of electronic 
databases to generate pedigrees in genetic health services. It identified only 
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four papers. A repeated literature search with the same search terms did not 
identify any new papers describing the clinical use of electronic databases in 
genetic counselling up to 2018. This outcome is intriguing, mainly due to 
great and growing interest in genealogy and genetic genealogy. The interest 
can be observed by the many available genealogy and genetic genealogy 
websites as well as within the news and social media discussion. Moreover, 
large genealogical and disorder databases are used for research as 
examples from, i.e. Utah, Scotland and the Scandinavian countries show 
(Ekbom, 2011; Cannon Albright et al., 2003;). Two research papers 
describing such use were among the four identified papers (Brewster et al., 
2004; Cannon Albright, 2006;). 
Consistent with this, no contacts have been made to inform me or my 
collegues about such use, despite the three studies presented in this thesis 
having all been published in international scientific journals and results from 
them introduced at international conferences. In addition, repeated questions 
by me to colleagues in other countries have not identified any such use. This 
further confirms that the use of electronic databases to construct pedigrees is 
either not, or only in a minimal way, used in clinical work outside of Iceland.  
There are several reasons why electronic databases would not be used 
for the construction of pedigrees. One reason might be lack of awareness of 
the possibility of using genealogy databases in clinical work. However, with 
the assistance of family history coordinators, some genetic counselling 
services gradually build up their own databases with information from 
counsellees themselves, with confirmation of cancer diagnosis from cancer 
registries and medical records when applicable. A second reason is that 
population databases of sufficient quality may not be available. The third 
reason is that evidence about the EGPs improved risk assessment is lacking. 
The fourth reason is limited information on the relationship between the size 
of pedigree and its efficiency in predicting risk and that the size of the optimal 
cancer pedigree is too large for generating it with traditional handmade 
methods. The fifth reason is that laws or regulations restrict the use of such 
databases in the clinic, even if they are sometimes used in research settings. 
These reasons are discussed further below. 
5.2 Availability of electronic genealogy databases 
Genealogy databases linked to health care information are already widely 
available, as reviewed in the Introduction section. Among them are the 
UPDB, in Utah USA, the Icelandic deCODE database and the Veteran 
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database  (Agarwala et al., 2003a; Cannon-Albright et al., 2013; Hakonarson 
et al., 2003). Increasingly, large genealogical databases have being created 
(Agarwala et al., 2003a). The most extensive examples to date are the 
Veterans Genealogy project with over 22 million records (Cannon-Albright et 
al., 2013) and the one described by Kaplanis et al., on genealogy data 
collected from the Internet. The pedigree derived from the collection 
comprises around 86 million individuals (Kaplanis et al., 2018). Another 
example of making genealogy database with clinical information would be 
one assessing EHR´s information, where next-of-kin is recorded. By this 
method, family information was collected from 7.4 million relationships and 
computer data on hereditability for 500 disease phenotypes. The phenotypes 
were diverse and were quantitative, as well as dichotomous (Polubriaginof et 
al., 2015). These and other similar data collections show that it is possible to 
use official data already available data to construct pedigrees that could be 
used in clinical settings if needed.  
Genealogy databases for constructing EGPs should be widely available.  
Quality, however, may be of concern in some instances. The best solution 
appears to be if the database is connected to a national registry and 
managed with sufficient resources, including careful curation. 
5.2.1 Genealogy genetics and cancer registries 
In the Western countries at least, much of the available data, both personal 
and non-personal, are kept in electronic databases. Recent developments 
have shed light on the immense data collection by various service providers. 
This results, in part, from the new General Data Protection 
Regulation (GDPR) in Europe, ensure that service providers are held 
accountable for keeping data secure (Trunomi, 2018). Because of this, new 
and updated Terms of Service have been sent out to users of websites that 
collect data. 
 Recently, investigators have been able to use a commercial genealogy 
service, where DNA genetic variants and information were uploaded and 
available to view by other users, to identify individuals who have committed 
crimes. This was done by comparing a sample of the criminal´s DNA found at 
the crime scene to available information on websites (Arango, 2018; Bolan, 
2018). It has led to concerns about the privacy and the possibility of the data 
being used for a different undisclosed purpose than was intended. Several 
direct-to-consumer (DTC) testing companies have agreed on assisting law 
enforcement in finding people (Daily Records, 2019). As shown above, it is 
relatively easy to construct enormous pedigrees only with information already 
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available on the Internet and the genetic data within the DTC databases will 
make it even easier.  
Cancer registries are mostly electronic and according to the International 
Agency for Research on Cancer (IARC) there are over 700 population-based 
cancer registries (PBCR) worldwide (IARC, 2016). Their purpose is to collect 
information on every case of cancer within a geographically defined area, 
analyze the data and report, (Bray F, 2014; Tyczynski JE, 2003). The PBCR 
have a critical role in cancer surveillance, in planning cancer prevention and 
cancer research. They rely on multiple sources for obtaining cancer 
information. Among those are laboratories, hospitals and death certificates. 
Many, but not all, require mandatory cancer registration. The ICR is a part of 
the IARC and is curated in a similar way, guided by regulations on what 
needs to be included and how the data is presented and accessed (Alþingi, 
2007; Sigurdardottir et al., 2012). This ensures the accurate and 
comprehensive information used in constructing EGPs.  
The Nordic countries have excellent PBCRs and genealogy data. In 
Ireland and Scotland at least, genealogy records exist very far back (Collyer 
& De Mey, 1987; Scottish/Northern Irish, 2003). In these countries as well as 
in most European countries, cancer registries are comprehensive and have 
the potential along with genealogy databases to be used in constructing 
EGPs to be used in a similar way as we have described.  
In accordance to the results from Study III, to be able to use a genealogy 
database in genetic health services in relation to cancer, it needs at a 
minimum to contain information about all those already listed in the cancer 
registry, and preferably their 3° relatives. 
As most population-based cancer registries in the Western countries were 
established after 1950, individuals alive then should be in the database. Most 
of the cancer registries in the Western countries have comprehensive 
information, although registration is not compulsory in all countries (Pineros 
et al., 2017).  
The Directorate of Health in Iceland holds vast information on population 
health, but the setup of data regarding other diseases than cancer does not 
allow for the integration of other disease information into pedigrees. In 
general, cancer registries appear to be the best-suited disease databases to 
use in constructing EGPs. It is preferable if the registration of cancers cases 
is mandatory to ensure the completeness of registration.  
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5.3 The efficiency of EGPs in risk assessment 
Using data from electronic databases to rapidly assembly large EGPs for 
HBOC genetic counselling, adds considerably to the information received 
from the counsellee only, due to the large size of the pedigrees and amount 
of cancer information included as demonstrated in Study III. Studies have 
shown that collecting information for large pedigrees by conventional 
methods can be difficult and is time- and labour consuming (Lu et al., 2014). 
Our method lessens the counsellee’s need to obtain information about 
relatives and health care professionals´ work in collecting various information, 
such as confirmation of cancer diagnosis, for the pedigree. 
Large EGPs can reveal clusters of cancers or patterns of disorders in 
families, sometimes different from what was expected. As such, they could 
be used to monitor disease burden within societies and families with the 
possibility to intervene and help identify those who should be offered genetic 
testing. One of the articles identified in the literature review described how 
large pedigrees were used to find relatives of those with hypercholesteremia 
by tracing known carriers of a PV to common ancestors and finding the oldest 
offspring in each lineage. Their method added considerably to the existing 
method of finding those at risk (Thorsson et al., 2003). Another example is a 
paper by Palsdottir (2008), demonstrating clearly in a large pedigree that 
there was a drastic reduction in life expectancy among those who had the PV 
associated with Hereditary cystatin C amyloid angiopathy (Palsdottir et al., 
2008). EGPs can affect surveillance plans by assessing the cancers within 
the larger family. Solomon et al., in 2015, published results from a study 
showing that extensive family histories are better in identifying those who 
should be referred for genetic counselling and testing (Benjamin Lev 
Solomon, 2015). This was supported by a study by Taylor et al., (2010) 
describing the use of the Utah Population Database with linkage to a state-
wide cancer registry to determine the risk of colon cancer. The main outcome 
from their study was that positive family history in second and third-degree 
relatives increased the proband´s risk of getting colon cancer significantly, 
supporting the value of extended family history (Taylor et al., 2010). These 
studies, combined with the clinical experience from Iceland, support that 
large and comprehensive EGPs add considerably to the conventional manual 
method as well as being more accurate.  
BRCA2 positive individuals are at increased risk for several cancers, 
among them pancreatic cancer (Mersch et al., 2015). The large EGPs have 
the potential to reveal pancreatic cancer in 3° or 4° relatives in BRCA2 
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families, thus changing the surveillance plan. Clear guidelines do not exist on 
surveillance for those at increased risk due to genetic status. The 
International Cancer of the Pancreas Screening (CAPS) Consortium has 
suggested that BRCA2 positive individuals with at least one affected first-
degree relative, or two affected relatives within second-degree, could be 
considered for surveillance for pancreatic cancer (Canto et al., 2013). In 
addition, at Landspitali, those with the Icelandic founder BRCA2 PV and one 
1° relative, two 2° relatives or three 3° relatives with pancreas cancer have 
been referred for surveillance. This is partly based on results from the study 
by Chiaro et al. (2015) in Sweden. In this study, 40 patients, with genetic risk 
for getting pancreatic cancer (three were BRCA2 positive), were enrolled in a 
screening program using non-invasive magnetic resonance imaging (MRI) 
Using MRI, 40% of the high-risk patients were found to have lesions, some 
requiring operation, but most were benign (Del Chiaro et al., 2015).  
5.3.1 The optimal size of pedigrees in cancer genetic 
counselling 
We used the BOADICEA risk assessment tool for calculating the likelihood of 
having the Icelandic founder BRCA2 PV. BOADICEA has been validated and 
is widely used in HBOC genetic services as well as in sutdies (Lee et al., 
2014; MacInnis et al., 2013). As such, the program calculates the likelihood 
of having a PV in selected genes and the risk of getting breast and ovarian 
cancer based on family history. At the time of our study, the BRCA genes 
were the only ones used in the risk calculation, other genes were added later. 
The program has its limitations. One is that it cannot calculate families larger 
than 275 individuals. The decision to use BRCA2 families only was due to the 
high frequency of the PV in Iceland and the fact that PV in the BRCA1 gene 
is not common in Iceland. 
To date, we are not aware of any studies evaluating the optimal size of 
the pedigree for risk assessment in cancer GC similar to the work in Study III. 
In this study, the genetic status of each proband was already known, and the 
risk calculations by BOADICEA could be verified. In a study by Moller (2007), 
a concern was raised about the general efficiency of the family history as a 
base for risk assessment regarding HBOC (Moller et al., 2007). There is, 
however, little information on how much this study reflected on the quality of 
the information in the pedigrees or if they were large enough.  
Our calculations in Study III, strongly indicate that the 3° pedigree is the 
optimal size for risk assessment in HBOC genetic counselling. The results 
were not self-evident, but at the same time not surprising. Adding 4° relatives 
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did not improve the outcome from 3°pedigrees. To ensure that the outcome 
was less based on the number of individuals, rather than the relatedness in 
the pedigrees, we divided the 3 and 4° pedigrees into smaller and larger 
pedigrees, based on the number of people in each group and calculated the 
risk of having the Icelandic founder BRCA2 PV. The number of individuals did 
not significantly change the outcome, indicating that the degrees of 
relatedness was the primary determinant of the outcome, 
A significant result from this work is that the optimal size of cancer 
pedigree is 3° large. Such a pedigree is very difficult and impractical to 
generate using the conventional handmade technique. This should create a 
motive to use EGPs. 
5.4 Ethical and legal restrictions 
There are two key questions when discussing the ethical and legal aspects of 
constructing and using EGPs. The first one is whether one can gather 
information on relatives based on presumed consent. The second main 
ethical question relates to the obligation of communicating relevant 
information to relatives.  
In genetic services, similar to other health care services, there are several 
stakeholders. Their rights and duties, harms and benefits must be considered 
carefully in genetic counselling. The primary stakeholder is the counsellee, 
whose rights it is to have the best possible service with minimal risk to 
autonomy, confidentiality and well-being. Second are the relatives of the 
counsellee, whose relevant rights are to confidentiality, privacy and 
autonomy. The third stakeholder is the counsellor whose interests include 
providing accurate information, risk assessment, and the best psychosocial 
care as possible, while ensuring privacy and confidentiality of all included. 
Last, there is the health care system, benefitting from the practical use of 
resources while providing quality care.  
The genetic counselling sessions can be complicated with lots of 
information and discussion of ways of contacting relatives for information 
purposes as well as an outcome from genetic testing, psychosocial issues 
and confidentiality. The counsellee or patient has a right to confidentiality 
regarding health care information and results of genetic testing. At the same 
time, the genetic information and test results can prove to be a benefit to the 
counsellee relatives' well-being (Lucassen & Hall, 2012). The need for 
information sharing and confidentiality must be considered. This may be 
especially important in Iceland where the population is small as in Iceland.  
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5.5 Consent  
A good and ethical practice, whether in healthcare or research, requires that 
valid consent is obtained from patients and participants. The consent must be 
simple enough to be understood by all in question, while including sufficient 
information to enable an informed choice. Genetic services differ from other 
healthcare services as the issues usually concern the family, rather than the 
counsellee or patient alone. Genetic germline tests which are often a part of 
the service, provide indirect information about relatives apart from the 
counsellee. Family health and genealogical history are collected to assess 
risk and clarify inheritance mode of the suspected or known disorder, most 
often from the counsellee or a family member. In Iceland, neither the initial 
handmade pedigrees nor the EGPs are a part of the counsellees medical 
records. They are kept separately in the genetics service files with limited 
access. The official medical records only contain information about the 
consent itself and general results on risk and diagnosis. This is due to the 
nature of the information within the pedigrees, i.e. the information about 
relatives. However, there is a clause in the initial consent form for generating 
the pedigree, on the update of the pedigree with new information emerging in 
the future.  
To ensure that the consent for generating the pedigree is freely given, the 
counsellees are informed that it is not obligatory. They receive information on 
how the pedigree, once made, would be used for their and their families’ 
benefit as a tool for risk assessment. This may put pressure on the 
counsellee to sign the consent, although this is standard practice in genetic 
counselling. Without family information, i.e. a pedigree, it is more difficult to 
assess the risk, unless there is a known PV in close relatives.  
The most important ethical question about the EGPs is whether presumed 
consent is sufficient to gather information on relatives, either from the 
counsellees or databases. An absolute requirement would be that there is no 
added information risk and that autonomy is preserved. 
5.6 GDPR and personal data 
European regulations on data protection are key documents in discussing the 
legal framework for using cancer registries to generate EGP based on 
presumed consent. In 2011, the European Network of Cancer Registries 
(ENCR) and the IARC published “Guidelines on Confidentiality and ethics for 
population-based cancer registration and linked activities in Europe”, version 
3. (European Network of Cancer Registries Working Group on Confidentiality, 
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2011). In article 3.5, they discuss the use of cancer registry data and genetic 
counselling. It begins by addressing the fact that genetic counselling is not of 
public interest, but rather a service to families and individuals. Large EGPs 
can have several thousand individuals, and in cancer GC, they include 
information from the Nationwide ICR. The article continues to state that data 
from cancer registries can only be used on the basis of informed consent 
from each living individual in a pedigree. Still, information about deceased 
individuals can be released without consent. They state without argument, 
that the exceptions to using personal data without consent, as listed in the-
then current Directive 95/46/EC of the European Parliament and of the 
Council on the protection of individuals, with regard to the processing of 
personal data and on the free movement of such data, based on public 
interest or preventive medicine, do not apply. Thus, they decide to follow the 
UK precedent that consent is needed for the release of data on living persons 
for genetic counselling. However, they also mention the risk of inaccurate risk 
estimation in genetic counselling that might be an issue of public interest. In 
May 2018, the new EU General Data Protection Regulation (GDPR) replaced 
Directive 95/46/EC. Similar to the old Directive 95/46/EC, the GDPR explicitly 
prohibits the processing of personal data without consent unless specific 
conditions are met. The text in Article 9, paragraph 1 states:  
“Processing of personal data revealing racial or ethnic origin, 
political opinions, religious or philosophical beliefs, or trade 
union membership, and the processing of genetic data, 
biometric data for the purpose of uniquely identifying a natural 
person, data concerning health or data concerning a natural 
person’s sex life or sexual orientation shall be prohibited." 
However, in paragraph 2, there are listed several exceptions to the rule. 
The following two exception clauses are relevant to this discussion:  
h) "processing is necessary for the purposes of preventive or 
occupational medicine, for the assessment of the working 
capacity of the employee, medical diagnosis, the provision of 
health or social care or treatment or the management of health 
or social care systems and services on the basis of Union or 
Member State law or pursuant to contract with a health 
professional and subject to the conditions and safeguards 
referred to in paragraph 3;" 
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"i) processing is necessary for reasons of public interest in the 
area of public health, such as protecting against serious cross-
border threats to health or ensuring high standards of quality 
and safety of health care and of medicinal products or medical 
devices, on the basis of Union or Member State law which 
provides for suitable and specific measures to safeguard the 
rights and freedoms of the data subject, in particular 
professional secrecy." 
In 2011, the GDPR had not been enacted, but as stated above, it does not 
forbid the use of data as these guidelines show. Participants in study II found 
the use of EGPs to be acceptable as a part of the services and the clinical 
experience supports that outcome. In some cases, participants expressed 
their belief that all the information needed to make the pedigrees were 
already available within the clinical services (Stefansdottir, V. et al., 2016). 
This has also been the experience in the clinic where counsellees have been 
surprised about the need to get information about them and their families 
from elsewhere than the hospital system. This can be partly because of the 
availability of genealogy information in Iceland, where genealogy is public 
and readily available for those interested and a favourite past-time activity. 
There is generally much trust regarding official information which is kept 
securely and used in a proper way for the inhabitants.  
In Study II, most participants said that they trusted the service and how 
the information was used and supplied. Participants also found the method of 
using data from relatives acceptable and useful if the data was secure, the 
pedigrees were used for the purpose they were meant for, and there was no 
threat of discrimination from the use. As for autonomy, during my over 13 
years of both academic and clinical experience of genetic counselling in 
Iceland, I have discussed the possible harms and benefits of using extensive 
family history in the clinic, with counsellees and professionals. No relative has 
been opposed to the use of his or her data for genetic counselling. 
Collectively, this experience shows that relatives very rarely, oppose to the 
use of their data being used for generating EGP with the objective of risk 
assessment of a relative given enough data protection. Infringement on 
autonomy has therefore been minimal.  
My understanding, like the European Network Registries, is that the 
European regulations are not absolute when it comes to releasing information 
on individuals in cancer registries without consent. Rather, they are subject to 
interpretation depending on the situation. My thesis work demonstrates the 
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importance of using EGP and that the optimal size of pedigrees is impractical 
to construct without electronic databases. These results should influence the 
interpretation of GDPR and whether genetic counselling with EGPs is of 
sufficient public interest and with relevance for public health and preventive 
medicine. The GDPR permits state legislation to permit this use if felt 
necessary. However, it is important that the information is handled by 
competent professionals in GC and that specific measures are in place to 
protect the rights and interests of the persons in the EGP. 
5.7 Presumed consent and EGPs 
It is impractical not to use presumed consent on behalf of relatives to 
construct EGPs. In health care, it is traditional to document the family history, 
with a presumed consent of relatives included in the pedigree. This applies 
both for manually made pedigrees and those made with information derived 
from genealogy records. In the context of family history taking, the presumed 
consent infers the expectation that relatives would not object to the use of 
their information if asked for permission. Indirect benefits for the relatives, 
should they come for GC, is that there will be already available information 
about the family, with risk assessment and the genetic status of any tested 
relatives. It would be challenging to contact every member of each family to 
ensure his or her consent and even cause alarm as some might be 
distressed of learning in this manner that they had a possibility of health risks 
(Lucassen et al., 2006).  
As for presumed consent for family information in health care, 
professionals exchange information about individuals and families when 
needed to provide for the best possible health care. The Joint Committee on 
Medical Genetics in the UK (2011), e.g. concluded that health professionals 
could share clinical information and family history given their duty of 
confidence (Royal College of Physicians, 2011). This practice is widely 
agreed upon as the information is used for the benefit of the counsellee and 
in many cases, other family members. 
The consent for the construction and uses of pedigrees in GC can in 
some ways be compared to consent for participation in scientific health 
studies. The study consent can be narrow and apply only to the current study 
or for a predefined period (Grady et al., 2015). It can also be broad, 
(Hofmann, 2009), applying to a number of studies or dynamic where the 
consenter has the option to withdraw the consent at any time. It should be 
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able to cover follow up studies, that his or her data are being used in 
(Hansson et al., 2006; Ploug & Holm, 2015). 
5.8 Ethical issues regarding this study 
Important ethical issues include the use of EGPs in genetic counselling, 
consent, especially presumed consent of relatives, autonomy, justice, 
confidentiality, disclosure and non-disclosure. These issues have been 
addressed in light of GDPR, which were implemented after the study period. 
When performing a study upon one´s patients or counsellees, there is always 
the possibility of a conflict of interest. It must be clear that participation in the 
study is genuinely voluntarily and that the research is unrelated to the 
treatment. The researcher must make sure that these conditions are met. All 
active participation in Study II was built on informed consent. Study III was 
done on data already present, and no personal identification information was 
used.   
5.9 Data privacy 
EGPs are not shown to the counsellees as they contain information about 
others in the family. In genetic counselling, where various health and 
genealogy data are collected, the genetic counsellor must ensure that there 
is no significant new risk associated with the procedure, in addition to the 
sensitive information already in the health care system.  
One of the findings from Study III was that no known data breach was 
identified by using EGPs. This is particularly important considering recent 
developments regarding data security such as data distribution to third 
parties and the GDPR. In Recital 54 of Article 9 in GDPR, states:  
“The processing of special categories of personal data may be 
necessary for reasons of public interest in the areas of public 
health without consent of the data subject. 2Such processing 
should be subject to suitable and specific measures so as to 
protect the rights and freedoms of natural persons. 3In that 
context, ‘public health’ should be interpreted as defined in 
Regulation (EC) No 1338/2008 of the European Parliament and 
of the Council (11), namely all elements related to health, 
namely health status, including morbidity and disability, the 
determinants having an effect on that health status, health care 
needs, resources allocated to health care, the provision of, and 
universal access to, health care as well as health care 
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expenditure and financing, and the causes of mortality. 4Such 
processing of data concerning health for reasons of public 
interest should not result in personal data being processed for 
other purposes by third parties such as employers or insurance 
and banking companies”. 
In light of the increase in genomic data, there is a need for more 
discussion about privacy and how data is collected and used in health care. A 
possible example of misuse could be an insurance company asking for 
medical records which include genetic test results. Genetic test results do not 
only apply to the person in question but also to relatives, making 
discrimination based on genetic information possible. Some of the 
participants in Study II, expressed worries over the possibility that data from 
the genetic services, the EGPs included, would be used by insurance 
companies. This in turn, could possibly result in higher premium cost or even 
in some cases, non-insurance for them and their descendants. To protect 
from such use, in addition to GDPR, the Genetic Information Non-
discrimination Act, protecting individuals from genetic discrimination, 
(Akulenko et al. 1991) by federal law, in health insurance and employment 
(Department of Health and Human Services (HHS), 2009), exists in the USA. 
In Iceland, there are specific laws on the protection of personal data, with 
similar text as in the GDPR, (Alþingi, 2018).  
There may be a need for specific regulation regarding who can access the 
pedigrees, to keep EGP data more secure. It must be considered whether 
and under what circumstances data can be transferred between services or 
even countries, given differences in rules and legislation. A decision should 
also be reached on whether and to what degree the pedigrees should 
become a part of a patient´s general medical record, taking the same 
arguments into account. There are pros and cons to that possibility; having 
access to the family history in a pedigree within the medical records could 
enable healthcare professionals to assess it quickly and therefore decide on 
testing based on pedigree information. As discussed above, a pattern of 
inherited disorders or early deaths or unusually common instance of a 
specific disease might be noticed in a pedigree. There has been some 
discussion about pedigrees used in genetic health care, how they should be 
kept and who should be able to access them apart from the professionals in 
each service. In a recent article, Scott and Trotter suggest that pedigrees with 
medical information should be kept as a part of electronic health records for 
easy access to possible familial diseases (Scott & Trotter, 2013). However, 
as discussed above, pedigrees include sensitive personal information not 
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only about the counsellee but relatives as well. Therefore, information about 
others would be included in the health records, which is not appropriate.  
Health data, EGPs included, already have in place strict access 
regulation. At Landspitali, the work and setup have already been evaluated 
by the data manager, accepting the access regulation in place (Stefansdottir, 
unpublished data).  
5.10 Trust 
Trust towards genetic services and professionals is important as the very 
nature of genetic counselling is based on discussion, assistance and 
resolution of sensitive issues. Our results from Study II showed that 
participants generally trusted the service, the professionals, and the EGPs. 
However, this may in part be because participants had, necessarily, 
consented twice before participation; first to receive genetic counselling, and 
later in agreeing to participate in the study. However, differences in social 
and cultural context may make people less or more trusting. Ford et al., found 
that African-American women in urban health care did not trust the health 
care system and that Caucasian women who had not received genetic 
counselling did not trust the accuracy of the genetic testing (Ford et al., 
2007). However, Riesgraf et al. found an overall favourable attitude towards 
genetic counselling in a rural community in the USA with 203 adult residents 
(Riesgraf et al., 2015). Icelanders are willing to participate in genetic studies 
and are very positive towards such studies (Rafnar et al., 2004). The positive 
experience of using EGPs in genetic counselling is consistent with this. As 
described elsewhere in this thesis, there is, in general, overall positive 
attitude to genealogy information being publicly available for all in Iceland. 
5.10.1 Information sharing 
Knowing one´s genetic risk is necessary for decision making, but some may 
not wish to know or like to control when andhow they receive the information. 
The counsellee is the one coming for genetic counselling and the one that 
receives the information about the potential risk to others should he or she be 
positive for a pathogenic variant. Therefore, the counsellee is customarily the 
one expected to inform relevant relatives who can then opt for genetic 
counselling. The right to know or not know is strong. At the same time, 
relatives need reliable information to be able to decide if they want genetic 
testing, they have a right to privacy and not to be disturbed by getting 
information they may not want. It is common practice to send information 
letters meant to be read by relatives. This method is not always applicable 
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due to various reasons such as not knowing their relatives, not being 
comfortable with contacting them, or not finding themselves able to explain 
the situation. In such cases, it is in some places possible, with permission 
from the counsellee, for the genetic services to contact relatives and inform 
them of the familial pathogenic variant. It is, however, already used in some 
situations, such as in familial hypercholesterolemia (Knowles et al., 2017). 
Another method could be to use health care portals such as Heilsuvera in 
Iceland (https://www.heilsuvera.is), where the information could be tied to 
genealogy data to identify and inform relatives. One possible implementation 
would be to inform 1° relatives, of those who have positive test results about 
the PV. If the proband agrees, this could possibly be enlarged to 2° relatives. 
This would work similarly to cascade screening, apart from the involvement of 
the counselee, as he or she would not need to inform relatives. However, as 
soon as an individual is informed and has positive testing results, he or she 
becomes the proband whose relatives will be contacted. Therefore, the 
connections would be like small interconnected clusters of people, increasing 
in numbers until the last person in the cluster tests positive. This method 
solves the problems regarding communicating genetic information about 
family members from other professionals or the counsellee (Lucassen et al., 
2006). Using some form of cascade screening, whether it is done by 
contacting relatives directly or using a health portal, does, however, open the 
question of if there is a duty to inform relatives. 
There is an ongoing debate on the return of incidental and secondary 
findings from research and clinical testing, where how and if to return them. 
Thorogood et al. (2019) published an article about the return of individual 
results from WGS, where the different laws and regulations are listed, some 
recited here: In Spain, the laws require the return of health information 
overriding the consent of patients [25, art. 4.7]. In France, physicians are 
required to give genetic test results to relatives, if the counsellee/patient 
refuses to do so [20, art. R1131-20-2]. In Italy, the law authorises the 
disclosure of genetic results to relatives [22, art. 9]. (Thorogood et al., 2019).	
Large EGPs contain information about relatives that can in some ways be 
compared to genetic test results and as discussed later, could perhaps be 
used to inform relatives of genetic risk should and whether they come for 
genetic counselling and testing.  
It must be kept in mind that relatives might have diverse reactions to the 
offer of genetic testing, offered without their prior knowledge of genetic risk 
within the family. Although not related to this research, the experience of 
web-based release information about BRCA2 status shows that individuals, 
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who had no idea beforehand about their genetic risk, react differently to the 
information from those who have been prepared (Stefansdottir, V. 
unpublished results). 
5.11 Awareness of genetic counselling in Iceland 
Genetic counselling in Iceland was formally organised as a part of the 
medical genetics department in 2006 when I started working there after 
having finished the MSc genetic counselling program at Cardiff University. 
Earlier, medical doctors with training in genetics and an oncologist had 
offered genetic counselling. At the beginning of my work, I noticed the 
relatively little awareness and experience counsellees had of genetic 
counselling. This, in turn, initiated some of the questions in Study II. This has 
changed, and in the last few years, awareness of genetic counselling has 
increased rapidly. At the end of 2018, very few counsellees expressed no or 
very little knowledge about genetic counselling when asked in or before the 
clinical appointment (Stefansdottir, unpublished results). In Study II, most 
participants had sought genetic counselling due to a family history of cancer 
or after receiving information about positive genetic test results from relatives. 
In the same study, the majority said that they had prior knowledge of genetic 
counselling. In comparison, two recent studies, one in Canada and the other 
one in the USA, showed that less than half of participants had prior 
knowledge of genetic counselling. In the Canadian study, 1000 individuals 
were asked about their knowledge, and 69% of respondents had not heard of 
genetic counselling (Maio et al., 2013). Another study from the Midwest in the 
USA had a similar outcome where few of the respondents had knowledge 
about genetic counselling (Riesgraf et al., 2015).  
Our results from Study II are interesting in the light of the short history of 
genetic counselling in Iceland compared to both Canada and the USA. 
However, most of the counsellees at Landspitali, which also were our 
participants in Study II, were in families with possible HBOC. They may have 
been following the discussion of inherited cancer in the Icelandic media more 
closely and therefore had a better knowledge of genetic health services than 
others in the society. Within the cancer GC service, knowledge about genetic 
counselling has been especially noted within families with HBOC 
(Stefansdottir, unpublished results), following Angelina Jolie´s letter to the 
Times in 2013. In this letter, she revealed her BRCA status and encouraged 
women to seek genetic testing (Angelina Jolie, 2013).  
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5.12 Family dynamics 
Genetic information such as test results, affects not only the counsellee but 
also other family members. In the Icelandic genetic services model, the test 
results are given to the counselee, who then decides whom to share the 
information with and the responsibility to do so. In families with poor 
communication or where there is emotional distance, there is a greater risk of 
failure to share the information (Daly et al., 2016). 
Family communication can be difficult, especially if the counselee has to 
inform relatives about the possibility of a genetic PV (Parker & Lucassen, 
2003). When deciding who of the relatives should be contacted with genetic 
information, counsellees weigh many factors such as relatives´ coping skills, 
their stage of live and perceived vulnerability. For some families in Study II, 
the knowledge of having a common PV appeared to strengthen the family 
bonds. Family communication was either unchanged or improved following 
genetic counselling and participants encouraged other family members to get 
genetic counselling. Some of the counsellees have formed closed social 
media groups where they can share results and information with relatives 
whom they may not be in much contact with otherwise (Stefansdottir, 
unpublished results). We did not assess how many relatives each positive 
counsellee informed about the results. However, my empirical experience 
shows that in many cases, first and second-degree relatives contact the 
service within the first week after the first positive test results. All those who 
tested positive received an information letter to distribute among relatives. 
This letter is important and allows counsellees to inform relatives as well as 
helping them to find out how to seek genetic counselling if they like. As one 
participant in Study II said: “I asked everyone if they wanted to get the 
letter… and all did... Most of those have been to GC and also their children 
who are old enough”. Not everyone finds a way to inform relatives. In a study 
performed in 2013, some family members only disclosed information to a 
very few selected relatives or not at all (Lafreniere et al., 2013). The overall 
attitude towards testing, disclosure of results and family communication in 
families with the Icelandic founder BRCA2 PV was positive in our study, and 
my clinical experience supports this. 
5.13 Implications for clinical practice 
Professional genetic service needs to have fast access to accurate and 
comprehensive pedigrees with relevant medical information for risk 
assessment and surveillance recommendations. Of note, the ASCO Expert 
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Statement (2014) stated that using digital health records could help collect 
and interpret family history in order to assess the cancer risk and that one of 
the goals should be the development of resources and electronic tools for 
integration of cancer genetics into the practice (Lu et al., 2014).  
In Study II, we found that counsellees, in general, had a positive attitude 
towards the use of EGPs. This may prove to be a valuable insight for other 
genetic health care services contemplating the use of electronic pedigrees. In 
cost-sensitive healthcare, using the combination of a comprehensive 
genealogy database and high-quality cancer registries to construct EGPs if 
possible, seems to be an effective use of limited health resources. Using less 
time and workforce to collect information for pedigrees, should lead to shorter 
waiting time for the service. 
As reviewed elsewhere in the Discussion section, the databases to 
support constructing EGPs should be available in several countries or could 
be made in many instances. The legal framework in Europe at least should 
not prohibit this use, or at least special law can be made to permit 
constructing EGPs. There do not seem to be any ethical issues that cannot 
be addressed. The approach described in this thesis, therefore, has the 
potential of being transferrable to other countries to facilitate GC in cancer 
genetics.  
5.14 Strength and limitations of the study 
A strength of this study was that the databases are population-based, 
accurate and include a whole nation. Such databases are not readily 
available elsewhere for clinical use, although extensive databases have been 
formed in some instances for use in scientific research. The study focussed 
mainly on one prevalent founder pathogenic variant with known prevalence in 
the population, so the risk assessment of having the Icelandic founder 
BRCA2 PV could be verified. The risk assessment program BOADICEA was 
unable to calculate risks in larger pedigrees than 275, which initially was 
thought to be a limiting factor, but turned out not to be. The limits of the 
technology implemented, however, are certain to diminish over time.  
Qualitative studies are a way of gathering non-numeriacal data in a a 
scientific way. They can enlighten why and how specific phenomenon may or 
has occurred and describe it. In light of the small cohort in Study II and mixed 
methods, the descriptive thematic analysis was chosen. It would have been 
possible to use constant comparison derived from grounded theory or a 
framework analysis and the findings might have been evaluated differently. 
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The approach of descriptive thematic analysis without a specific theory may 
have been a limiting factor.  Thematic analysis method enables rich data to 
be collected and analysed without restrictive prior categories and has minimal 
organisational effects. It allows for searching for patterns across the entire 
data set, rather than within each interview or data for each participant 
separately 
A limiting factor was that this study was conducted in a small country, with 
a relatively small study group with one type of inherited cancer in a society 
where most individuals have a similar culture. This setting may not be 
applicable elsewhere. 
5.15 Reflective account 
This PhD project was somewhat challenging as some of my former 
counsellees were also my study cohort. To be able to look at both the clinical 
and the academic side of genetic counselling has, in my mind, reinforced my 
knowledge of both areas. My clinical work has been and will be influenced 
and structured by the added knowledge obtained from the study, while the 
study benefitted from my experience with clinical work. In fact, I find that 
being a genetic counsellor for this patient group made it very difficult not to 
perform the study. However, juggling the responsibility of extensive clinical 
responsibilities at the same time as undertaking a PhD project certainly 
required me to prioritise clinical work over continued progress on the 
research project. 
Genetic counselling is a profession that fundamentally is concerned with 
people and their genetic status. Working with people has always been of 
interest to me, especially if it is possible to assist with issues arising from 
genetic information. When I finished my MSc degree in genetic counselling 
and returned to Iceland to work, I had the vision of working primarily in the 
field of rare disorders and at-risk pregnancies. Hereditary cancers were low 
on my list of priorities, possibly because of my long-time fear of cancer. 
However, as soon as I began working in cancer genetic counselling, my 
interest in the families and the variation in family history and their penetrance 
increased and soon became a passion.  
Early in the process of genetic counselling, the genetic services at 
Landspitali received permission to use the genealogy database in the clinic 
and the ability to obtain information from the cancer registry for better risk 
assessment. This enabled the generation of large pedigrees, and 
consequently, my interest in these families increased. I wanted to know more; 
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to understand how the Icelandic founder BRCA2 PV segregated within 
families, know if other pathogenic variants could explain strong cancer family 
history, how the Icelandic founder BRCA2 PV had spread in the country and 
what kind of cancers were in the families where the BRCA PV variants were 
found. One possible future study option was to assess the differences in 
penetrance between families. These are interesting topics for future study but 
not directly relevant to this thesis.  
Performing a study on the main subject of one´s work is simultaneously 
easier and more complicated than using something completely unrelated. 
Genetic counselling is performed on a highly personal level, which impacts 
the process and the outcome. Everyone has a face and a name rather than 
existing as a record in an Excel file, as is often the case in scientific studies. 
The boundaries between work and study can become blurred, especially 
when the studies directly concern one´s counsellees. It is, however, 
imperative not to confuse the study with the clinical work. 
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6 Conclusions and further studies 
In this thesis, I aimed to identify and analyse the work already published on 
the use of genealogical databases to generate pedigrees in genetic health 
care. The next part of the thesis was a qualitative study to examine the view 
of the user, the counsellee. In the last part, I looked at the experience and 
practicality of using EGPs in clinical services. The main findings in this work 
(Studies I-III) are that, although electronic databases are not used in cancer 
genetic counselling in general, in other countries, their use facilitates a more 
accurate and comprehensive family history. 
From the results of the literature review (Study I), there was little evidence 
of the use of genealogy by others as a source for pedigrees in genetic health 
services although there seems to be an interest. In some cases, we found 
e.g. articles about the possibility of using electronic databases to either 
lessen the workload or make family history more accurate and 
comprehensive. A new systematic literature search could evaluate the impact 
of the search terms. New and added search terms would be “inheritance”, 
“familial”, Fhx, and “computer-based family history”. These terms were 
frequently used in the articles identified both in my searches.  
In the qualitative part of the study (Study II), the main aim was to assess 
the counsellees´ experience where EGPs were used in HBOC genetic 
counselling. We found that participants in the study, who all had been to 
cancer genetic counselling prior to the study, were in general positive 
towards using EGP´s for risk assessment and trusted the service and 
information used for generating the pedigrees. These results concur with our 
13 years of experience of using the EGPs in the genetic counselling service 
in Iceland, where counsellees have in many cases found it self-evident to use 
available genealogy and cancer registry. 
We gained valuable insight into family dynamics and communication in 
families with high risk or confirmation of having a BRCA mutation. Replies to 
questions about the service gave us information about how to make it better. 
Our conclusion from this study was that counsellees received the use of 
EGPs well. The counsellees also valued the extensive information aiding risk 
assessment. The method of using online focus groups was unusual, and it 
could be interesting to repeat the study with different methods. To further 
assess the method, using participants of different age and gender and 
compare to a similar cohort as in this study would be interesting. Using three 
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different methods for comparison; a face-to-face focus group, online focus 
group and questionnaires could reveal a difference in outcome due to the 
method alone. Additionally, having different age groups in the study could 
shed light on different views of young people versus older ones. Another 
possible angle would be to contact individuals from the study and follow up 
on the questions asked to see if views or family dynamics have changed over 
time. 
Of personal interest initially would be to collaborate with investigators in 
other countries, to better assess the attitude toward using EGPs elsewhere. It 
would be particularly interesting to set up a program using a genealogy 
database to generate pedigrees and study the effects in a country different 
from Iceland. 
In the last of the three studies, we aimed to determine the practicality of 
using large EGP ́s in HBOC genetic counselling. This included calculating the 
optimal size of a pedigree for risk assessment, balancing the cost of 
ascertainment. The optimal pedigree size included 3° relatives and adding 4° 
relatives did not add information to the risk assessment. The clinical 
experience supports the use of EGPs as we have not experienced any 
adverse effects of using them. It is impractical to try to do large pedigrees by 
hand and seeking all relevant information for them. In clinical work, the larger 
pedigrees enabled finding remote relatives who had also been tested. Larger 
pedigrees can also be used to determine if a counsellee has a distant relative 
with a BRCA PV, thus potentially changing the risk assessment of the 
individual.  
This study only included HBOC cases. It would be informative to test 
EGPs for other types of common cancer syndromes, preferably syndromes 
where tumours are not mainly gender-specific. One ideal subject would be 
Lynch syndrome which is relatively common with a prevalence of about 1 in 
500 (Steinke et al., 2013). In Iceland, it is estimated that 1 in 226 has a 
genetic predisposition to Lynch syndrome (Haraldsdottir et al., 2017). It is 
non-gender specific and increases the risk of many cancers. Such a study 
may shed light on several existing problems. Applying EGPs in studies of 
other genetic non-cancer syndromes would also be of interest in the hope 
that the results may reveal a pattern. However, in Iceland, at least, no equally 
comprehensive disorder databases other than the cancer registry are 
currently available, although groups of people with the same diagnosis could 
be found by using ICD numbers. Such registries might have to be set up prior 
to the conduction of any such studies and it would have to be highly curated. 
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It is challenging to determine the cost of generating pedigrees, but we 
attempted to calculate the workload in Iceland. We found the cost to be 
reasonable, taking into the account how much information the pedigrees 
include and when comparing to the work needed elsewhere to collect various 
information for risk assessment. Our results indicate that using EGPs is cost 
effective and work reducing. This could be interesting to pursue further by 
doing a comparison study with comprehensive questionnaires, between 
Iceland and other countries, assessing the actual workload. 
Using EGPs in practice has been established in Iceland, where this 
approach has been used for over 13 years in the genetics clinic. It is efficient 
and without complications such as breach of data and mistrust on behalf of 
the counsellees. This thesis reflects the experience of the clinical service and 
enhances the belief that EGPs can be used in other countries where some or 
all the resources are readily available. 
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Abstract The use of electronic genealogical databases
facilitates the construction of accurate and extensive pedi-
grees for potential use in genetic services. Genealogy data-
bases can be linked to specific disease databases, such as
cancer registries, in order to increase the accuracy of pedi-
grees used, and inform the genetic risk assessment. To
review the published literature on the use of genealogy
databases to construct pedigrees for risk assessment in
genetic health service, a systematic literature search was
undertaken using 12 combined search terms to identify all
relevant published articles. Data sources: EbscoHost,
PubMed, Web of Science, Ovid and the “grey literature”,
as well as the reference lists of identified studies. Of 1,035
titles identified, two papers described a study on the use of
genealogy databases in cancer risk assessment and two were
discussion papers. While authors of the four papers
described the potential use of genealogy databases in clin-
ical genetic services, such use has not been adequately
investigated and further research is required.
Keywords Genealogy databases . Genetic service . Cancer
registry . Risk assessment . Systematic review . Genealogy .
Databases . Health services
Introduction
Genealogical records, both private and public, exist in many
forms and have often been kept for a long time. Examples of
old genealogy records are from the Royal Family of Japan,
the genealogy descriptions in the Holy Bible and in an Irish
textbook written in 1649 describing the Irish settlement
(Wikipedia 2011; Firbishigh 1649–1653?). Recently, geneal-
ogy data have been stored in an electronic format and are
sometimes available online (General Register Office for Scot-
land 2007). As an example “The Scotland’s People” database,
holding approximately 50 million records, which is accessible
to those paying a small fee (General Register Office for
Scotland 2007). The Mormon Church in Utah maintains a
large public genealogy database, “FamilySearch” (New Fam-
ilySearch 2007) and has supported genealogical research for
decades. This database is widely accessible and includes
information on living or deceased individuals. Members
of the church are encouraged to supply information
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about their family history, relationships, and other data
(New FamilySearch 2007; Cannon Albright 2008). The
Utah Population Database (UPDB; Cannon Albright
2008) is another large database holding genetic, demo-
graphic, epidemiological, and medical information on
approximately 6.4 million people, mostly Utah Mormon
pioneers and their descendants. This database was created for
research only and has restricted access. In some cases, data-
bases have been formed to enable genealogical studies to
identify specific disease genes. One example is the Anabaptist
Genealogy Database of Old Order Amish of Lancaster County
(Agarwala et al. 1999).
The Scandinavian countries and some other countries
have National Population Registries that are updated regu-
larly (Population Registry Centre 2006; Ekbom 2011;
CPR-kontoret (http://www.skra.is/pages/1003); Hagstofan
2007; Folkeregisteret 2007). The information documented
is demographic, i.e. names, dates of birth and death,
addresses, identification numbers and citizenship. Other
databases containing personal information on a large num-
ber of people are disease registries and of those, the cancer
registries are the most common. Available in most Western
countries, population-based cancer registries provide a
source of information on the occurrence and outcome of
cancer in defined population groups (Ringborg et al. 2008).
Another example of specific disease registries are the rare
bleeding disorder registries (Peyvandi and Spreafico 2008).
Iceland has a number of population-based genealogy
databases, due to a longstanding general interest in geneal-
ogy. The first census to cover a whole nation was conducted
in Iceland in 1703 (Tulinius 2011). As the Icelandic popu-
lation has been historically stable and detailed genealogy
records have been kept for centuries, genealogical records in
Iceland are highly reliable and comprehensive, making
ancestral tracing relatively straightforward (Stefansson and
Taylor 2006; Tulinius 2011). One large electronic database
is the genealogy database of the Genetical Committee of the
University of Iceland (GCU) available for research and
clinical use (unpublished data/personal communication,
15). The GCU database was launched in the 1960s and is
now run jointly by Landspitali–National University Hospital
and the University of Iceland. This database was constructed
using the records from the national census from 1910
onwards and has, since 1953, been updated with data from
the National Registry. Information from old parish records
on births, deaths and marriages were added to the database
as well as available information on migration. The database
holds accurate information on almost all Icelanders born
after 1840 and a number of individuals born before that
time. To link individuals, a “mother’s record” has been
created for each woman who has given birth, including her
name and identification as well as the name and identifica-
tion code for each of her children and the father of each
child (Tulinius 2011). A large number of studies that have
been based on the database have been published; among
them, most of the Icelandic cancer family studies. Islendin-
gabok, another recent and large Icelandic genealogy data-
base, is run by deCODE Genetics (OoSPa 2004). It is
privately owned and accessible with restrictions to all Ice-
landers with a unique Icelandic personal identification num-
ber (kennitala). Individuals are able to use the database for
themselves; to find out how they are linked to other Ice-
landers and to trace their ancestry. Islendingabok is not used
in clinics and has been used in research by deCode Genetics.
The database has been used in numerous research projects
such as in mapping of loci-affecting disease phenotypes and
other genetic traits (Gulcher et al. 2001).
The Icelandic National Registry (Þjóðskrá 2007) was
established in 1953. It holds extensive information on all
Icelanders (Íslands) and is accessible to all Icelanders in a
restricted way. The population-based Cancer Registry is
operated by the Icelandic Cancer Society (2010). In Iceland,
cancer diagnosis recording is mandatory, making the regis-
try comprehensive and accurate for its use in surveillance
and research. Information regarding the accuracy and com-
pleteness of the Cancer Registry has not been published, but
these parameters are thought to be up to 99 % (personal
communication).
The pedigree is an essential tool for identifying individ-
uals at risk of genetic diseases, to determine needs for
genetic testing and for genetic counselling (Bennett et al.
1995). Genealogy databases have the potential to facilitate
the construction of pedigrees. For instance, the clinical
genetics service at Landspitali, the Cancer Registry and the
GCU has collaborated in generating cancer pedigrees for
genetic counselling since 2006 (personal communication).
The accuracy of databases may however differ depending
on how the data was collected and this may limit their
clinical application. We were interested in identification
and analysis of existing work on the use of genealogical
databases in genetics healthcare. We did this by performing
a systematic literature review (22) of the published literature
in English. In this paper, we describe our results and discuss
the possible reasons for the apparently very limited use of
such databases.
Materials and methods
Data sources and searches
We conducted a systematic review following the method
described by the Centre for Reviews and Dissemination
(Dissemination CfRa 2009). We carried out a systematic
search in October 2011 for papers in English on the use of
genealogy databases in genetic health care. Four electronic
2 J Community Genet (2013) 4:1–7
databases, PubMed, Web of Science, OVID and CINAHL
EbscoHost were searched for papers published in peer-
reviewed journals, theses, reference lists of relevant papers
and articles in the “grey literature”. The “grey literature”, is
“the term used for documents and ephemeral material issued
in limited amounts outside the formal channels of publica-
tion and distribution” (Library HS Grey Literature 2011).
The search was conducted using the following combined
search terms:
& Genealogy database* AND genetic risk AND family
history
& Genealogy database* AND clinical genetics
& Genealogy Database* AND medical AND family
history
& Cancer registry AND genetic service
& Cancer registration AND clinical genetics AND
genealogy
& Database* AND family history AND genetic risk
assessment
& Genealogy database* AND cancer registry
& Database* AND genealogy AND genetics
& Genealogy AND database
& Genetic counsel* and clinical genetics AND genealogy
& Cancer genetic counsel* and genealogy.
The inclusion and exclusion criteria are described in
Table 1.
Abstracts of the identified papers were reviewed for
relevance by the authors VS and HS using the inclusion
and exclusion criteria. In total, 1,035 titles were
retrieved (Fig. 1). Of those, 260 were double publica-
tion, 598 were excluded on the basis of title alone. Of
the remaining 125 papers, 121 were excluded after
further examination, leaving four articles for inclusion
in the review (Table 2).
Quality appraisal
The authors VS and HS used the quality appraisal tool
for cohort studies designed by the Critical Appraisal
Skills Program (Health SfP Critical Appraisal Skills
Programme 2010) to evaluate the research-based paper
(Brewster et al. 2004). The score was set at 93 %. The
quality of the discussion-based papers was not formally
appraised.
Data analysis
We constructed a table of the papers to record the salient
features of each (Table 2). The papers were then themati-
cally analysed (Clark 2003) for key codes, categories and
themes within and across papers. As a meta-analysis was not
possible, we present the findings in textual form under
themes.
Findings
Description of selected papers
The search resulted in identification of two discussion
papers from the USA (Cannon Albright 2006; Tu and
Mason 2004) and two research papers, one from Scotland
(Brewster et al. 2004) and the other one Icelandic (Thorsson
et al. 2003). The Scottish research paper, described the use
of a cancer registry-based service health care (Brewster et al.
2004). The Icelandic paper described how using a geneal-
ogy database in finding relatives for screening for familial
hypercholesterolemia (FH) identified more patients than the
conventional method. Overall, we found very little written
evidence in the literature of the use of genealogy databases
in genetic health service. However, none of the selected
articles argued against such use. On the contrary, the main
concept of the four articles was the recognised need for
electronic genealogy databases and their possible linking
to medical records or disease databases. The key outcomes
of each paper are presented in Table 2. We present the
findings under the themes (1) perceived value of electronic
databases, (2) privacy issues and (3) future use of genealogy
databases.
Perceived value of electronic databases
The perceived use of databases differed in the selected
papers. While both the Scottish one and the Icelandic one
(Brewster et al. 2004; Thorsson et al. 2003), described the
use of a genealogy database in clinical service, Cannon
Albright (2006) discussed the enormous possibilities of
using such databases in both clinical service and research.
Table 1 Inclusion and exclusion criteria
Parameter Inclusion criteria Exclusion criteria
Location Any country
Population Human genealogy databases Epidemiological studies
Language English Non-English
Time
frame
January 1970–October 2010
Type of
paper
Research articles,
conference papers,
discussion papers, thesis
Magazine and newspaper
articles, internet news
Main
theme
Focused on the use of
genealogy databases in
genetic health services
Focused solely on use of
genealogy databases for
the purposes of genetic
research rather than
clinical service (e.g.,
mapping a gene)
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Tu and Mason (2004) focused on the value of linking
different databases to facilitate better surveillance in clin-
ical care. Genealogy databases, linked to medical history
or disease databases, could be used to guide medical
decision making (Cannon Albright 2006), to identify indi-
viduals at risk (Thorsson et al. 2003), to make accurate
risk assessment, for evaluation of cancer screening and
treatment services (Brewster et al. 2004) and to follow up
and coordinate service for individuals and whole families
even if the family structure changes (Tu and Mason 2004;
Thorsson et al. 2003). It was also described how the
cancer registry-based genealogy service using the online
public records of the General Register Office of Scotland
(birth, death and marriage records) led to changes in
the family history and enabled different risk categorisation
and management for a number of counselees over a
12-month period (Brewster et al. 2004). Their article did
not report on differences in accuracy when using the
database as opposed to proband-generated pedigrees.
The tracing of FH probands to common ancestors,
using a genealogy database, added considerably to the
conventional method of FH cascade screening, where
first-degree relatives are tested (Thorsson et al. 2003).
The possibility of linking data from different databases,
some already existing, by either of two methods was
described (Tu and Mason 2004). The first method was a
first-order linkage where information on a single indi-
vidual could be linked together in different databases.
Fig. 1 Retrieval and selection
of papers
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This is a similar method to the one many cancer registries
use, with limited personal identification. The second
method they called a second-order linkage. With this
method, individuals can be organised into large family
pedigrees within available databases if the appropriate
fields are used. One way would be to create an individual
ID for each person and include mothers and fathers iden-
tifier fields in the databases in question. This is a similar
method to the one used in the Nordic countries for the
National Population Registries and in the widely used
Genealogical Data Communication data standard.
Although the article focuses on birth defect registries, the
formation and design of a family pedigree database is
described. Similar is the possibility of linking genealogical
resources such as the Veterans Administration data and the
Social Security Death Index to the already available UPDB
database, expanding their use (Cannon Albright 2006).
Authors agreed on the great impact that genealogy data-
bases linked to disease registries, can have on research.
Cannon Albright has described the UPDB and the Icelandic
genealogy database as examples of such use (Cannon
Albright 2006; Tu and Mason 2004).
Privacy issues
Cannon Albright (2006) discussed how the use of
genealogy databases in clinical service required dealing
with many issues, among them privacy and security
issues concerning the data, as well as the liability
implied in their use. Similarly, Tu and Mason recog-
nised the potential concerns regarding privacy and con-
fidentiality as it is possible that some could view such
data linkage as intrusive (Tu and Mason 2004). They all
stressed the importance of defining clear rules and pro-
cedures for the use of linking data. Brewster et al.
mentioned the fundamental principles of the UK Data
Protection Act 1988 (Brewster et al. 2004; Archives
1998).
Future use of genealogy databases
As for the future, Cannon Albright envisioned in her paper
that a US genealogy database could be made by using
already available data, such as the Veterans Administration
Database and Social Security Death Index (Cannon Albright
2006). Tu and Mason pointed out the benefits that linked
databases could have for applied public health service, using
their suggested second-order linkage (Tu and Mason 2004).
That method would probably be better than first-order link-
age as name changing is frequent in the USA due to mar-
riages. Also, families may move between states, making
surveillance and paper follow-up difficult. Lastly, Brewster
et al. claimed that the interaction between cancer registries
and genetics clinics would likely increase in the future
Table 2 Main outcome of selected papers
Authors Title Type of paper Description Results Conclusion
Tu and
Mason
(2004)
Organising population
data into complex family
pedigrees: application of
a second-order data
linkage to State Birth
Defects Registries
This paper is a
discussion paper
and includes no
primary data
Discusses the possibility of
using previously collected
data in clinical health care.
Also describes the best
way of organising and
collecting such data
Description of available
data in diverse national
and regional databases
and how the data can be
used
The power of data
collected routinely into
regional and national
databases is underused
in clinical health care
Cannon
Albright
(2006)
Computerized genealogies
linked to medical
histories for research
and clinical care—a
national view
Symposium
proceedings.
This is a
discussion paper
with no primary
data collection
or results
Discussion of the
possibilities of combining
genealogy data with
medical histories
The use of linked genealogy
databases and medical
histories can enhance the
power of research and
make clinical care better
Genealogy data can
contribute widely to the
understanding of
familial and genetic
factors in human health
and disease
Brewster
2004
Impact of a cancer
registry-based geneal-
ogy service to support
clinical genetics services
Short research
paper describing
a survey
The paper describes the
effect of database-
generated pedigrees on
cancer genetic risk assess-
ment in four major centres
in Scotland
The pedigrees provided by
the Scottish Cancer
Registry were accurate
and extensive and often
changed risk category
(41 %) and management
(23 %)
Linking of pedigrees to a
cancer registry results
in more comprehensive
family history and can
change cancer genetic
counselling
Thorsson
. 2003
Systematic family
screening for familial
hypercholesterolemia in
Iceland
Research paper
comparing two
methods of
screening
The paper describes a novel
approach in screening for
familial
hypercholesterolemia and
compares it with
conventional method
The systematic family
screening identified 19 %
more individuals than the
conventional one
The new method adds
considerable to the
conventional method of
FH screening
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(Brewster et al. 2004). They also stressed the benefit of such
linking while Thorsson et al. discussed the limitation of
using genealogy databases in clinical service caused by the
lack of a comprehensive and accurate genealogy informa-
tion in large multi-ethnic populations (Thorsson et al. 2003).
Authors agreed on that suggestions for future genealogy
databases used in clinical service will need to comply with
strict requirements for privacy.
Discussion
This systematic review reports the results of a comprehensive
search for papers describing the use genealogy databases in
health care. Only four papers were identified, of which two
described the actual existing use a genealogy database. The
other two were discussion papers describing potential use.
Presently, we are only aware of the use of genealogy databases
in health care in Iceland and cancer genetics service in Scot-
land (Brewster et al. 2004; Thorsson et al. 2003). Thus the use
of genealogy databases in health care appears very limited.
However, it is possible that there is an ongoing use of data-
bases that we are not aware of since reports may not have been
published. Such use is unlikely to be common without us
being aware of it from experience or through literature search.
As an example of non-published use, except in a conference
abstract form (Jonsson 2009) in Iceland, the GCU genealogy
database is used by the cancer genetic counselling service.
Files from the Icelandic Cancer Registry and the GCU data-
base are linked to generate cancer pedigrees allowing for the
construction of three to five generation pedigrees with cancer
diagnosis. Similarly to the suggestion made by Tu andMason,
the linking used in the GCU database is made with a specific
ID number issued to all Icelanders (Tu andMason 2004).With
this method, it is possible to make large family trees and to
link almost all Icelanders. The GCU database is also used to
generate pedigrees for other clinical use and to trace relation-
ships between individuals. The FH familial screening method
described by Thorsson et al. is a good example of such use
(Thorsson et al. 2003).
Although we searched with many combinations of
keywords and in comprehensive databases, the search
may not have identified all papers. For example, the
article by Thorsson et al. was not found by the search
and only identified through a personal communication
(Thorsson et al. 2003).
Genealogy databases of the size and quality suitable for
clinical use are rare. However, this is likely to change. Family-
based genealogy databases are becoming more common
reflecting a growing interest in family history and user
friendly computer programs. Such databases can now be
generated with a modest effort by knowledgeable individuals.
Large genealogy databases can be created with a reasonable
effort, as the examples from Iceland and Utah show. Data from
various existing demographic and family-based genealogy
databases can be used to facilitate the creation of larger data-
bases. There are existing databases that could potentially be
used for health care with some modification and added infor-
mation where needed. One is the Swedish Multi-generation
Register (Ekbom 2011) and another one is the large UPDB in
Utah which includes several million individuals coming from
different countries (Cannon Albright et al. 2005). Some other
large public genealogy databases exist and could potentially
be linked with clinical information, given that the accuracy
and reliability is acceptable. As for disease databases, cancer
registries are well suited for such linking due to their size,
formation and amount of information collected.
Our findings of limited publication may reflect legal or
regulative restrictions based on perceived autonomy or infor-
mation risk as well as worry about perceived risk for invasion
of privacy. This is interesting as census microdata (Minnesota
2011) as well as large genealogy databases are freely available
on the internet, making genealogy information public. Cannon
Albright has suggested that the use of resources to assess an
individual’s risk of a disease requires different methods than
for scientific research (Cannon Albright 2006). The quality of
the available genealogical data must be very good and a
medical history with diagnosis must be accessible and avail-
able for linking. Care must be taken to ensure privacy and to
restrict the information to those who need it for the benefit of
the family in question. It is debatable to what degree privacy is
more endangered when linked databases are used by genetic
professionals to form familial genetic risk assessment, as
contrasted by the usual way by using the information received
from the counselee. Of interest in this regard is the accepted
practice of sharing genetic family trees between health serv-
ices, apparently without risking privacy or needing specific
consent of all family members. Genetic professionals are
using family histories in their work, most often received only
from counselees. The family information supplied by the
counselee is often not fully accurate potentially causing risk
misclassification (Janssens et al. 2012; Bensen et al. 1999). In
some cases, there is information available about both affected
and unaffected members of the family, either from previous
communication or from Cancer Registry files. Cancer regis-
tries are generally accurate and comprehensive. In contrast,
the disease information reported by health professionals on
relatives is often incomplete. Linking information from cancer
registries to genealogy databases should improve the effi-
ciency of cancer genetics clinics (unpublished data; Reis et
al. 2006; Gregory et al. 2007).
Genealogy databases have great potential for risk
assessment in genetic health care but their use apparently
very limited. Further studies are needed to address the
benefits and drawbacks including requirements for data
accuracy.
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Abstract While pedigree drawing software is often utilised in
genetic services, the use of genealogical databases in genetic
counselling is unusual. This is mainly because of the unavail-
ability of such databases in most countries. Electronically gen-
erated pedigrees used for cancer genetic counselling in Iceland
create pedigrees that automatically incorporate information
from a large, comprehensive genealogy database and nation-
wide cancer registry. The aim of this descriptive qualitative
study was to explore counsellees’ experiences of genetic ser-
vices, including family history taking, using these electroni-
cally generated pedigrees. Four online focus groups with 19
participants were formed, using an asynchronous posting
method. Participants were encouraged to discuss their re-
sponses to questions posted on the website by the researcher.
The main themes arising were motivation, information and
trust, impact of testing and emotional responses. Most of the
participants expressed trust in the method of using electroni-
cally generated pedigrees, although some voiced worries
about information safety. Many experienced worry and anxi-
ety while waiting for results of genetic testing, but limited
survival guilt was noted. Family communication was either
unchanged or improved following genetic counselling. The
use of electronically generated pedigrees was well received
by participants, and they trusted the information obtained via
the databases. Age did not seem to influence responses. These
results may be indicative of the particular culture in Iceland,
where genealogical information is well known and freely
shared. Further studies are needed to determine whether use
of similar approaches to genealogical information gathering
may be acceptable elsewhere.
Keywords Electronic pedigrees . Genetic counselling .
Genealogy database . Risk assessment . Cancer genetics .
Patient satisfaction
Introduction
Recording the family health history to gain insight into possi-
ble inheritance patterns for a specific disorder has been a ma-
jor tool in medical genetics for many decades (Bennett 2009).
This process includes obtaining accurate information about
family members, preferably for at least three generations
(Eccles 2004). The family history information includes num-
ber of individuals, current ages or ages of death of relatives, as
well as relevant health information. The information gathering
may be done face-to-face, by telephone or via a written ques-
tionnaire (Bennett 2012). In the course of taking a pedigree,
medical information on relatives is often provided by a family
member without the explicit consent of the person concerned.
Genetic counsellors increasingly use electronic recording
methods in their work. In 2013, a study of how genetic coun-
sellors use electronic family history tools found that over 70%
had used such tools to record family histories. The same study
found that the majority of genetic counsellors felt that linking
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electronic medical records to a family history tool would be
time saving (Widmer et al. 2013). This has been supported by
other studies concluding that time and effort could be saved by
enabling counsellees to record their family history by elec-
tronic methods (Guttmacher et al. 2004, Hulse et al. 2011).
One context in which accurate family history is particularly
important is in the field of cancer genetics, where counselling
can benefit both the counsellee and his or her family by iden-
tifying those at risk, providing options for surveillance and
preventive treatment (Brewster et al. 2004, Stefansdottir
et al., 2013a, Nelson et al. 2014).
While staff of many genetic services uses pedigree-
drawing software, the electronically generated pedigrees used
for genetic counselling in Iceland differ, as they automatically
incorporate information from a large, comprehensive geneal-
ogy database and the nation-wide cancer registry. This ability
to link cancer and genealogical registries to the pedigree can
be used to generate relevant information for the family history,
which in turn can be used in cancer genetic counselling
(Stefansdottir et al., 2013b). In order to do this, counsellees
consent to have their family tree generated from the genealogy
database of the Genetical Committee of the University of
Iceland, which holds accurate genealogy information about
Icelanders back to at least 1840 (Tulinius 2011). The history
of cancer(s) is then added, using the population-based Cancer
Registry operated by the Icelandic Cancer Society
(http://www.krabbameinsskra.is). By this method,
comprehensive, electronically generated pedigrees (EGP) are
made, enabling very accurate family history for risk assess-
ment and calculations (Stefansdottir et al., 2013a, Lee et al.
2014). However, like other methods of family history taking,
this may also help to identify individuals who may be at in-
creased risk of having a mutation in either the BRCA1 or
BRCA2 gene, (hereafter referred to as BRCA mutations) or
other inherited cancer predisposition. Specific founder muta-
tions in BRCA genes are present in the Icelandic population.
The BRCA2 c.771_775del5 mutation (formerly known as
BRCA2:999del5) is carried by appr. 0.6 % of the Icelandic
population (Thorlacius et al. 1997) while the:5193G>A is rare
and the population frequency has not been determined.
Although only 5–10 % of breast cancers can be explained
by inherited mutations in the BRCA genes, the risk of muta-
tion carriers developing breast or ovarian cancer is consider-
ably raised compared to women in the general population
(Janavicius 2010) and early clinical surveillance is advised.
Therefore, cancer genetic counselling can benefit both the
counsellee and his or her family. Some family members may
be aware of their risk, but for others, this may occur without
their knowledge. Counsellees are therefore not shown the
family EGP to protect the privacy of other family members.
Using family history to assess risk of hereditary cancers is a
widely used method and an important part of genetic health
services. We were, however, unable to indentify published
literature on the counsellees’ experience of having a family
history taken, with or without the use of EGPs. The aim of this
study was to gain insight into the counsellees’ experience of
cancer genetic counselling where EGPs were used to docu-
ment accurate family history and make a risk assessment. In
this study, EGPs were created using information from two
databases: a comprehensive genealogy database and a
nation-wide population cancer registry.
Methods
A qualitative descriptive approach (Sandelowski 2000) was
used to ascertain the views of the counsellees. Focus groups
are generally used to collect data through exploration of a
topic with a number of participants, where one or more group
facilitators moderate the focus group (Kevern and Webb
2001). Using online focus groups is an adaption of the con-
ventional face-to-face group methods in qualitative research
(Hansen and Hansen 2006), where all text is available after
replies have been made. On the other hand, online focus
groups lack the human presence of face-to-face group sessions
(Schneider et al. 2002). Some participants find it easier to
participate if they do not have to travel or be at a specific place
on a specific time (Chen and Hinton 1999). In addition, the
visual anonymity of the Internet makes it sometimes easier to
give personal information without being identified (Montoya-
Weiss et al. 1998), thus giving participants the chance of re-
vealing only what they want about themselves. Online focus
group studies can be done in two different ways. We used an
asynchronously method, where the participants log on in their
own time to read contributions from others and then post
contributions themselves (Tates et al. 2009, Zwaanswijk and
van Dulmen 2014). The other way is synchronously, where
participants log on at the same time and exchange written
sentences on the chosen forum (Fox et al. 2007). The choice
of method must be made according to the topic and availabil-
ity of participants.
Participants
The participants were individuals from families identified as
having a BRCA mutation and had attended for cancer genetic
counselling between 01.01.2007 and 31.12.2012. In all, there
were 158 eligible females and 67 eligible males. All partici-
pants had been tested for one of the two known Icelandic
founder mutations: the BRCA1:5193G- > A, and the BRCA2
c.771_775del5 mutation, the majority for the BRCA2 muta-
tion. An invitation letter was sent to eligible participants de-
scribing the study objectives and requesting participation. We
aimed to recruit between six and 10 individuals to each focus
group, with variation in terms of age, gender and genetic sta-
tus. We believed saturation was reached after the first two
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focus groups, but continued to recruit to test this. As all par-
ticipants in the first three groups were women, a decision was
made to purposively invite only males to the 4th group.
In all, 26 returned consent forms by either email or post and
19 remained as participants, 17 females and two males. The
average age of those invited (n = 225) was 50.4 (range 23–
86 years), while the average age of participants was 52.2
(range 33–69 years). Group 1 had three women, groups 2
and 3 seven women in each and group 4 had two males.
Eleven participants were mutation positive and eight were
mutation negative.
Forum
The Phpbb forum https://www.phpbb.com/, a free flat-forum
bulletin board was chosen for the study. The forum was
hosted on the Icelandic Human Genetics Society site,
www.mannis.is. To ensure privacy, the board was closed
from others than the participants. The Internet Protocol
(IP) numbers and email addresses of participants were
concealed. Users chose their own user names and passwords
when registering. When each group finished, the board was
taken down and all communications completely deleted.
Questions
Groups 1 and 2 received the same ten questions, posted
on the board one at a time. A reminder was sent by email
to the group each time a new question had been posted. In
the reminder and on the board, participants were encour-
aged to post their own questions and comments. A second
reminder was sent when a week had passed without re-
plies. When the first two groups were completed, a deci-
sion was made to make small changes to the questions, as
is usual in qualitative studies where data collection is
influenced by concurrent data analysis (Green et al.
2007). Therefore, groups 3 and 4 received 15 questions.
Although the content had not been changed, complex
questions were presented as several simpler questions.
Based on the experience of limited response from the first
two groups, for group 3, the first seven questions were put
on the board all at once, followed later by the last eight
questions. These changes resulted in better return of re-
plies. The questions are listed in a supplemental file.
Data analysis
We followed the approach used by Braun and Clarke
(2006) for thematic analysis of data. All comments were
initially independently coded, by two of the authors (VS
and HS) by hand using descriptive coding. The codes
were sorted into categories and themes and discussed by
both researchers until a consensus was reached.
Results
Emerging themes arising from the results were motivation
for testing, informational need for testing, impact of test-
ing, emotional response to testing and EGP (Table 1). One
main outcome was that participants did not oppose the use
of, and most trusted, the information from the electronic
databases from which the EGPs were sourced. There was
some concern about data privacy; however, concern about
other family members’ attitudes to use information from
databases was limited and family communication
remained the same or increased.
Theme 1: motivation.
The strongest motivation for seeking genetic counselling
was knowledge of the family history of breast cancer:
BI decided to ask for genetic counselling as my mother died
at 49 because of breast cancer and my mother’s sister at 69,^
(female age 45, mutation negative).
Some had knowledge about the mutation in the family:
BI have an aunt who got breast cancer and she had been
asked to relay the information to us that we might carry the
gene,^ (female age 57 , mutation positive).
Few of the participants had information on genetic counsel-
ling from their relatives. For some, the idea of better cancer
surveillance was one of the triggers:
BI had heard about genetic counselling and found it to be of
interest mainly because of the surveillance available to BRCA
carriers,^ (female age 55, mutation positive).
Theme 2 : electronic pedigrees.
While many knew about the use of pedigrees, some did not
but were nevertheless impressed by the possibilities offered:
BI had no idea. This is a very cool tool both for families and
professionals,^ (female age 36, mutation negative).
Some were already aware of the use of EGPs:
BI knew about it. This gene is common in my family and my
pedigree has been mapped,^ (female age 56. mutation
positive).
Theme 3: information and trust.
The majority trusted that the information from the data-
bases was correct and that the professionals could be trusted
with the information:
BYes I trust the service as much as possible. Still, it is vital
to ensure that insurance companies will not be able to access
the information^ (male age 46, mutation positive).
However, some voiced concern over the amount of
data available and were worried that it—especially the
mutation results—could be used against them or their de-
scendants later on:
BI had not thought much about it, but knew that something
like this had to exist. Of course it is fabulous that this can be
mapped, but then it is a question of how long it will be so. Will
my children or their children be able to buy life insurance or
will it be like: Bno, you belong to this family and therefore we
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will not insure you, and so on?^ (female age 44, mutation
positive).
Others shared this opinion:
BIt is important that information like this is available
for the individual himself, asking for them, but not for
others. No such information used in research should be
identifiable. On the other hand, the individuals them-
selves should be able to get them,^ (female age 56,
mutation positive).
Information about data privacy was mentioned by
participants:
BI have to agree with those who question what hap-
pens to the information (genetic). If doing this will re-
sult in institutes being able to access the information
and use it against individuals or their family in any
way, then I am not sure about how good this is. I think
it will always be a question of information privacy,^
(female age 45, mutation negative).
Table 1 Main themes and
categories, arising from analysis Themes Categories
1. Motivation Family history
Experience of condition
Family experience of mutation or testing
Awareness
Experience (self or family) of genetic counselling
2. Electronic pedigrees (EGP) Knowledge
• Prior knowledge of EGPs or genetic counselling
• No prior knowledge of EGPs or genetic counselling
Family attitude—no worries
Requirement
Positive attitude towards EGPs
Diverse attitude towards EGPs
3. Information and trust Information
• Sufficient
• Would have liked more later
Trust
• EGPs
• Genetic counselling
• General
Data protection/privacy issues/worries
Insurance worries
4. Emotional response Emotions
• Negative
• Relief
• Positive
• Verification
5. Impact of testing (not covered in the article) Waiting time
• Difficult or long
Family communication
• No change or positive
• Little
• Other
Decision making about future
Survival guilt
• None
• Little
• Definitely
Lifestyle changes
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Some of those who broadly supported the idea of using
EGPs were concerned about protection of privacy:
BYes I knew that it was possible to make such pedigrees. I
think it is good if privacy issues are taken care of,^ (female
age 64, mutation negative).
Experience of genetic counselling
The last question was about the quality of the service. The
majority of comments were positive. BWhen we came before
the testing and also when the results were ready, I found the
information to be good,^ (female age 34, mutation positive).
BI found the whole procedure nice. The interviews were of
good quality. From the beginning I felt secure and that they
were really good people^ (female age 55, mutation positive).
However, some talked about the possibility of improving
the follow-up:
BI got warm welcome and good information. However,
when the results had been given, I felt that the overall man-
agement could have been better. But I know I should have
asked for further counselling,^ (female age 45, mutation
positive).
This was in agreement with others:
BIf there was something, it might be that the whole proce-
dure was sort of mapped beforehand so that you would always
know what was happening,^ (female age 56, mutation
positive).
Discussion
It is estimated that over 96 % of all Icelanders have access to
the Internet (Iceland 2016). This was the basis of using an
online focus group for the study instead of the more conven-
tional face-to-face method. To our knowledge, this method
has not been used before in similar studies in Iceland. The
asynchronously method enables participants to connect and
comment on their own time instead of logging on at specific
times but at the same time does not encourage discussion
between participants. As for the ratio of males to females, it
reflects the clinical situation in breast and ovarian cancer ge-
netic counselling clinics.
The family history taking is an important part of genetic
counselling as risk assessment is based on the outcome. The
outcome of genetic counselling in families with cancer history
has been studied (Codori et al. 2005), but to our surprise, we
did not find previous studies on the counsellees’ experiences
of the procedure of family history taking itself.
Trust is an important part of health services. Our partici-
pants expressed trust in our method of using EGPs although
some mentioned data privacy in the context. This may have
been confirmed by our policy not to share the EGP with the
counsellee or other family members in case they hold sensitive
information not known to others in the family. However, some
participants voiced worries about the possibility that insurance
companies or others might use the information Bagainst^ the
participant or family. The nature of insurance companies de-
mands that all relevant health information is provided, and as
genetic testing is increasingly a part of health services, results
from them may be included (Joly et al. 2003). However, few
had any concerns for the attitudes of other family members
regarding giving and accessing genealogy and cancer infor-
mation about the family. This may have to do with the general
attitude towards genealogical information in Iceland, where
genealogical and other personal information is freely ex-
changed and discussed.
Those who seek genetic counselling usually do so on the
basis of family history or their own medical history. It is the
job of professionals to evaluate the family history and make
decisions about genetic testing based on the level of risk of the
person having a particular condition or mutation. A family
history of breast or ovarian cancer was the most common
reason to seek genetic testing, followed by a family experience
of genetic counselling and/or prior testing of other family
members.
Good information and support enhance the counsellee’s
ability to communicate to family members about the testing
and the outcome (Lafreniere et al. 2013). Family communica-
tion is an important way of disseminating information about
genetic testing and many individuals share test results, at least
with first-degree relatives (Finlay et al. 2008). One of the roles
of a genetic counsellor is to help individuals and families
understand complex genetic information and share it with
the family (Genetic Alliance 2009). Those receiving addition-
al information are more satisfied, especially if this leads to
better understanding (Roshanai et al. 2009). This may indicate
that the opportunity for a follow-up session to reinforce and
expand on the information given could be valued and useful to
counselees. As can be expected, when more family members
learn about the family mutation, the number of people with
some knowledge prior to genetic counselling grows. This can
help when giving complicated information to the counsellee,
as other family members may have already shared their
knowledge and experience. However, the counselee’s prior
knowledge does not mean that the counsellor should give less
information or shorten the process.
Many of our participants found that family communication
had either not changed or was positively affected during the
process of genetic counselling. Having the mutation in com-
mon seemed to strengthen the bonds in some families. This
has been supported elsewhere (Forrest et al. 2008) and genetic
counsellors are well aware of the importance of addressing the
family communication with counselees (Mendes 2015).
To our knowledge, the use of EGPs, which utilise informa-
tion from genealogy databases with linkage to disease data-
bases, to assist the genetic professional are not used in genetic
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health services elsewhere than in Iceland, but should perhaps
be promoted as means of easier, better and more accurate
information for the genetic counsellor. It may be argued that
in a country like Iceland where much genealogy information
is already available and easily found, the attitude may be dif-
ferent from other countries. However, it has been suggested
that national and regional databases hold valuable information
and are an under-used and neglected source of information
(Bain et al. 1997). In any genetic health service in the world,
family history taking is an integral part as well as in many
medical services. There, abundant information about families
can be found - often without most of the family members
being aware of it. This situation is therefore not unique and
trust may be in part due to the knowledge that all health re-
cords should be confidential. Also, various large genealogy
databases exist on the Internet where they can be easily
accessed.
While EGPs in this form are not used elsewhere, we
suggest that the experience from this study and others
(Stefansdottir et al., 2013a, b) can be used to facilitate ways
of using existing secure databases as means to improve risk
assessment. This could especially apply where electronic
databases are available, such as in the Nordic countries
where comprehensive information is available in both na-
tional and cancer registries (Stefansdottir et al., 2013a, b,
Bauer 2014).
Strength and limitations of the study
All participants in our study had been counselled at the same
place by members of the same genetics team. Over the period
where participants had received genetic counselling, the ser-
vice evolved and this may have had an impact on differences
in experience. While one of the limitations of the study was a
relatively low response rate, we felt that saturation of themes
was achieved. It may reflect the lack of familiarity with use of
an online forum or reluctance to revisit a difficult period in the
life of the participant.With increasing use of social media, this
is likely to change. The ratio of males to females reflects the
clinical situation in breast and ovarian cancer clinics.
Conclusions and implication for practice
The use of EGPs enables the genetic counsellor to make a
faster and more comprehensive risk assessment. While our
participants did not oppose the use of the EGP in genetic
counselling and gavemainly positive feedback, further studies
are needed to determine to what degree this can change clin-
ical management. It is possible that some of our results were
culture dependant, as the knowledge of genealogy is high in
Iceland. However, similar to other nations, Icelanders are also
concerned about data privacy. Our results indicate general
patient support for wider use of electronic databases in genetic
counselling, although we are aware of the importance of care-
ful planning and evaluation to ensure that systems are fit for
purpose and practice.
For genetic counselling practice more generally, it is crucial
that counsellors appreciate client concerns about protection of
data, as this has implications for the trust relationship between
clients and counsellors, with an ultimate impact on the way in
which clients view the information provided to them (Skirton
2001). Stringent systems of consent to access personal infor-
mation, offering support for discussion with relatives and pro-
tection of confidential information, are already key compo-
nents of service in many genetic counselling settings
(Committee on Health Research and the Privacy of Health
Information 2009). However, while genetic health profes-
sionals may understand this, it is important that clients are also
made aware of the arrangements to access and protect their
data. This will enable maximum use of genealogical and dis-
ease history information for patient benefit, while enhancing
patient confidence in the process.
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Abstract
A comprehensive pedigree, usually provided by the counselee and verified by medical records, is essential for risk assess-
ment in cancer genetic counseling. Collecting the relevant information is time-consuming and sometimes impossible. We 
studied the use of electronically ascertained pedigrees (EGP). The study group comprised women (n = 1352) receiving 
HBOC genetic counseling between December 2006 and December 2016 at Landspitali in Iceland. EGP’s were ascertained 
using information from the population-based Genealogy Database and Icelandic Cancer Registry. The likelihood of being 
positive for the Icelandic founder BRCA2 pathogenic variant NM_000059.3:c.767_771delCAAAT was calculated using the 
risk assessment program Boadicea. We used this unique data to estimate the optimal size of pedigrees, e.g., those that best 
balance the accuracy of risk assessment using Boadicea and cost of ascertainment. Sub-groups of randomly selected 104 
positive and 105 negative women for the founder BRCA2 PV were formed and Receiver Operating Characteristics curves 
compared for eﬃciency of PV prediction with a Boadicea score. The optimal pedigree size included 3° relatives or up to 
five generations with an average no. of 53.8 individuals (range 9–220) (AUC 0.801). Adding 4° relatives did not improve 
the outcome. Pedigrees including 3° relatives are diﬃcult and sometimes impossible to generate with conventional methods. 
Pedigrees ascertained with data from pre-existing genealogy databases and cancer registries can save eﬀort and contain 
more information than traditional pedigrees. Genetic services should consider generating EGP’s which requires access to an 
accurate genealogy database and cancer registry. Local data protection laws and regulations have to be addressed.
Keywords Cancer genetic counseling · BRCA2 · Electronically generated pedigrees · Breast cancer · Genealogy database
Introduction
Family history is an important tool to assess risk in can-
cer genetic counseling, but recommendations diﬀer regard-
ing the size of pedigrees. Most guidelines call for a three-
generation or third-degree family history for assessment of 
hereditary cancers [1]. Concern has been raised about the 
eﬃcacy of family history in predicting risk assessment in 
hereditary breast and ovarian cancers (HBOC) [2], but to 
what degree this reflects too small or inaccurate pedigrees 
has not been determined.
Solomon et al. found that 19% of high-risk colon cancer 
and 72% of high-risk breast cancer candidates would have 
been excluded from testing without extended family history 
[3]. However, it can be diﬃcult to obtain an accurate can-
cer family history from a patient, especially when the fam-
ily is large [4, 5]. Barriers to identifying a clear pattern of 
inheritance from family history include a small family [6], 
 * J. J. Jonsson 
 jonjj@hi.is
1 Department of Genetics and Molecular Medicine, 
Landspitali – National University Hospital, Hringbraut, 101, 
Reykjavik, Iceland
2 Faculty of Health and Human Sciences, Plymouth University, 
Plymouth, UK
3 Department Of Medical Oncology, Landspitali – National 
University Hospital, Reykjavik, Iceland
4 Icelandic Cancer Registry, Icelandic Cancer Society, 
Reykjavik, Iceland
5 Department of Biochemistry and Molecular Biology, 
Univ. of Iceland, Reykjavik, Iceland
6 Faculty of Medicine, Univ. of Iceland, Reykjavik, Iceland
7 Genetical Committee of the University of Iceland, Reykjavik, 
Iceland
154 V. Stefansdottir et al.
1 3
limited knowledge of relatives with cancer, misinformation, 
unwillingness to talk about other family members and lack 
of communication within the family [7, 8]. People tend to 
know more about cancers in their closest relatives [8–11]. In 
addition, health care providers do not always obtain adequate 
cancer family history [12]. Wood et al. did a pilot test on the 
quality of cancer family history for 10,466 patients from 
over 200 practices participating in QOPI (practice-based 
quality assessment and improvement program). Their result 
showed that 79.8% of patients with either breast or colorec-
tal cancer had their first-degree family history recorded and 
64.6% their second-degree history. Complete family history, 
with diagnosis and age of diagnosis for first- and second-
degree relatives was present for 32.9% of breast cancer 
patients and 22% of colorectal cancer patients [13]. Obtain-
ing comprehensive cancer family history with conventional 
methods remains problematic, and alternative approaches 
should be considered.
Breast cancer and the BRCA genes
The lifetime risk of breast cancer is close to 1 in 8 among 
women in Western countries [14, 15]. During 2010–2014, 
on average, 202 women were diagnosed with breast cancer 
in Iceland each year, at the average age of 61 years [16]. The 
incidence is similar to other Western countries. Registra-
tion of cancers is mandatory in Iceland and the other Nor-
dic countries [17] resulting in comprehensive and accurate 
registries.
Pathogenic variants (PV’s) in the five high-risk genes; 
BRCA1, BRCA2, CHEK2, TP53, and PTEN are collectively 
thought to account for 5–10% of all breast and ovarian can-
cer cases and the BRCA genes for the majority of HBOC 
[18]. The Icelandic population has one prevalent BRCA2 
founder PV NM_000059.3:c.767_771delCAAAT with an 
estimated population carrier frequency of 0.8% [19]. At 
the beginning of this study, one Icelandic founder PV was 
known in the BRCA1 gene, NM_007294.3:c.5074G > A, 
with unknown but very low population frequency. Recently, 
other rare BRCA PV’s have been found in the Icelandic pop-
ulation, mainly family specific. It has been estimated that 
7–8% of Icelandic women with breast cancer had the BRCA2 
founder PV [20]. However, this may be an overestimate and 
has not been confirmed recently in a larger study of unse-
lected patients.
The risk of HBOC varies depending on family history and 
the nature of the PV [21]. A recent study showed that the esti-
mated cumulative breast and ovarian cancer risk by age 80, in 
women with a BRCA2 PV, is 69% and 17%, respectively [22]. 
Estimates of breast cancer penetrance in Iceland due to the 
founder BRCA2 PV were lower when including many dec-
ades of diagnosis, or 17% and 37% by age 50 and 70 years, 
respectively [20]. In contrast, in women diagnosed after the 
year 2000, the estimated risk was 72% (95% CI 45.9–100.0) 
before age 70 years [23].
Genealogy database
In the 1960s, large and extensive multi-generation Icelandic 
Genealogy Database was set up in Iceland as part of a large 
research project [24]. It comprises data from all living Iceland-
ers and their ancestors and is largely complete and accurate 
since the mid nineteenth century [24]. The database is used in 
scientific and private research (by genealogists, clergy, inherit-
ance lawyers), as well as in genetic health services [25].
Genetic counseling in Iceland
Iceland has one clinical genetics clinic at Landspitali—The 
National University Hospital [25]. Uniquely, the clinical genet-
ics service at Landspitali has permission to use information 
from the Icelandic Genealogy Database and the population-
based, high-quality, Icelandic Cancer Registry [26, 27] to 
construct electronically ascertained pedigrees (EGP’s) [25]. 
Explicit consent for generating a pedigree is required from the 
counselee who does not get access to the pedigree, but receives 
only the final personal risk assessment. This approach enables 
construction of extensive pedigrees with information on exact 
diagnosis, age at diagnosis, and tumor type. These extended 
pedigrees ascertained from electronic databases can augment 
pedigree information provided by the counselee. Using this 
approach allows for more accurate risk assessment and better 
surveillance recommendations than with conventionally made 
pedigrees. General methods to calculate risk in pedigrees have 
been developed and used [28, 29]. In the Icelandic Genetics 
Clinic, we use the Boadicea risk assessment model which has 
been validated and is commonly used in HBOC genetic coun-
seling [30]. In this study, we took advantage of the unique 
situation in Iceland where inherited breast cancer risk is to 
large extent due to one founder BRCA2 PV.
Study aims
We determined the practicality of using large EGP’s in can-
cer genetic counseling. Secondly, we made use of this unique 
dataset of large and accurate pedigrees to determine the opti-
mal degree of relatives to include balancing the accuracy of 
risk assessment using Boadicea, and cost of ascertainment.
Methods
Study population
The study population comprised all individuals of Icelan-
dic origin, tested for the two Icelandic founder BRCA PV’s 
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relating to HBOC in genetic counseling at Landspitali, 
between December 2006 and December 2015 (n = 1352). 
The group was organized into carriers and non-carriers 
of the founder BRCA2 PV. From both groups, randomly 
selected women were added into sub-groups by the RAND 
function in Excel. The sub-groups comprised 209 women, 
104 positive and 105 negative for the founder BRCA2 PV. 
ROC analyses was used to assess the eﬀect of family size 
on predicting the presence of the founder BRCA2 PV with 
a Boadicea score (Breast and Ovarian Analysis of Disease 
Incidence and Carrier Estimation Algorithm) [31].
Data analysis
The pedigree software ClinicalPedigree™ was used to ascer-
taine the pedigrees [32]. Excel software was used for statisti-
cal analysis. Boadicea was used to estimate the likelihood 
of having a BRCA2 PV, using Icelandic allele frequency 0.3 
for the founder BRCA2 PV, search sensitivity 0.8 and cancer 
incidence rates for Iceland. The MedCalc™ Receiver Oper-
ating Characteristic (ROC) Curve Analysis and C-statistics 
based on pair-wise comparison were used to evaluate the 
eﬀect of increasing pedigree size on the risk estimates [33], 
and 95% CIs were obtained based on exact binomial func-
tion. Statistical tests were two-sided at the significance level 
of 0.05 [34]. For calculating the statistical significance of 
the diﬀerence between the ROC curves, based on a number 
of individuals, we used VassarStats for ROC curve analysis 
(http://vassa rstat s.net/roc_comp.html) [35].
Electronically ascertained pedigrees
For ascertainment of the EGP’s, genealogical information 
was obtained from the Genealogy Database [24] and relevant 
information on cancer in relatives added by record linkage 
with the ICR. A full EGP set for each person comprised 
eight pedigrees, each containing all descendants from one 
of the great-grandparents of the proband. Some individuals 
appeared in more than one EGP. Counselees were not shown 
the pedigrees.
Ethical approval for the study was obtained from the 
National Bioethics Committee (no. 11–147). No personal 
information based on EGP’s was disclosed.
Results
Between December 2006 and end of December 2015, 1352 
individuals, in 370 EGP’s had been tested for one or both of 
the Icelandic founder BRCA PVs. In 314 EGPs, no BRCA PV 
had been found, whereas in 56 EGPs the founder BRCA2 PV 
had been found (Table 1), with the largest EGPs comprising 
4197 and 2031 individuals, respectively. Of the 1352 indi-
viduals tested, 340 tested positive for the founder BRCA2 
PV, 233 females and 107 males (Table 2). There was some 
overlap of individuals in EGPs within the two categories. In 
four cases, it was not possible to construct an EGP due to 
unknown paternity/maternity or adoption. In those cases, the 
counsellee was oﬀered genetic testing for the two founder 
BRCA PV’s.
Work required in constructing EGP’s
The estimated amount of all work creating the EGP’s for 
each proband, with all relevant cancer information and at 
least 4° relatives, took up to three working hours depend-
ing on the size of the pedigrees. Each probands family was 
traced back to great-grandparents, resulting in eight pedi-
grees for each counsellee. Pedigrees include the date of birth 
and death, age at diagnosis, type of cancers back to 1954 
(the first year of the ICR) and breast cancer back to 1911 
due to the collection of comprehensive countrywide data 
Table 1  Size of the EGPs attending the cancer genetic clinic, between 1.12.2006 and 31.12.2015 at Landspitali
Data only includes those alive in 1955 and born before 1996
EGP’s where no known BRCA PV was 
found
EGP’s where the BRCA2 
NM_000059.3:c.767_771delCAAAT 
was found
Number of EGP’s 314 56
Average number of individuals in EGPs 497 514
Female relatives 46,403 9432
Male relatives 48,470 9950
Females married into the families 18,958 3835
Males married into the families 19,805 3786
Max. number of individuals 4197 2031
Min. number of individuals 13 40
Counsellees without genealogy information 1 3
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on all breast cancer diagnosed in 1911–1954, for a doctoral 
thesis [36].
Experience of using the EGP’s in genetic counseling
Obtaining consent and explaining the use of EGPs for risk 
assessment was a straightforward process without complica-
tions. No known security breach or misuse of the informa-
tion occurred. Questions occasionally asked by counsellees 
included (1) whether permission was needed from other rela-
tives, (2) whether the counselee could see/own the EPG, (3) 
whether possible former unknown family members would be 
revealed to them and (4) whether all disorders in the family 
was recorded. All the answers were negative.
Genetic services collect various types of information on 
counsellees and relatives. Relatives of counselees may not 
always know the nature of information obtained or avail-
able in the clinic. In some cases, the extended family history 
acquired using the EGP’s revealed a distant relative with a 
known PV. In a number of cases, this resulted in an oﬀer of 
genetic testing where it might not have been oﬀered without 
the extended information.
The optimal size of pedigrees for risk assessment
ROC analysis based on the Boadicea score was used to 
assess the association between the size of the pedigree and 
the eﬃciency of risk assessment for BRCA2 PV in HBOC 
cancer genetic counseling To test this eﬀect, we randomly 
selected individuals from the study group, into two sub-
groups comprised 209 women, 104 positive and 105 nega-
tive for the BRCA2 PV. Model pedigrees were ascertained 
for those women, where we incrementally added individuals 
more distantly related to the proband. Table 3 shows the 
average number of individuals, and range, for each degree 
of relatedness. The 6° pedigrees were not included in ROC 
analysis as Boadicea™ could only calculate up to max 275 
individuals.
Table 3 also shows the average score and range of results 
from risk calculations for being a carrier for the founder 
BRCA2 PV with Boadicea, according to a diﬀerent degree 
of relatedness. The lowest score was 0.1% in all degrees 
of relatedness, and the highest risk was 93% in a pedigree 
with 4° of relatedness. ROC analysis on the eﬃciency of 
predicting whether the proband had the founder BRCA2 PV 
according to inclusion of increasing degrees of relatedness 
can be seen in Figs. 1 and 2. Adding 2° relatives to the 1° 
degree relatives increased the C-statistic from 0.62 to 0.70 
(p < 0.001), and adding 3° relatives increased the C-statistic 
from 0.70 to 0.77 (p < 0.001) (Fig. 1). In contrast, the inclu-
sion of 4° relatives did not significantly aﬀect the C-statis-
tic which decreased to 0.76 (p = 0.33) (Fig. 2). To further 
evaluate the relationship between the size of the pedigree 
Table 2  Number of subjects tested positive for the Icelandic 
BRCA2:c.771_775delTCAAA from 1.12.2006 and 31.12.2015 and 
their associated cancers diagnosed 1955–2015
Females, number (%) Males, number (%)
Positive individuals 233 107
Breast cancer 86 (37%) 7 (6.5%)
Two breast cancers 11 (4.7%) 2 (1.8%)
Prostate cancer – 9 (8.4%)
Ovarian cancer 10 (4.2%) –
Table 3  The number and range of individuals and Boadicea risk 
scores in pedigrees including diﬀerent degrees of relatedness for 
ROC curve analysis
Degree Average no. Individuals Boadicea risk score 
(%)
Range Average Range
1° 9 (3–22) 8 (0.1–39)
2° 26 (6–92) 12 (0.1–88)
3° 54 (9–220) 14 (0.1–86)
4° 103 (15–257) 15 (0.1–93)
5° 146 (15–498) 14 (0.1–88)
6° 166 (15–565) 11 (0.1–88)
Fig. 1  ROC curves demonstrating the eﬀect of pedigree size on the 
eﬃciency of Boadicea risk calculations in predicting the presence of 
the BRCA2 NM_000059.3:c.767_771delCAAAT1A. Pedigrees with 
1°, 2° and 3° relatives. Pedigrees with 3° relatedness showed the best 
outcome
157Electronically ascertained extended pedigrees in breast cancer genetic counseling 
1 3
and eﬃciency of risk assessment, we divided the 3° pedi-
grees into two groups ranked by the number of individuals 
in each pedigree. The lower number group (n = 105, aver-
age no. of individuals 30, range 9–46) had a C-statistic of 
0.718, but the higher number group (n = 104, average no. of 
individuals 133, range 46–220) had a C-statistic of 0.822. 
We also divided the 4° pedigrees in two according to size. 
The lower number group (n = 103, average no. of individuals 
56, range 15–87) had a C-statistic of 0.719, but the higher 
number group (n = 103, average no. of individuals 145, range 
87–257) had a C-statistic of 0.815. The C-statistics for 3° 
and 4° relative pedigrees were very similar and not signifi-
cantly diﬀerent. We converted the lower number group in 
3° pedigrees into 4° relative pedigrees, but there was no 
improvement in the C-statistic (0.718).
From these results, we concluded that in this application, 
there was no gain of eﬃciency by including the 4° relatives.
Discussion
Family history with detailed demographic and medical infor-
mation is an essential tool for risk assessment in genetic 
counseling, but constructing accurate and large enough 
pedigrees is work- and time-consuming. We demonstrate 
the feasibility of using EGP’s and the advantage of using 
them instead of conventionally made pedigrees. Further, by 
comparing diﬀerent pedigrees with diﬀerent degree of relat-
edness with ROC curves, we show that 3° relatedness is the 
optimal size risk assessment in cancer genetic counseling 
due to the risk of having a pathogenic variant in BRCA2. To 
our knowledge, this study is the best objective estimate of 
the optimal pedigree size with respect to accuracy of can-
cer risk assessment. Giving the referral indication, HBOC, 
other cancer syndromes were only suspected in rare cases 
when assessing the EGPs. Results from other than the two 
BRCA genes were not included. We suggest that the same 
approach could be used for other inherited cancer syn-
dromes, although the optimal size of pedigrees will likely 
depend on both the incidence of the relevant cancers and 
the gene penetrance. Presumably, large pedigrees will also 
be found advantageous where inherited cancer syndromes 
comprise common cancers with incomplete penetrance. The 
benefit of using extended family history for risk assessment 
is supported further by other research studies where large 
genealogy databases and information from cancer registries 
identified distant relatives in colorectal and breast cancer 
families within a familial cluster of cancer [3, 37].
Work eﬀort in creating the pedigrees
The actual workload or cost of obtaining conventional 2–3 
generation cancer family history, in the genetics clinic, is 
diﬃcult to evaluate as it diﬀers considerably between cases 
and services. However, sending out family history forms and 
recording information as well as collecting various tumor 
and health records from diﬀerent healthcare institutions, 
after obtaining informed consent, involves considerable 
work. Therefore, we estimate that constructiong the EGP’s, 
which eliminates most of this work by doing record link-
age between electronic databases, saves considerable work 
and money and is an important consideration in resource 
allocation. However, the work involved in ascertaining the 
pedigrees could be significantly reduced, if approved by data 
protection authorities, with a more purposeful, integrated 
electronic data system. This method allows the counselor 
more time to review pedigrees, make a risk assessment and 
organize relevant testing and surveillance according to the 
family history.
Factors related to the Icelandic population
This study builds on our previous work; a systematic lit-
erature review on the use of electronic genealogy data-
bases in genetic health services [38] and a qualitative study 
exploring counselees’ experiences of genetic services using 
EGP’s [39]. Our former study shows that counsellees in 
general trust the use of EGP’s [39]. This trust can perhaps 
be explained partly by the fact that Icelanders are used to 
having good access to genealogy data, both in books and 
online [40] and genealogy is a major interest in the popu-
lation. Demographic information is readily accessible, and 
importantly, record linkage is very accurate in Iceland due 
Fig. 2  Comparison of pedigrees including 3°and 4° relatedness. 
Increasing the size of the pedigree did not improve prediction
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to the unique 10-digit personal identification number that is 
assigned to all newborns and residents. Icelanders are gen-
erally ready to participate in genetic studies, even knowing 
that their samples would be connected to various databases 
[41]. Therefore, the idea of constructing EGPs with infor-
mation from electronic databases may be more generally 
acceptable to Icelanders than citizens of other nations.
Presumed consent
In genetic health services, the counselee gives information 
about other family members, usually without their explicit 
consent, i.e., the consent is presumed. The information is 
used for risk assessment on the assumption that there is a 
minimum risk of harm and that the assessment could benefit 
the counselee and indirectly other family members. Genetic 
health professionals sometimes obtain relevant health infor-
mation from preexisting databases for the sole purposes of 
genetic risk assessment. As an example, The Joint Commit-
tee on Medical Genetics in the UK (2011) concluded that 
health professionals could share clinical information and 
family history given their duty of confidence [42]. Large 
databases with comprehensive information based on pre-
sumed consent are the foundation of genetic population stud-
ies [19, 43–47]. We argue that if it is ethically acceptable to 
use extensive data on genealogy and disease in research, it 
should be satisfactory for clinical use as well.
Generating EPG’s in other counseling practices
In cost-sensitive healthcare, using EGPs when feasible 
seems to be the most eﬀective use of resources and provide 
the best results in cancer genetic counseling. High-quality 
cancer registries and genealogy databases are necessary to 
create EGPs in cancer genetic counselling. In the Nordic 
countries, both genealogy databases and comprehensive 
cancer registries are available and could be used similarly 
as in Iceland. Similarly, Scotland and Ireland have excellent 
genealogy records and cancer registries [48, 49]. However, 
the use of the available data and pedigrees must be legally 
permissible.
There are 535 listed members in the International Asso-
ciation of Cancer Registries [50]. Registries diﬀer in how 
comprehensive they are and whether registering individual 
cases is mandatory. The Nordic countries e.g., have high-
quality, compulsory cancer registries and unique personal 
identification numbers that allow accurate record linkage, 
and thus have the required conditions for accurate EGP’s 
[51]. Various registries of specific hereditary cancers are 
available in many countries.
Genealogy databases [52] are becoming increasingly 
easy to create, e.g. the Veterans Genealogy project with 
over 22 million records [47]. Additionally, Kaplanis et al., 
have shown how easy it is to collect millions of profiles 
from online data to generate population scale pedigrees 
[53]. Of note, electronic information-sharing, sometimes 
via social media, has become common in our cultural envi-
ronment [54]. These developments plus electronic two-
way personal medical records between health worker and 
a patient will facilitate generation of genealogy databases. 
This also facilitates obtaining accurate cancer information 
on relatives based on either presumed or informed consent.
Pedigrees and next generation sequencing (NGS)
Next generation sequencing identifies pathogenic vari-
ants and variants with unknown significance [55], facili-
tating accurate genetic counseling. As the eﬀect of the 
pathogenic variants can be family-dependent, pedigrees 
can be important when evaluating penetrance, impact 
and segregation of a PV in the family. Pedigrees are also 
important in evaluating VUS by examining how well a 
cancer spectrum in a pedigree fits with cancers known to 
be associated with pathogenic variants in the particular 
gene. High-quality pedigrees will, therefore, continue to 
be very relevant with an increased adaptation of NGS [56].
Implications for practice
In the genetics clinic, the optimal situation is to have access 
to large and accurate pedigrees constructed with minimum 
cost. In this study, we show that cancer pedigrees can be 
ascertained based on data in preexisting genealogy databases 
and cancer registry. We also show that the eﬃciency of risk 
estimates based on pedigrees are mainly dependent on the 
degree of relatedness. Importantly, the eﬃciency of risk 
assessment was improved up to 3° relatedness. Construc-
tion of 3° pedigrees with traditional methods is very diﬃcult 
and time-consuming, and it may be nearly impossible if little 
or no knowledge is available on relatives. Genetic services 
are therefore advised to consider if they can generate EGPs 
locally using available data. Adaption of our, or similar elec-
tronic methods, to construct EGP will require careful consid-
eration of the local legal and regulatory environment. Data 
Protection Laws and regulations may in many cases need to 
be modified before EGP’s can be used in genetic counseling.
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Supplementary material 
Questions for group 1 and 2 in Study II 
1. Why did you go for genetic counselling and what were your ideas 
about it beforehand? 
2. I would like you to ponder about the EGP´s we use for the risk 
assessment, made with  the information from the genealogy database 
and Cancer Registry. Did you know anything about them 
 beforehand – if it was possible to make them? What were 
your thoughts about the capability to make such extensive 
pedigrees? 
3. Did you have anything against using EGP´s in the genetic 
counselling and were you worried about other family member’s 
issues or attitude regarding the extensive information in the 
pedigree? 
4. Do you trust the information in the EGP? Any thoughts? 
5. What did you think about also having to give your information for a 
handmade pedigree? 
6. When you had to make decision about the genetic testing, how did 
you feel about your decision? Describe your feelings during the 
waiting period. 
7. Can you describe your emotions right after and for the first few days 
after you got the results? What about later? 
8. Has the family dynamics and communication changed after the 
genetic counselling. In what way? 
9. Do you think that anyone in your family is suffering from survival 
guilt? (Survival guilt can be described as when one feels “guilty” 
when not having a mutation, when others in the family have it). 
10. Question 10: This question is a bit complicated and long: What do 
you think has been well done during the genetic counselling? What 
do you think can be done better? A) Information before the testing, b) 
information after the testing, c) anything else? Also, is there anything 
else you want to share? 
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Questions for group 3 and 4 in Study II 
1. Why did you come for genetic counselling? 
2. What ideas had you about the genetic counselling prior to your visit?  
3. Did you know anything about EGP´s prior to genetic counselling?  
4. Can you tell us about your thoughts when you knew that it was 
possible to get the extensive information from the electronic 
databases? 
5. Were you against using EGP´s in the genetic counselling?  
6. Did you worry about others in the family because of the use of the 
EGP and the information they contained? 
7. What did you think about also having to give your information for a 
handmade pedigree? (This is only for those who had no relatives that 
have come before to genetic counselling).  
8. Do you trust the information in the EGP? Any thoughts? 
9. When you had to make decision about the genetic testing, how did 
you feel about your decision?  
10. The waiting period for the results – can you say something about 
that? 
11. Can you describe your emotions right after and for the first few days 
after you got the results? What about later? 
12. Has the family dynamics and communication changed after the 
genetic counselling. In what way? 
13. Do you think that anyone in your family is suffering from survival 
guilt? (Survival guilt can be described as when one feels “guilty” 
when not having a mutation, when others in the family have it). 
14. What do you think the genetic counselling has done well? 
15. What do you think we can do better?  
 a) Information before the genetic testing 
 b) Information after the genetic testing 
 c) Anything else you want to add? 
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Introduction letter for participation in Study II 
Kynningarbréf fyrir þátttöku í vísindarannsókninni:  
Upplifun ráðþega og fjölskyldna þeirra þegar notuð eru rafræn ættartré í 
krabbameinserfðaráðgjöf 
Kæri viðtakandi 
Tilefni þessa bréfs er að biðja þig um taka þátt í vísindarannsókn sem 
hefur að markmiði að kanna langtímaáhrif erfðaráðgjafar vegna krabbameina 
á einstaklinga og fjölskyldur þeirra. 
Ástæða þess að leitað er til þín varðandi þessa rannsókn er sú að þú 
hefur komið í erfðaráðgjöf vegna krabbameina á Landspítala en allir sem 
komu í erfðaráðgjöf á skilgreindu og fyrirfram ákveðnu tímabili fá samskonar 
bréf.  
Rannsóknin er hluti af doktorsverkefni Vigdísar Stefánsdóttur 
erfðaráðgjafa. Ábyrgðaraðili er Jón Jóhannes Jónsson, yfirlæknir erfða- og 
sameindalæknisfræðideildar LSH. Símanúmer hans er 543 5032 og 824 
5917. Tölvufang hans er jonjj@landspitali.is. Erfða- og 
sameindalæknisfræðideild er í K-byggingu Landspítala við Hringbraut. Aðrir 
sem að rannsókninni standa eru nefndarmenn í doktorsnefnd Vigdísar: Óskar 
Þór Jóhannsson sérfræðingur í krabbameinslækningum á Landspítala, 
Laufey Tryggvadóttir framkvæmdastjóri Krabbameinsskrár, Hrafn Tulinius 
prófessor emeritus við Háskóla Íslands og Heather Skirton prófessor við 
Plymouth háskóla.  
Tilgangur og markmið rannsóknarinar eru tvíþætt. Annars vegar sá að 
kanna hvernig einstaklingar og fjölskyldur upplifa krabbameinserfðaráðgjöf 
þar sem notuð eru rafræn ættartré og gerðar erfðarannsóknir og hins vegar 
að leita leiða til þess að bæta þjónustu erfðaráðgjafaeiningar erfða- og 
sameindalæknisfræðideildar LSH.  
 
Í þátttöku felst eftirfarandi: 
• Að senda okkur undirritað meðfylgjandi upplýst samþykki þar sem 
fram kemur heiti sem þú velur þér á spjallborðinu.  
o EÐA svara í tölvupósti (vigdisst@landspitali.is) og samþykkja 
þátttöku. 
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• Að taka þátt í umræðum og svara spurningum á netinu. Útbúið 
verður spjallborð á netinu sem þátttakendur skrá sig inn á með 
lykilorði. Þeir sem taka þátt gera það án þess að þeirra rétta nafn 
komi fram eða að þeir fái að vita nöfn annarra þátttakenda. 
• Að taka þátt í umræðum og svara 20 spurningum.  
• Á umræðuborðið verða settar fram spurningar sem þátttakendur 
svara ýmist hver fyrir sig eða í umræðum sín á milli.  
• Tímalengdin er að mestu á valdi þátttakenda sjálfra.  
Þátttökuskilyrði fyrir rannsókninni eru: 
a) Að hafa leitað til LSH vegna erfðaráðgjafar krabbameina á 
rannsóknartímabilinu. 
b) Að geta lesið og skilið íslensku. 
c) Að vera orðin 18 ára og sjálfráða. 
Útilokunarskilyrði eru:  
Engin. 
Réttur þinn sem þátttakanda 
Þér er ekki skylt að taka þátt í þessari rannsókn og þú getur hætt þátttöku 
hvenær sem er án útskýringa. Ákveðir þú að hætta þátttöku verður 
gögnunum sem þú hefur skráð á spjallborðið eytt. Hafnir þú þátttöku mun það 
ekki hafa áhrif á þjónustu sem veitt er af heilbrigðiskerfinu. Heimilt er að 
sleppa spurningum ef þú telur þær ekki eiga við þig eða vilt ekki svara þeim. 
Æskilegt er þó að sem flestum spurningum sé svarað eins nákvæmlega og 
unnt er til þess að niðurstöður verði sem bestar. 
Meðferð gagna 
Rannsóknaraðilar skuldbinda sig til að gæta fyllsta trúnaðar varðandi þær 
upplýsingar sem verður aflað. Farið verður að íslenskum lögum í hvívetna 
varðandi persónuvernd, vinnslu og eyðingu frumgagna. Einungis 
rannsóknaraðilar munu hafa aðgang að svörum einstaklinga á spjallborði en 
umræður veða sýnilegar öllum þátttakendum. Gögn verða geymd án 
persónuauðkenna. Niðurstöður rannsóknarinnar verða ekki tengdar við nöfn 
þátttakenda. Eftir því sem best er vitað er þetta í fyrsta sinn sem svona 
rannsókn er gerð á neti á Íslandi. Spjallborðið er einungis sýnilegt þeim sem 
boðið er til þess og ekki er hægt að rekja IP tölur þáttakenda.  
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Áhætta og ávinningur 
Ávinningur þátttakenda er enginn. Áhætta þáttakenda er talin lítil en 
mögulegt er þó að sumum finnist erfitt tilfinningalega að ræða um 
erfðaráðgjöf, erfðarannsóknir og áhrif þeirra. Þeim sem þess óska býðst 
aðstoð sálfræðings og erfðaráðgjafa.  
Þátttakendur eru ekki sérstaklega tryggðir vegna rannsóknarinnar.  
Niðurstöður og birting rannsóknargagna 
Niðurstöður rannsóknarinnar verða birtar í doktorsrannsókn Vigdísar en 
einnig í ritrýndum vísindatímaritum. Engar persónugreinanlegar upplýsingar 
verða í birtum gögnum.  
Rannsóknin er unnin með samþykki Vísindasiðanefndar og tilkynning 
hefur verið send til Persónuverndar. 
Ef þú hefur spurningar um rétt þinn sem þátttakandi í vísindarannsókn eða 
vilt hætta þátttöku í rannsókninni, getur þú snúið þér til Vísindasiðanefndar, 
Hafnarhúsi, Tryggvagötu 17, 101 Reykjavík. Sími: 551-7100, fax: 551-1444.  
Með fyrirfram þökk fyrir þátttökuna. 
     
 ________________________________________ 
 Jón Jóhannes Jónsson  
 Ábyrgðarmaður rannsóknar 
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The risk score table. 
 
Mut stat Family size 1° 2° 3° 4° 5° 6° 1° 2° 3° 4° 5° 6°
0 148 9 27 56 84 87 87 0,1 0,2 1,3 1,3 1,3 1,3
1 137 11 43 67 102 137 137 56,2 64,9 70,5 70,3 70,4
1 297 10 19 50 116 192 247 2 2,3 6,7 3,9 3,8 3,8
0 432 12 37 51 64 86 115 3,3 2,4 2,2 2,1 2,1 2,1
1 617 9 21 32 67 152 313 43,1 62,9 54,2 35,2 32,7
1 70 10 34 57 70 4 44,8 60,3 60,3
1 397 12 60 147 223 35,7 56,2 67,9 66,4
0 445 4 10 36 97 256 0,2 7,6 9,5 6,2 5,7
0 1046 3 8 21 43 88 145 0,3 1,7 1,5 1,4 1,4 1,4
1 197 4 10 21 48 75 119 0,7 37,2 36,4 36,7 37,1 35,9
1 463 10 20 29 57 166 16,3 24,1 32,8 44 43,8
0 345 5 10 29 53 104 193 0,2 0,5 0,5 0,4 0,4 0,4
0 427 10 32 84 213 403 290 19,6 4,4 2,8 2,7 2,8
1 229 7 19 61 107 200 119 2,2 3,6 4,1 2 1,9
0 100 10 21 45 73 91 93 4,1 2,3 2,1 2,4 2,4 2,4
1 184 8 22 37 64 101 167 2,9 17,1 45,7 56,5 58,3
0 419 9 23 55 114 195 0,3 2,3 5,9 2,4 2,9
1 554 5 9 16 30 57 121 1 3 3,6 3,5 2,6 2,2
1 312 9 13 28 54 115 202 0,3 0,8 5,2 5,2 6,2 6,2
0 885 8 12 25 65 195 8,2 7,5 6,7 49,3 52,8
0 567 19 64 109 202 275 280 1,8 1,5 1,5 1,5 1,5
0 1966 9 15 26 89 257 7,3 6,4 5,8 5,2 5
0 149 4 15 27 48 75 131 0,1 1,4 4,9 5,1 4,8 4,8
1 161 12 49 100 63,1 46,6 47,2
1 338 6 13 55 117 239 7,1 22,5 13,5 31,8 26
1 463 7 12 34 95 224 311 14,2 27 49,9 37,9 74,8
Likelihood of having the BRCA2  PVNumer of individuals  in different degrees 
